Engineering AAV-2 Targeting Vectors: A New Insertion Site and scFv Driven Vectors by Martins Boucas, Jorge Miguel
Inaugural-Dissertation zur Erlangung des  
Doktorgrades der  Mathematisch-Naturwissenschaftlichen 
Fakultät der Universität zu Köln 
 
 
 
 
 
Engineering AAV-2 Targeting Vectors: 
A New Insertion Site and 
scFv Driven Vectors 
 
 
 
 
 
 
 
 
 
 
 
vorgelegt von 
Jorge Miguel Martins Bouças 
aus Lissabon, Portugal 
 
 
Köln, August 2008 
 i 
Berichterstatter/in: 
Prof. Dr. Manolis Pasparakis 
Prof. Dr. Herbert Pfister 
PD Dr. Hildegard Büning 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tag der mündlichen Prüfung: 28. Oktober 2008  
 
 
 ii 
 
 
 
Eidesstattliche Erklaerung 
Ich versichere, daß ich die von mir vorgelegte Dissertation selbständig angefertigt, die 
benutzen Quellen und Hilfsmittel vollständig angegeben und die Stellen der Arbeit – 
schließlich Tabellen, Karten und Abbildungen -, die anderen Werken in Wortlaut oder 
dem Sinn nach entnommen sind, in jedem Einzelfall als Entlehnung kenntlich 
gemacht habe; daß diese Dissertation noch keiner anderen Fakultät oder Universität 
zur Prüfung vorgelegen hat; daß sie – abgesehen von unten angegebenen 
Teilpublikationen – noch nich veröffentlicht worden ist sowie, daß ich eine solche 
Veröffentlichung vor Abschluß des Promotionsverfahrens nicht vornehmen werde. 
Die Bestimmungen dieser Promotionsordnung sind mir bekannt. 
 
 
 
 
 
Köln, 19. August 2008                                         Jorge Miguel  Martins Bouças 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 iii 
 
 
I thank PD Dr. Hildegard Büning for accepting me in her group, for constant 
and valuable scientific advice and for personal support during these years. 
 
I would like to thank Prof. Dr. Michael Hallek for opening me the doors to the 
group of PD Dr. Büning and creating the opportunity that led to the realization of this 
work. 
 
 Also, I thank Prof. Manolis Pasparakis for supporting my thesis. 
 
All this work would have not been as successful and exciting without the 
collaboration of all my friends and colleagues of the Büning group and of the 
University of Cologne.  
 
A especial thank goes to Prof. Dr. Hinrich Abken, Prof. Dr. Dagma 
Moersdorf, Prof. Dr. Ulrike Protzer,  Dr. Andreas Hombach, Dr. Sibille Quadt-
Humme, Dr. David Kofler, Dr. Luca Perabo, Dr. Kerstin Lux, Dr. Marianna Hössel, 
Dr. Caro Kopecky, Dr. Venkateswara Rao Simhadri, Dr. Marcus Chmielewski, Dr. 
Natascha Schuhmann, Stefanie Stahnke, Hanna Janicki, Stefan Maersch, Anke Huber, 
Silke Uhrig, Tobias Riet, Heike Köhler, Martin Zuther and Patrick Schmidt for 
stimulating discussions and practical help. 
 
I thank all those that so kindly received me in Cologne with open arms.  
 
Finally I thank my mother and my cousins for continuous support over a life 
span. I thank to all those that during the last decade treated me as brother and 
especially to who, without any obligation, treated me as a son. 
 
I especially thank Mareike for the extraordinary help, understanding and 
patience, along the years involving this work. 
 
 
 
 iv 
 
 
Die vorliegende Arbeit wurde in der Zeit von August 2005 bis August 2008 an der 
Klinik I für Innere Medizin der Medizinische Fakultät der Universität zu Köln unter 
der Anleitung von PD Dr. Hildegard Büning verfasst. 
 
 
 
Im Verlaufe dieser Arbeit wurden folgende Veröffentlichungen angefertigt: 
 
Perabo L. Goldnau D., White K., Endell J., Boucas J., Humme S., Work L.M., 
Janicki H., Hallek M., Backer A.H. and Buning H. (2006). Heparan sulfate 
proteoglycan binding properties of adeno-associated virus retargeting 
mutants and consequences for their in vivo tropism. J Virol 80(14), 7265-9. 
 
PCT/EP2008/004368; Buning H., Lux K., Nieland J., Boucas J., Ritter M., Hoerer 
M., (2008) Mutated structural protein of a parvovirus. World Intellectual 
Property Organization 
 
Perabo L., Boucas J., Coutelle O., Hallek M. and Buning H. 2008. Engineering of 
viral capsids to evade the host immune system. In R. Herzog (ed.), 
Immunology of Gene Therapy. John Wiley & Sons. In press. 
 
Boucas J., Lux K., Huber A., Schievenbusch S., Perabo L., Quadt-Humme S., 
Odenthal M., Hallek M., Buning H. (2008). Engineering AAV-2 based 
targeting vectors using a new insertion site – 453 – and single point 
mutations. J Gene Med, under review. 
 
Boucas J., Hombach A., Hallek M., Abken H. and Buning H. (2008). Construction of 
scFv-VP2 directed AAV-2 vectors. Manuscript in preparation. 
 
 
 
 
 v 
 
 
 
 
 
 
 
During all those years of experimentation and 
research, I never once made a discovery. All my 
work was deductive, and the results I achieved were 
those of invention, pure and simple. 
Thomas Edison 
 
 
 
 
 
To my mother 
 
 1 
ZUSAMMENFASSUNG 4 
SUMMARY 8 
1. INTRODUCTION 11 
1.1. GENE THERAPY 11 
1.1.1. TYPES AND METHODS 11 
1.1.2. VECTORS 12 
1.1.3. STATE-OF-THE-ART AND PRESENT GOALS 13 
1.2. ADENO-ASSOCIATED VIRUS 16 
1.2.1. GENOMIC ORGANIZATION OF AAV 17 
1.2.2. INFECTIOUS BIOLOGY OF AAV 19 
1.2.3. TISSUE DISTRIBUTION OF AAV ISOLATES 25 
1.2.4. IMMUNE RESPONSES TO AAV 25 
1.2.5. PRODUCTION OF RECOMBINANT AAV VECTORS 26 
1.3. TARGETING VECTORS 29 
1.3.1. GENETIC CAPSID MODIFICATIONS 29 
1.3.2. NON-GENETIC CAPSID MODIFICATIONS 36 
1.3.3. COMBINING GENETIC AND NON-GENETIC CAPSID MODIFICATIONS 37 
2. OBJECTIVES 38 
3. MATERIALS 40 
3.1. CHEMICALS, SOLUTIONS AND ENZYMES 40 
3.2. PLASMIDS 41 
3.3. PRIMERS 45 
3.4. ANTIBODIES AND PROTEINS 47 
3.5. BACTERIA STRAIN 48 
3.6. EUKARYOTIC CELLS 49 
3.7. DATA TREATING SOFTWARE 50 
3.8. GI AND ACCESSION NUMBERS 50 
3.9. LABORATORY EQUIPMENT, DISPOSABLES AND KITS 50 
 
 2 
4. METHODS 52 
4.1. VISUALIZATION OF STRUCTURES AND MOLECULAR MODELING 52 
4.2. BACTERIA CULTURE 52 
4.2.1. CULTIVATION OF BACTERIA 52 
4.2.2. PREPARATION OF COMPETENT BACTERIA 52 
4.2.3. TRANSFORMATION OF BACTERIA 53 
4.3. DNA TECHNIQUES 54 
4.3.1. PLASMID AMPLIFICATION AND EXTRACTION 54 
4.3.2. DNA QUANTIFICATION 56 
4.3.3. RESTRICTION ENZYME DIGEST 56 
4.3.4. AGAROSE GEL ELECTROPHORESIS 56 
4.3.5. CLONING 57 
4.4. EUKARYOTIC CELL CULTURE 59 
4.4.1. CULTIVATION OF CELLS 59 
4.4.2. TRYPSINISATION 59 
4.4.3. SEEDING / PASSAGING 59 
4.4.4. FREEZING AND THAWING CELLS 60 
4.4.5. COUNTING 60 
4.5. PRODUCTION OF AAV-2 VECTORS 60 
4.5.1. PRODUCTION OF HBS-BUFFER 60 
4.5.2. AAV VECTOR PACKAGING 61 
4.5.3. IODIXANOL GRADIENT PURIFICATION 62 
4.6. VECTOR TITRATION 62 
4.6.1. GENOMIC TITER 62 
4.6.2. TRANSDUCING TITER 63 
4.6.3. CAPSID TITER 64 
4.7. CELL TRANSDUCTION 65 
4.7.1. COMPETITION STUDIES 65 
4.7.2. BINDING PARTICLES 66 
4.8. PROTEIN TECHNIQUES 66 
4.8.1. PROTEIN QUANTIFICATION 66 
4.8.2. WESTERN BLOT 66 
4.8.3. ELISA 68 
4.9. IMMUNOPHENOTYPING 70 
4.10. BIODISTRIBUTION STUDY IN MICE 70 
 3 
 
5. RESULTS 71 
5.1. G453 AS A NEW AAV-2 INSERTION SITE 71 
5.1.1. INSERTION OF THE RGD4C PEPTIDE 72 
5.1.2. INSERTION OF THE NGRI PEPTIDE 83 
5.1.3. INSERTION OF AN N587 DISPLAY LIBRARY SELECTED PEPTIDE 86 
5.1.4. TRANSLATION TO OTHER PARVOVIRINAE 88 
5.2. FUSING SCFVS TO AAV-2’S VP2 FOR THE GENERATION OF NEW TARGETING 
MUTANTS 91 
5.2.1. GFP IS LOCATED ON THE OUTER SURFACE OF THE CAPSID 91 
5.2.2. ACD30-GFP-VP2 92 
5.2.3. ACD30NVP2 95 
5.2.4. OPTIMIZING EXPRESSION IN CIS 96 
5.2.5. OPTIMIZING EXPRESSION IN TRANS 97 
5.2.6. FUNCTIONAL SCFV 100 
5.2.7. TRANSDUCTION OF TARGET CELLS 101 
5.2.8. ANTI-CA19.9 SCFV 105 
5.2.9. ANTI-CEA SCFV 106 
6. DISCUSSION 109 
ABBREVIATIONS 122 
REFERENCES 123 
 
  
 4 
Zusammenfassung 
Die Gentherapie ist eine alternative Strategie zur Behandlung von 
Gendefekten und malignen Erkrankungen, die als therapeutisches Agens eine 
Nukleinsäure verwendet. Essentiell für den Erfolg vieler gentherapeutischer Ansätze 
ist ein effizienter und Zell-spezifischer Gentransfer. Hierzu werden Zell-spezifische 
Vektoren, sogenannte Targeting-Vektoren, benötigt. 
Für das in dieser Arbeit verwendete Vektorsystem, das auf dem nicht-
pathogenen Serotyp 2 des Adeno-Assoziierten Virus (AAV-2) beruht, wird bevorzugt 
das direkte oder genetische targeting verwendet. Hierbei werden Peptidliganden in 
das AAV-Kapsid eingefügt, die dann die Interaktion mit dem gewünschten zellulären 
Rezeptor vermitteln. Als besonders geeignete für die Insertion und Präsentation von 
Peptidliganden hat sich hierbei die Aminosäureposition 587 (sowie die benachbarte 
Position, 588) erwiesen. In Ermangelung einer 3D-Struktur wurde zu ihrer 
Identifizierung ein Sequenz-Alignment mit einem verwandten Parvovirus, dem 
Canine Parvovirus (CPV) von dem entsprechende Strukturinformationen vorlagen, 
durchgeführt.  
In der vorliegenden Arbeit wurde zum ersten Mal die nun vorhandene 3D-
Struktur des AAV-2-Kapsid verwendet, um eine neue Klasse von Insertionsmutanten 
zu generieren. In silico-Analysen ermöglichten die Identifizierung der 
Aminosäureposition 453 als eine mögliche Insertionsstelle, die aufgrund ihrer deutlich 
besser exponierten Lage eine effizientere Interaktion zwischen einem hier inserierten 
Liganden und seinem Rezeptor ermöglichen sollte. Dies wurde mit Hilfe des Modell-
Liganden RGD4C (ACDCRGDCDFCA), der an αVβ3 und αVβ5 Integrine bindet, 
untersucht. Hierzu wurde der Modell-Ligand genetisch in die Kapsidposition 453, 587 
oder in beide Positionen gleichzeitig eingefügt. Da eine Insertion in 
Aminosäureposition 453 – im Gegensatz zu einer Insertion in 587 - nicht mit der 
Bindung des AAV-2-Kapsid an seinen Primärrezeptor Heparansulfatproteoglykan 
(HSPG) interferiert, wurde parallel ein zweiter Mutantensatz generiert, bei dem die 
Insertionsmutanten zusätzlich zwei Aminosäuresubstitutionen (R585A und R588A) 
enthielten. Diese Aminosäuresubstitutionen (A2) führen zum Verlust der 
Bindungsfähigkeit des Kapsids an HSPG.  
Alle Mutanten konnten effizient hergestellt werden und waren mit Ausnahme 
der Doppelinsertionsmutanten zur effizienten Transduktion von HeLa-Zellen 
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(permissiv für AAV2) befähigt. Interessanterweise scheint die „Unfähigkeit“ zur 
Transduktion, die für die Doppelinsertionsmutanten beobachtet werden konnte, nicht 
in einer „Unfähigkeit“ zur Zell- oder Rezeptorbindung begründet zu sein, da sowohl 
eine Zellbindung als auch die Rezeptorbindung nachgewiesen werden konnte. In 
einem im Rahmen dieser Arbeit entwickelten ELISA konnte gezeigt werden, dass alle 
Insertionsmutanten die Fähigkeit zur Bindung des Zielrezeptors aufweisen. 
Interessanterweise, zeigten alle Mutanten, die zusätzlich zur Insertion die A2-
Mutation trugen, eine deutlich effizientere Rezeptorbindung als die „reinen“ 
Insertionsmutanten. Die effizienteste Mutante war r-RGD4C-453-A2 mit 
Peptidinsertion in der „neuen“ Insertionsstelle und zusätzlicher A2-Mutation. Diese 
Mutante war zudem deutlich effizienter als rAAV-2 (mit unmodifiziertem Kapsid) 
und als die übrigen Mutanten in der Transduktion der HSPG-defizienten Zelllinie 
CHO psA-745. Kompetitionsexperimente mit löslichen Peptiden sowie mit Heparin 
(lösliches Analogon des HSPG) auf verschiedenen Zelllinien sowie auf primären 
HUVEC (Human Umbilical Vein Endothelial cells) zeigten, dass der inserierte 
Ligand die Zelltransduktion vermittelt, wenn die natürliche (HSPG-) 
Rezeptorbindung verhindert wird. Die in Maus durchgeführte Bioverteilungsstudie 
machte deutlich, dass – nach Eliminierung der HSPG-Bindung – die Bioverteilung 
von Targetingvektoren, die eine Insertion in Position 453 oder 587 tragen, allein vom 
inserierten Liganden bestimmt wird. 
Die Insertion eines alternativen Peptids (NGRI) in 453 führte zur Generierung 
des AAV-Targetingvektors r-NGRI-453, mit dem HeLa-Zellen effizienter transduziert 
werden konnten als durch rAAV-2. Mit diesem Peptid konnten zudem infektiöse 
Doppelinsertionsmutanten hergestellt werden. Ein Peptid, dass durch AAV Peptide 
display für die Position 587 selektioniert worden war, konnte zwar erfolgreich in die 
Position 453 eingebaut werden; der entsprechende Vektor wies aber keine verbesserte 
Transduktionseffizienz auf. Zusätzlich wurde mit Hilfe der NCBI Concerved domain 
database zu 453 im AAV-2 Kapsid homologe Positionen in anderen Parvoviren 
identifiziert, um die Anwendungsmöglichkeiten der in dieser Arbeit identifizierten 
und optimierten Insertionsstelle zu erweitern. 
Somit konnte in diesem Teil der Arbeit gezeigt werden, dass sich die 
Aminosäureposition 453 zur Insertion von Tropismus-modulierenden Peptidliganden 
eignet. Doppelinsertionsmutanten (Peptidliganden in Position 453 und 587) können 
ebenfalls generiert werden. Ihre Infektionsfähigkeit scheint jedoch peptidabhängig zu 
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sein. Ein weiterer interessanter Befund ist die deutliche Verbesserung der 
Rezeptorbindungsfähigkeit durch Kombination von RGD4C-Insertion und A2-
Mutation. Dies stellt das erste Beispiel für die Bedeutung von Punktmutationen zur 
Optimierung von Targeting-Vektoren dar. Auf diesem Hintergrund wird die 
Wichtigkeit von evolutionären Ansätzen und high throughput-Selektionen für die 
Vektorentwicklung noch einmal deutlich. In diesen Ansätzen werden aus 
Bibliotheken von Kapsidmutanten für die jeweilige Anwendung optimierte Mutanten 
selektioniert.  
Die sich mehrenden Berichte über die hohe Spezifität von 
Antikörperfragmente (single-chain Antikörper; scFv) motivierte das zweite Projekt 
dieser Arbeit. Da scFv aufgrund ihrer Größe ungeeignet für eine Insertion innerhalb 
von AAV-Kapsidproteinen z.B. an Position 453 oder 587 sind, wurde in dieser Arbeit 
der Versuch unternommen, Fusionsproteine zwischen scFv und dem N-Terminus von 
VP2 (zweitgrößtes AAV-Kapsidprotein) in das Kapsid von AAV einzubauen. Da wir 
vor kurzem zeigen konnten, dass Fusionsproteine aus GFP und VP2 in das Kapsid 
eingebaut werden, dass das GFP auf der Kapsidoberfläche exponiert wird, und dass 
GFP-markierte Viren infektiös sind, wurde zunächst ein Fusionsprotein aus anti-
CD30 scFv-GFP-VP2 hergestellt. Diverse Optimierungen des Verpackungsprotokolls 
waren nötig, um anti-CD30 scFv-GFP-VP2 enthaltende Vektorpartikel zu generieren. 
Diese Mutanten konnten HeLa-Zellen transduzieren und interagierten mit einem anti-
idiotypischen Antikörper. Es konnte jedoch keine spezifische Transduktion von 
CD30-positiven Zellen nachgewiesen werden. Außerdem konnte weder nach einer 
noch nach vierstündiger Inkubation der Zellen mit Vektorlösung Vektor-DNA in oder 
an Zellen nachgewiesen werden. Weder die Eliminierung des GFP-Anteils noch das 
Einbringen von linker-Sequenzen führte zu einer Verbesserung der Bindungs- oder 
Transduktionseffizienz. Der Austausch des anti-CD30 scFv gegen ein anti-CEA scFv 
und ein anti-CA19 scFv führte zu denselben Ergebnissen, woraus geschlossen werden 
kann, dass die mit anti-CD30 scFV erhaltenen Ergebnisse nicht spezifisch für den 
anti-CD30 scFv sind. 
Vergleicht man Studien, die vollständige Immunglobuline verwenden, mit 
dieser Studie, so könnte die geringe Vektorpartikelkonzentration einen limitierten 
Faktoren darstellen. Zudem finden sich pro AAV-Kapsid nur 5 VP2-Proteine, d.h. es 
können maximal 5 VP2-Fusionsproteine eingebaut werden. Dies ist deutlich weniger 
als bei Targeting-Vektoren, die einen Ligand z.B. in Position 453 inseriert enthalten. 
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Hier wird der Ligand in alle 60 Kapsidproteinen eingebaut und steht so deutlich 
häufiger für eine Rezeptorbindung zur Verfügung.  
Trotzdem darf festgehalten werden, dass durch die hier durchgeführte Arbeit, 
das bisher größte Fusionsprotein (~ 127 kDa) in das AAV-Kapsid eingebaut werden 
konnte. Diese Tatsache zusammen mit der Beobachtung, dass sich sowohl das GFP 
als auch der anti-CD30 scFv auf der Kapsidoberfläche befinden, eröffnet viele neue 
Möglichkeiten der Anwendung. So könnte AAV-2 gleichzeitig als Proteincarrier 
(Fusion mit dem N-Terminus) und als Gencarrier (Transgen) fungieren.  
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Summary 
Gene therapy can be defined as the introduction of nucleic acids into cells with 
the purpose of altering the course of a medical condition or disease. In many clinical 
settings, efficient and successful gene therapy relies on the delivery of genes to 
specific cells in the human body. Such specific delivery can only be achieved through 
the design of vehicles/vectors that are able to recognize the target cell – targeting. 
Adeno-associated virus type 2, a non-pathogenic human virus, has received an 
increased amount of attention as a vector for gene therapy since it was first cloned 
into a bacterial plasmid in 1982. Although the first attempt to construct an AAV-2 
targeting vector made use of a single chain antibody fragment, it was the insertion of 
small peptide ligands into the AAV-2 capsid that marked the beginning of AAV-2 
vector targeting. Sequence alignment of AAV-2 with CPV led to the discovery of 
amino acid position 587. Several reports have shown that small peptide ligands, once 
inserted in this position, are able to mediate transduction of the respective target cells, 
and that target specificity is retained in vivo.   
In this work, the available three dimensional structure of AAV-2 is used for 
the first time for the rational design and construction of targeting vectors. In silico 
analysis revealed that insertions at position 453 should result in a better exposure of 
the inserted peptides and, as a consequence, in a more efficient interaction with the 
target receptor. The RGD4C peptide – a ligand for αVβ5 and αVβ3 integrins – was 
inserted in position 453 and/or 587. Moreover, loss of AAV-2 wild-type (wt) tropism 
was achieved by R585A and R588A – A2 – mutations that abolish binding to the 
primary receptor – heparan sulfate proteoglycan, HSPG.  
All mutants were able to efficiently package and, with the exception of the 
double RGD4C mutants, to transduce HeLa cells. Interestingly double insertion 
mutants – r-RGD4C-453&587 and r-RGD4C-453&587-A2 – were able to efficiently 
bind to cells. Cell free based assays, involving targeting vectors and one target 
receptor revealed that all insertion mutants were able to bind the target receptor. 
Surprisingly, addition of A2 mutations to targeting vectors resulted in an increased 
amount of bound receptors. A mutant containing RGD4C at 453 and A2 mutations – 
r-RGD4C-453-A2 – emerged as the most efficient mutant. This mutant was also the 
most efficient vector for the transduction of an HSPG ko cell line – CHO pgsA-745. 
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Competition studies with soluble peptides verified specificity of transduction in this 
and other cell lines, as well as in primary Human Umbilical Vein Endothelial Cells – 
HUVEC, which often serve as a model for tumor endothelial cells. In vivo 
biodistribution studies revealed that, once HSPG binding is abolished, vector 
distribution is determined by the inserted peptide, independent of the insertion 
position and independent of the modification that led to elimination of the wt tropism. 
Insertion of the NGRI peptide in position 453 – r-NGRI-453 – resulted in a 
vector that was more efficient than wt AAV-2 in the transduction of HeLa cells. 
Furthermore, double insertion mutants remained infectious. Insertion of an N587 
display library selected peptide in position 453 was not detrimental but did not result 
in a vector with improved transduction efficiencies. NCBI’s Conserved Domain 
Database was used to identify 453 homologues in other vector systems.  
In summary, 453 emerged as a suitable position for the insertion of targeting 
peptides in AAV-2 and other vector systems. Double insertion mutants will have to be 
analyzed for each specific case. The increased targeting efficiency after single point 
mutations of residues linearly distant from the inserted peptide shows for the first time 
how such mutations can indeed be relevant for the design of targeting mutants. 
Moreover, high-throughput selection protocols emerge as master tools and should be 
put into practice for the identification of similar mutants and for the optimization of 
targeting vectors. 
The rising number of reports on the high efficiency of antibody fragments for 
the construction of targeting molecules motivated the fusion of single chain antibody 
(scFv) fragments to the capsid of AAV-2. Being most likely too large for insertions in 
non-terminal positions like 453 or 587, we decided to genetically fuse a scFv to the N-
terminus of a viral protein - VP. Furthermore, vectors containing a GFP-VP2 fusion 
protein have previously been shown to be useful tools for infectious biology studies. 
Our analysis of this GFP labeled vectors revealed that at least a part of the GFP 
molecule is present on the outer surface of the capsid. These observations led to 
generation of an anti-CD30 scFv fused to the N-terminus of a GFP molecule that was 
fused to the N-terminus of VP2.  
Optimization of the packaging procedure, by increasing the amount of the 
fusion protein encoding plasmid, resulted in an efficient packaging of scFv-AAV-2 
mutants. Mutants were able to effectively transduce HeLa cells and to bind an anti-
idiotypic antibody homologue to the recognized antigen epitope. Despite this, 
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targeting mutants were not able to specifically transduce CD30 positive cells. 
Furthermore it was not possible to detect vector DNA with target cells neither 1 nor 4 
hours post-transduction. Engineering similar constructs without the GFP molecule 
and with or without linker sequences did not result in an improved binding or 
transduction efficiencies. Substitution of the anti-CD30 scFv by an anti-CEA scFv or 
an anti-CA19 scFv revealed that the results observed with the anti-CD30 scFV 
targeting mutants were not idiotype specific. When compared to studies made with 
whole immunoglobulins, the low vector particle concentration emerges as one of the 
limiting steps to the application of such targeting approaches. Moreover, while each 
capsid possesses sixty repeats of G453, only five VP2 proteins exist per capsid. 
Despite this, the scFv-GFP-VP2 fusion represents the largest fusion (~127 kDa in 
total) ever assembled in an AAV capsid. This, together with the fact that both GFP 
and anti-CD30 scFv molecules could be recognized by respective antibodies 
reinforces the idea that the N-terminus of VP2 can indeed be displayed on the outer 
surface of the capsid. Our results open the door to many other therapeutic designs 
where the vector can be used as a carrier for genes and at the same time for high 
molecular weight proteins assembled in pentavalent forms. 
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1. Introduction 
1.1. Gene therapy 
Genes, which are carried on chromosomes, are the basic physical and 
functional units of heredity. Genes are specific sequences of bases that encode 
instructions on how to make proteins. Although genes get a lot of attention, it’s the 
proteins that perform most life functions and even make up the majority of cellular 
structures. When genes are altered so that the encoded proteins are unable to carry out 
their normal functions, genetic disorders can result. 
The application of recombinant DNA technology and gene cloning (which 
started in the 1980s) and the resulting increase in genomics data during the 1990s 
have contributed to define some disease-causing genetic factors and to explore the 
potential of new therapies based on engineered genes and cells (161, 190)  
Gene therapy can be defined as the introduction of nucleic acids into cells for 
the purpose of altering the course of a medical condition or disease. In general with 
some exceptions, the nucleic acids are DNA molecules encoding gene products or 
proteins. The original ideas were directed toward treating monogenic (single-gene) 
disorders, but it has become clear that the gene can be considered a new 
pharmaceutical agent for treating many types of diseases (96).  
Gene therapy is a complex process, involving multiple steps in the human 
body (delivery to organs, tissue targeting, cellular tracking, regulation of gene 
expression level and duration, biological activity of therapeutic protein, safety of the 
vehicle and gene product, to name just a few) most of which are not completely 
understood. 
 
1.1.1. Types and methods 
Gene therapy approaches can be divided into two types: germ line therapy and 
somatic therapy. In the first type, a gene is inserted into the DNA of the germline cells 
(egg or sperm) so that the offspring of the patient will have the inserted gene. This 
more recent approach, theoretically, should be highly effective in counteracting 
genetic disorders. Somatic gene therapy involves the manipulation of gene expression 
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in cells that will be corrective to the patient but not inherited by the next generation 
(somatic cells include all the non-reproductive cells in the human body). 
For the correction of faulty genes four different approaches are normally used: 
a) a normal gene may be inserted into a nonspecific location within the genome to 
replace a nonfunctional gene; b) an abnormal gene can be swapped for a normal gene 
through homologous recombination; c) the abnormal gene can be repaired through 
selective reverse mutation, which returns the gene to its normal function; d) the 
regulation (the degree to which a gene is turned on or off) of a particular gene could 
be altered. 
Transfer of the genetic material can be achieved either ex vivo or in vivo. In 
the first case the patient cells are harvested and cultivated in the laboratory. After 
incubation with carrier molecules containing a corrective or therapeutic gene the cells 
with the new genetic information are then harvested and transplanted into the patient. 
Although normally less feasible for wide-scale application due to its complexity, this 
method is quite attractive due to the improved safety gained by the possibility to 
separate target from non-target cells. In most cases though, efficient therapy requires 
direct in vivo administration of the vehicle. Although, in situ administration may help 
avoiding the transfer of genetic material to non-target cells, the carrier molecule needs 
in this case to discriminate between target and non-target cells. Thus, carrier 
molecules are one of the masterpieces of most gene therapy designs. 
 
1.1.2. Vectors  
A carrier molecule called a vector must be used to deliver the therapeutic gene 
to the patient's target cells. There are two major classes of vectors: viral vectors and 
non-viral vectors. 
Some researchers believe that viral vectors will be most successful because 
viruses have evolved for millions of years to become efficient vesicles for transferring 
genetic material into cells, whereas others believe that some of the side effects of such 
viral vectors and possible previous exposures to the respective viruses rendering the 
host resistant to transduction (gene transfer into the cell) will preclude their long-term 
use in gene therapy.  
There is no "perfect vector" that can treat every disorder. Like any type of 
medical treatment, a gene therapy vector must be customized to address the unique 
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features of the disorder. Furthermore, interpatient variations can not be forgotten and 
must be taken into account. For such reasons, a wide variety of vectors have been 
used in clinical trials worldwide (Figure 1). 
 
 
Figure 1. Vectors used in gene therapy clinical trials worldwide. Includes data relative to 1,347 of 
approved, ongoing or completed clinical trials worldwide. As of March 2008. (1) 
  
 
1.1.3. State-of-the-art and present goals 
Gene therapy is not a new idea. In 1963, Joshua Lederberg (1925-2008) wrote: 
“We might anticipate the… interchange of chromosomes and segments. The ultimate 
application of molecular biology would be the direct control of nucleotide sequences 
in human chromosomes, coupled with recognition, selection and integration of the 
desired genes…It will only be a matter of time… before polynucleotide sequences can 
be grafted by chemical procedures onto a virus DNA.” Less than 30 years later, the 
first clinical study using gene transfer was reported (31). 
The disease states that have been approached with gene therapy are now 
widely diverse, including autossomal dominant disorders, many forms of cancer, HIV, 
and other infectious diseases, inflammatory conditions, and intractable pain (Figure 
2). In most instances, the nature of the disease may dictate the vector to be used, since 
it may involve a specific cell type, expression level, and duration of expression that 
will be required for therapeutic effect. In general, genetic diseases will require long-
lasting gene expression, and so may indicate the use of a gammaretrovirus, lentivirus, 
or AAV vector; while a tumor vaccine or cytotoxic gene approach to cancer may 
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require a short burst of gene expression, such as might be produced by an adeno or 
non viral vector.  
 
 
Figure 2. Diseases addressed by gene therapy clinical trials. Includes data relative to 1,347 of 
approved, ongoing or completed clinical trials worldwide. As of March 2008. (1) 
 
For a disease to be a good candidate for gene therapy, the role of the 
therapeutic gene in disease pathophysiology must be clearly understood. It seems 
likely that in future, more gene therapy targets will be identified, primarily as a result 
of the rapid ability to identify specific gene associations with human diseases, 
particularly after the completion of the Human Genome Project. This includes both 
single gene diseases, and, multifactorial diseases in which complex networks of gene 
and environmental effects are elucidated, and key genetic determinants of disease are 
identified within those pathways. The future remains uncertain regarding the ultimate 
clinical impact that gene therapy will have in each of those very distinct fields. 
Indeed, clinical progress has been slow. After the first clinical trial in 1990 
using a gammaretroviral vector a major setback occurred in September 1999 when a 
widely publicized death resulting from a gene therapy trial was reported (19, 155). 
The resulting investigation concluded that the patient died from a massive immune 
reaction against the used Adenovirus type 5 vector. Fortunately, less than 1 year after 
a successful trail was published. Two children suffering from a severe combined 
immunodeficiency disorder (SCID-XI), which had restricted them to life in an 
isolated environment, were able to leave the hospital and resume normal lives after 
ex-vivo transduction of their lymphocytes with a gammaretrovirus vector (26). Out of 
the approximately 18 patients that were treated with the same type of vector 5 
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developed leukemia  (50, 52). While in 4 of these patients the complications resulted 
from vector integration in a nonrandom manner near the LM02 gene, in the 5th patient 
unphysiologic expression of the IL2RG transgene is suspected to contribute to the 
development of the complications (50). Although chemotherapy already led to 
sustained remission in 3 of the patients with T cell leukemia, it failed in one (70). A 
clinical trial to correct a clotting disorder, Factor IX deficiency, by hepatic gene 
transfer using an AAV vector recently showed that transient correction was possible 
but quite limited in time because of subsequent immune reaction (116). In the end of 
2007, 3 patients having an inherited blind disease with onset during childhood 
underwent subretinal delivery of an AAV vector. Each patient had a modest 
improvement in measures of retinal function on subjective tests of visual acuity (114). 
Recently, a clinical setting for the treatment of ADA-SCID using a gammaretrovirus – 
GIADA1MLV retroviral vector – showed that ADA gene transfer is an efficacious 
treatment for ADA-SCID (25). 
The development of versatile vectors with defined and controlled functions is 
without any doubt one of the present major goals in the field. Indeed, while the 
natural target cell of one vector might make it the best candidate for the designed 
therapy, the lack (or not) of integration capacity might make it inadequate. The low 
amount of vector preparations utilized in most trials linked to the small number of 
subjects involved in average in each gene therapy clinical trial reveals how important 
basic aspects like production are still to be optimized (121). Development of massive 
production and high purification methods that result in stock solutions with high titers 
and purity is indeed part of the present goals. A lot has been made in the vector field 
during the last 18 years. Transferring the knowledge obtained with one vector system 
to another as shown efficient results but many lessons are still to be learned. 
Furthermore, the lack of more multifunctional groups working each one with a wider 
variety of systems and the need for more work to be done in vivo and ex vivo using 
adequate animal models has created a dependency on other areas of research that 
made the field develop in short steps.  
Despite the early high expectations and the subsequent set-backs, one has to 
recognize that this new therapeutic modality is still in its infancy. It will neither 
deliver medical “miracles” (as its early prophets predicted) nor will it “disappear'” 
because of a few disappointing cases (as some of its recent antagonists predict). As 
with all new technologies, gene therapy has to run its course in its present  
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“development phase” before it reaches “maturation”, when its full potential will be 
exploited. This in turn will offer significant opportunities to effectively target the 
causative factors for several disabling diseases afflicting mankind.  
 
 
1.2. Adeno-associated virus 
Adeno-associated virus (AAV) was discovered in 1965 when different groups 
described small, uniformly formed, virus like particles which were noticed during 
electron microscopical examination of simian adenovirus type 15 (SV15) (7). These 
particles were 18-20 nm in diameter and showed an icosahedral symmetry (119). 
Staining with acridin orange demonstrated that these particles contained DNA, which 
contributed to the suggestion that those particles were viruses. The particles replicated 
only in cells that were coinfected with adenovirus. The authors named the particles 
adeno-associated virus (7).  
Today, AAV has been classified as a member of the Parvoviridae. With a 
diameter of only 18 to 30 nm the Parvoviridae are among the smallest known viruses 
(latin: parvum = small). Viruses of this family contain a single-stranded DNA 
genome of approximately 5 kb and a non-enveloped icosahedral capsid. The family of 
Parvoviridae contains two subfamilies: the Densovirinae which infects invertebrates 
and the Parvovirinae which is specific for vertebrates. The subfamily Parvovirinae 
includes the genera Parvovirus, Erythrovirus and Dependovirus. Adeno-associated 
viruses belong to the Dependovirus genus. Parvovirus B19 is the only human 
pathogen within the Parvoviridae (Erythrovirus genus) and causes Erythema 
infectiosum, hydrops fetalis and abortion (23, 185). All other representatives of this 
family, including AAV, are not pathogenic for humans (17). On the contrary, AAV 
seems to be protective against bovine papillomavirus and adenovirus mediated 
cellular transformation (34, 82, 98, 118) and to have cytotoxic effects in malignant 
cells (154).  
In contrast to the Parvovirus and Erythrovirus genus, which are autonomous 
Parvoviridae, AAV replication, and thus a productive infectious life cycle, depends 
on co-infection with unrelated helper viruses e.g. adenovirus (Ad), herpesvirus 
(HSV), human cytomegalovirus (HCMV), or papillomavirus (16, 129). In the absence 
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of a helper virus AAV establishes a latent form of infection by stably integrating its 
genome into the host cell genome. Helper viruses can be partially replaced by 
chemical or physical carcinogens (80, 204-206). This leads to the conclusion that 
helper viruses induce specific changes in the host cell and thereby providing 
competence for AAV replication.  
Until now, 12 serotypes which share different levels of sequence homology, 
have been identified (56, 58, 126). AAV-1 to -4 and -6 have been detected as 
contaminants of adenoviral preparations. AAV-5 was isolated from penile 
condylomata lata (human wart) (11), AAV-6 seems to be a recombination between 
AAV-1 and -2 (199). AAV-9 was isolated from human tissues (56). AAV-7 and 
AAV-8 have been detected in Rhesus monkey, AAV-10 and AAV-11 in Cynomolgus 
monkey (58, 126). Sera epidemical studies suggest that AAV-2, AAV-3 and AAV-5 
are epidemic in humans, whereas AAV-4, -7-11 are endemic in nonhuman primates 
(58). The natural occurrence of AAV-1, -6 and -12 is not known.  
Although the other serotypes have attracted increasing attention during recent 
years, AAV-2 is still the best characterized serotype, being the first isolated and 
cloned. 
 
1.2.1. Genomic organization of AAV 
Wild type AAV-2 contains a single stranded DNA genome of 4679 
nucleotides (178). The genome can be divided into three functional subunits. These 
are the two open reading frames (ORF) rep and cap flanked by the inverted terminal 
repeats (ITR) (24). It contains three promoters (p5, p19 and p40) and a common 
polyadenylation signal (Figure 3). The 5’-ORF rep encodes four Rep proteins, a 
family of multifunctional, nonstructural proteins. The different Rep proteins are 
named upon their molecular weight: Rep78, Rep68, Rep52 and Rep40. The larger 
Rep proteins are controlled from the p5, the smaller Rep proteins from the p19 
promoter (112). Splicing of a common intron leads to Rep68, a splice variant from 
Rep78, and Rep40 from Rep52. The larger Rep proteins are important for site specific 
integration, control of replication and transcription (27, 142-144). The smaller Rep 
proteins seem to be involved in accumulation and packaging of single-stranded DNA 
into the preformed capsid (45, 100). The Rep proteins can act as transactivators of 
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transcription in the presence of helper virus functions and as repressors of the three 
viral promoters in absence of a helper virus (106, 142).  
 
 
Figure 3. Organization of the AAV genome. The AAV genome encompasses 4680 nucleotides, 
divided into 100 map units. Indicated are the two inverted terminal repeats (ITRs), the three viral 
promoters at map position 5, 19, and 40 (p5, p19, and p40) and the polyadenylation signal at map 
position 96 (poly A). The open reading frames are represented by rectangles, untranslated regions by 
solid lines and the introns by nicks intercepting the solid lines. Large Rep proteins (Rep78 and Rep68) 
controlled by the p5 promoter and small Rep proteins (Rep52 and Rep40) driven by the p19 promoter 
exist in spliced and unspliced variants (Rep68 as a splice variant of Rep78; Rep40 as a splice variant of 
Rep52). The cap genes encoding the three different capsid proteins VP1, VP2, and VP3 are controlled 
by the p40 promoter. Figure kindly provided by Dr. N. Huttner. 
 
The 3’-ORF cap encodes the three capsid proteins VP1, VP2 and VP3, which 
form the 60 subunits of the viral capsid in a 1:1:10 ratio (105). All three capsid 
proteins are controlled by the p40 promoter and use the same stop codon. VP2 and 
VP3 are N-terminal truncated variants of VP1. Synthesis of VP1 is regulated by 
alternative splicing whereas VP2 is initiated from an unusual translation initiation 
codon (ACG) (14, 15). The molecular weight of VP1, VP2 and VP3 is 90 kDa, 72 
kDa and 60 kDa, respectively. VP3 alone is sufficient for capsid formation, but VP1 
is required for viral infection (189). At least ex vivo VP2 seems not essential for 
capsids formation and infectivity (113, 189). Capsid assembly takes place inside the 
nucleus (193, 194).  
The 145 bp long ITRs form hairpins of a T-shaped structure which contains 
Rep binding sites (RBS) and a terminal resolution site (TRS) which is a specific 
cleavage site for Rep proteins (90, 120, 176). They serve as origin of replication, are 
important for site-specific integration and rescue of the provirus from the human 
chromosome 19 (107, 122, 164). 
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1.2.2. Infectious biology of AAV 
1.2.2.1. Virus cell contact 
Of all the serotypes, AAV-2’s infectious biology is the best characterized. 
However, a detailed understanding of intracellular trafficking, endosomal release and 
viral uncoating is still missing. Moreover, most experiments were performed within 
the same cell line, the human cervix carcinoma cell line HeLa. The current model of 
the infection process is depicted in Figure 4. 
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Figure 4. The AAV infection pathway. AAV touches the membrane several times before entering the 
cell. Attachment to its primary receptor HSPG and co-receptors such as FGFR and αvβ5 integrin is 
triggering a receptor-mediated endocytosis in a dynamin dependent manner into clathrin coated pits. This 
internalization is facilitated by the activity of Rac1. Activation of Rac1 subsequently stimulates PI3K pathways 
which regulate endosome trafficking along the cytoskeleton. The exact mechanism of endosomal release is not 
clear yet. Viral uncoating takes place before or during nuclear entry. Viral DNA enters the nucleus by an unknown 
mechanism. (Figure modified from Büning et al. 2003.) 
  
Single Virus Tracing (SVT) studies characterized the motion of AAV-2 
outside the cell as normal diffusion with a diffusion coefficient of D = 7.5 µm2/s. In 
this studies AAV-2s’ diffusion decelerated as it approached the cell membrane, and 
finally stopped when AAV got in contact with the cell membrane with a mean 
touching time of 62 ms. Most virions showed multiple contacts to the cell before 
entering or being finally released from the cell membrane. In average 4.4 repetitive 
touching events are observed. It is not clear whether these multiple touching events 
represent a binding and release process to viral receptors or adsorption to cellular 
structures (170).  
Heparan sulfate proteoglycan (HSPG) has been identified as the primary 
receptor of AAV-2 (182). HSPG binding residues are located within the VP3 region 
(which is common to all capsid proteins). 5 amino acids have been identified to be 
involved in HSPG binding: R484, R487, K532, R585 and R588. Mutational analysis 
showed that especially R585 and R588 are essential for the interaction with HSPG 
(97, 135, 198). Even though HSPG has been described as AAV-2’s attachment 
receptor, it was shown that AAV-2 is able to enter some cells in the absence of HSPG 
(21). It was proposed that HSPG is also the primary receptor for AAV-3 whereas a 
2,3-O- and 2,3-N-linked sialic acid was identified as the attachment receptor for 
AAV-4 and -5, respectively (76, 92, 153). For AAV-6 the situation is quite complex. 
Seiler and colleagues observed that the use of sialic acid as attachment receptor for 
AAV-6 is dependent on cell type and cell differentiation status (169). Moreover, 
although AAV-6 can bind to heparin, it does not interfere with viral infection when 
applied together with virus onto the cell (74). The 37/67-kDa lamin receptor (LamR) 
was recently described as receptor or AAV-8. AAV-1 does not appear to utilize 
heparan sulfate, sialic acid or LamR and its receptor remains unknown (152). The 
same holds true for AAV-7. However, since it closely resembles AAV-1, they may 
share a common receptor (152). Even less is known about potential (attachment) 
receptors for AAV-9 to -12 (56, 57, 126, 167). 
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In addition to the attachment receptor, secondary receptors are required for 
viral infection. Five coreceptors have been described for AAV-2 so far, human 
fibroblast growth factor receptor I (hFGFR I), αVβ5-integrin, α5β1-integrin, 
hepatocyte growth factor receptor (HGFR) and LamR (6, 95, 149, 152, 181). Human 
FGFR I was also shown to interact with AAV-3 (18). For hFGFR I a function in 
enhancing the interaction of virion and HSPG was proposed (149). The function of 
HGFR is not known yet. Since blocking of αVβ5-integrin with antibodies can prevent 
internalization of rAAV-2 into HeLa cells it was suggested that binding to αVβ5-
integrin mediates endocytosis (165). α5β1-integrin is thought to be an alternative 
coreceptor to αVβ5 (6). For AAV-5 platelet derived growth factor receptor (PDGFR) 
was identified as coreceptor (38). PDGFR was also discussed to act alone as a 
receptor for AAV-5 because it is in itself a sialo-glycoprotein (33). 
 
1.2.2.2. Receptor mediated endocytosis of AAV 
The endocytotic process was studied for AAV-2 and 5. Following receptor 
binding AAV-2 enters the cell by a receptor mediated endocytosis through clathrin 
coated pits in a dynamin dependent manner (13, 43). Single Virus Tracing 
measurements showed an individual viral uptake within milliseconds. AAV-5 was 
also predominantly localized in clathrin coated vesicles. However, in rare situations, 
AAV-5 was found to be endocytosed in noncoated vesicles, representing probably 
caveolae (10). Similar to ligand-receptor interaction, it was shown that receptor 
binding of AAV-2 causes intracellular signal transduction. Binding to αVβ5 activates 
(in addition to mediate endocytosis) Rac1, a small GTP binding protein, stimulating 
thereby phosphoinositol-3 kinase (PI3K) which facilitates the rearrangement of 
microfilaments and microtubuli (165). Treatment of infected cells with nocodazole, 
which leads to depolymerization of microtubules, or with cytochalasin B, which 
disrupts microfilaments, reduces perinuclear accumulation of AAV-2 (165). 
 
1.2.2.3. Endosomal processing of AAV 
Intracellular trafficking and endosomal processing of the virion are further 
complex steps which are known to be important for efficient cell transduction. These 
processes seem to be the rate limiting step in many cell types. For example, AAV-2 is 
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endocytosed in polarized airway epithelial cells from the apical and the basolateral 
surface. Although the apical in contrast to the basolateral surface does not contain 
HSPG and αVβ5 integrin, only a 3- to 5-fold reduction in endocytosis was detected. 
However, transduction of cells from the apical surface is reduced >200-fold, 
indicating that in addition “postendocytotic” barriers exist for AAV mediated gene 
transfer (44). It has been shown that several viruses can penetrate barrier cells 
(epithelia and endothelia) by transcytosis (20, 136, 195). This process is cell type and 
serotype specific. For AAV-5 it was shown that this transport pathway is distinct from 
transduction, cell type and serotype specific (37).  
Studies evaluating subcellular distribution of AAV-2 following infection 
remain ambiguous and sometimes controversial. It was proposed that AAV-2 is 
released from the early endosome (200) or might traffic through late endosome 
compartments (42, 77). It was also shown that AAV-2 colocalizes with transferrin 
(43). Transferrin is known to be recycled through the perinuclear recycling endosome 
(PNRE) (158, 177). Therefore, it was suggested that this compartment might be 
involved in the processing of AAV. Recently a dose dependent trafficking was 
described, observing a predominant trafficking of AAV-2 to the late endosome at low 
multiplicities of infection (MOI, 100 genomes/cell) and trafficking of AAV-2 to the 
PNRE at high MOI (104 genomes/cell). In addition, dose-response curves showed that 
viral movement through the PNRE is more competent for transgene expression than 
movement through the late endosome (41). Furthermore, it was proposed that AAV-2 
and -5 localize inside the golgi compartment (10, 137). 
 
1.2.2.4. Endossomal escape of AAV 
In addition, to the unsolved question when and where AAV escapes from the 
endosome, the mechanism of endosomal release is not known. Acidification inside the 
endosomes seems to be essential in priming AAV for nuclear entry. This assumption 
is based on the observation that microinjection of AAV-2 particles directly into the 
cytoplasm (instead of natural infection) did not result in gene expression (40). The 
same effect can be reached by the addition of inhibitors of acidification like 
bafilomycin A1 or ammonium chloride (13). It might be that this acidification leads to 
a conformational change inside the viral capsid. Interestingly, it has been shown that 
the N-terminal region of VP1 contains a domain that resembles a secretory 
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phospholipase A2 (sPLA2); a domain that was not known to exist in virus capsids 
(209). A mutation in the catalytic center of the PLA2 motif of AAV-2 causes a 
dramatic drop in infectivity (64). PLA2s catalyze the hydrolysis of phospholipid 
substrates at the 2-acyl ester (sn-2) position to release lysophospholipids and free fatty 
acids (9, 36, 104). This VP1 domain is located inside the AAV-2 capsid and was 
shown to be exposed after heat shock (105). This domain might be involved in 
endosomal escape or nuclear uptake. 
 
1.2.2.5. Nuclear translocation of AAV 
Viral translocation into the nucleus is, in contrast to endocytosis and 
trafficking to the perinuclear region, a slow and inefficient process. Perinuclear 
accumulation can be observed from 30 min p.i. on (13) and persist also many hours 
after gene expression has already started (200). Only very few information is 
available about the mechanism of nuclear import. Having a diameter of 25 nm AAV 
can potentially pass the nuclear pore complex (NPC). However, it is not clearly 
demonstrated whether AAV uses the NPC to enter the nucleus. It was shown that 
AAV interacts with nucleolin, a nuclear shuttle protein (150). Others have suggested a 
nuclear entry independent of the NPC (78). Inside the unique VP1 and VP2 regions 
nuclear localization sequence (NLS) are located which are important for capsid 
assembly (88) but it is not known whether this NLS has a function for an incoming 
virus. There are also controversial data about the compartment in which uncoating 
(release of the viral genome out of the capsid) takes place and whether an intact 
capsid or only the DNA is shuffled into the nucleus. Some groups detected viral 
capsids inside the nucleus (13, 165). Xiao and colleagues observed a significant 
difference in the efficiency of nuclear translocation of the viral capsid dependent on 
presence or absence of a helper virus (200). In the absence of adenovirus, only the 
viral genome seems to be transported into the nucleus, while in presence of 
adenovirus, a shuffling of intact viral capsids into the nucleus was observed. By 
Single Virus Tracing directed motion (reminding of microtubule dependent 
movements) of viral capsids inside the nuclear area was also observed. The authors 
suggested that those particles move along nuclear invaginations that are continous 
with the cytoplasm. Studies with nocodazole which inhibited such directed motions 
strengthened this hypothesis (170). Recent studies showed no efficient transport of 
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intact viral capsids, but of viral genomes into the nucleus independent of the presence 
of a helper virus. Data were generated by taking advantage of a new confocal 
microscopic software which allowed a more precise localization of signals within the 
z axis (113). With this method the authors also detected capsids within nuclear 
invaginations confirming the hypothesis made by SVT studies.  
Another interesting aspect of AAV infection is the enhancement of 
transduction by proteasome inhibitors. This was shown for several serotypes in 
different cells (AAV-2 (44, 207), AAV-1-4 (72), AAV-5 (207)). An effect of 
proteasome inhibitors was also observed for AAV-2 in vivo in some organs from 
AAV treated mice: proteasome inhibitors augmented the transduction efficiency in 
lung from 0 to 10% and liver from 0.5 to 5% whereas inhibitors had no effect on 
transduction efficiency in muscle and heart muscle (44). Furthermore, it was shown 
that denaturated capsids of AAV-2 and AAV-5 are ubiquitinated in contrast to intact 
capsids which were no substrate for ubiquitination (44, 207). This suggests that only 
AAV capsids that passed the endosomal processing, and thereby underwent a 
conformational change, are accessible for ubiquitination (207). 
 
1.2.2.6. Latent or lytic cycle 
Upon nuclear entry, the presence or absence of a helper virus determines 
whether AAV enters a lytic or latent life cycle. In the absence of helper functions 
AAV enters a latent cycle which leads to integration of the viral genome into 
chromosome 19q13.4 (46). This locus is called AAVS1 (46, 103). Before viral 
integration, second strand synthesis and a basal expression of the Rep proteins are 
activated (22, 157). A complex of Rep78 and Rep68 was shown to bind to both, the 
Rep binding site (RBS) in the viral ITRs and to a homologous sequence in the 
AAVS1 locus, mediating thereby integration (109, 191).  
After super infection with a helper virus, the integrated AAV enters the lytic 
cycle, leading to viral gene expression, rescue and replication of the AAV genome 
with subsequent production of viral progeny (17). In the presence of a helper virus 
during AAV infection, induction of gene expression and replication takes place 
directly. 
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1.2.3. Tissue distribution of AAV isolates 
The isolation of new serotypes as well as the study of Gao and colleagues led 
to some important findings on molecular epidemiology of AAV in primate 
populations (57). This study included 479 non-human primate (NHP) tissues from 
258 animals of 7 different species and 259 human tissues from 250 individuals. For 
NHP, an average of 19% of tissue samples screened were positive for AAV, among 
which lymph nodes, liver, spleen and heart were the tissues where AAV sequences 
were most frequently found. Gao and colleagues assumed that the high frequency of 
AAV detection in lymphoid tissue may implicate the importance of co-infection with 
helper viruses such as adenovirus which often reside in these tissues. Serological 
analysis of NHP (Rhesus macaques, Cynomolgus macaques, Japanese and Pig-tailed 
macaques, Chimpanzees and Baboons) revealed a clear prevalence for AAV-7 and 
AAV-8. 
In the case of human tissue nearly the same frequency (18%) of integrated 
AAV sequences was detected among the analysed tissue. In contrast to the NHP 
study, AAV was not detected in lymph nodes and heart. However, this may be due to 
the limited amount of lymph node and heart samples. Tissues with a high frequency 
of integrated AAV sequences were bone marrow (39%), liver (33%), spleen (30%), 
small bowl (22%) and colon (15%). From their results, Gao and colleagues assumed 
that oral transmission is one of the common routes for AAV infection in humans.  
 
1.2.4. Immune responses to AAV 
AAV vectors have been shown to stably transduce many therapeutic targets in 
vivo in the absence of immunological sequelae (186). Yet, in a clinical trial of liver 
directed gene transfer this rule did not hold true (116). Parameters that determine 
these and similar occurrences have been proposed to be pre-existing immunity to 
AAV, the route of administration, the kinetics of expression, the dose, the vector 
serotype and its ability to transduce antigen-presenting cells (APCs) as well as host 
species and nature of the specific transgene product (186).  
Gene transfer vectors in general and AAV in particular are theoretically 
capable of activating all arms of the host immune system. For AAV most of the focus 
has been on its interaction with the adaptive immune system on both human and 
cellular level. Previous studies on AAV mediated activation of innate immunity 
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provide an insight into one of its most important strengths as a gene therapy vector: its 
apparent minimal pro-inflammatory potential (210). AAV does not appear to engage 
pattern recognition receptors such as toll-like receptors (TLRs) known to initiate such 
responses (81). The pro-inflamatory context or ‘signal zero’ is known to determine 
the many parameters of the immunological outcome. If AAV indeed is ale to evade 
detection by innate immunity’s sensors, the responses of the host should be quite 
blunted. However, further research is necessary to determine if this holds true.  
In regard to a humoral immune response, it is of notice that approximately 
80% of the human population has antibodies against the AAV-2 capsid. Furthermore, 
18%-35% of the population has AAV-2 neutralizing antibodies. This is indeed, one of 
the hurdles for AAV-2 based gene transfer (131). 
  
1.2.5. Production of recombinant AAV vectors 
The structural properties of the AAV capsid allow the production of 
recombinant viral particles that carry an up to approximately 4.5 kb long DNA 
molecule flanked by ITR sequences (183). The production protocol takes advantage 
of the ability of the two viral genes (rep and cap) and of the ITR sequences to 
accomplish their role in the replication of the viral DNA and in the packaging of 
mature virions even when provided to the host cell in trans on exogenous plasmids 
(108, 163). Therefore, transduction in a permissive cell of two plasmid species, one 
encoding the two viral ORFs (rep/cap plasmid), and the other coding for an 
exogenous DNA sequence flanked by ITR sequences (vector plasmid), leads to the 
production of viral particles containing a DNA molecule coding for the exogenous 
sequence flanked by the ITRs (Figure 5). Given the absence of the packaging 
sequences on the rep-cap coding plasmid, no contamination of wt virus will be present 
in the final viral preparation. Another requirement of this procedure is the 
concomitant action of a helper factor for the replication of the viral genome. This can 
be provided by co-infecting the cells with adenovirus. In this case however, the 
resulting viral preparation will contain adenovirus progeny. Adenovirus free AAV 
preparations can be obtained by providing the helper function as a third plasmid that 
contains the essential Ad helper genes (E4, VA and E2a) but lacks the Ad structural 
and replication genes (29, 67, 201). AAV viral progeny can be harvested 48 h p.i. by 
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lysing the transfected cells and purified to high titers by one of several described 
protocols (2, 3, 8, 29, 55, 59, 68, 91, 94, 110, 124, 125, 160, 184, 188, 201, 211). 
 
 
Figure 5. Schematic representation of the rAAV production protocol. Progeny capids carry the 
DNA sequence comprised between the ITR sequences of the vector plasmid. The resulting vector 
preparation is devoid of wt AAV and of adenovirus particles. Kindly provided by Dr. Luca Perabo. 
 
The traditional method used to purify AAV from infected or transfected cells 
has been density equilibrium gradients (cesium chloride, CsCl) (162). Because cesium 
atoms are heavy, concentrated solutions of CsCl can form density gradients after only 
a few hours of ultracentrifugation. This method allows the physical separation of full 
particles (AAV packaging a genome) from empty particles based on their differences 
in density but it has several disadvantages. Two or three rounds of CsCl 
centrifugation must be carried out to get purified AAV. Dialysis of CsCl fractions 
containing AAV against a physiological buffer is necessary prior to in vivo use 
because CsCl can exert toxic effects on animals in the study. Furthermore, it has also 
been shown that, even after CsCl purification, 1% of the input infectious Ad and/or 
Ad proteins can still be found as contaminates.  
These limitations led to the development of an immunoaffinity column to 
purify AAV-2 particles (67, 193). This approach makes use of the monoclonal 
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antibody A20 which recognizes assembled AAV-2 capsids but not unassembled 
capsid proteins. Despite the low recovery (70%) and purity (80%) of the eluted 
particles, this method allows a fast and easy preparation of AAV-2 stocks from a cell 
homogenate. 
Zolotukhin and colleagues developed a novel way of purifying rAAV from 
crude lysates that involved the use of iodixanol gradients and heparin column 
purification (211). To purify rAAV utilizing iodixanol, step gradients of 15%, 25%, 
40%, and 60% were generated and the crude lysate was placed on top of the 15% step. 
After an hour of centrifugation, the majority of the rAAV bands were within the 40% 
density step. Approximately 75–80% of the rAAV in the crude lysate is recovered in 
the iodixanol fraction. For further purification after isolation of rAAV from iodixanol 
gradients, heparinized columns were used. HPLC chromatography utilizing UNO-S1 
heparin columns was capable of yielding a rAAV product that is greater than 99% 
pure based on polyacrylamide gel electrophoresis and silver staining. A five-fold 
higher recovery of rAAV particles and a greater than 100-fold increase in infectivity 
was obtained using this method of purification when compared to the traditional CsCl 
gradient purification. The main disadvantage to using this system of purification is 
that AAV must have the ability to bind heparin/HSPG. 
Recently, methods have been developed that have the ability to purify all 
AAV serotypes by utilizing ion exchange chromatography (55, 93, 151). Of notice is 
the work of Qu and colleagues (151).  They separated empty capsids from genome 
containing capsids by making use of the less anionic character of empty particles. 
AAV-2 vector purification and particle separation using a cation exchange resin 
followed by an anion exchange resin allowed a yield of 74% with 86-fold reduction in 
empty capsids. 
In summary, numerous methods have been developed for the production and 
purification of AAV that are focused on acquiring high vector yields free from 
contaminating cellular and helper virus proteins and are amenable to scaling up for 
human clinical trials. Needless to say, as better methods are developed for generating 
high yields of rAAV, better methods of purification must be generated to acquire 
them in pure form. In addition, the biotechnology industry is building upon these 
numerous methods to produce rAAV by scaling up production utilizing large 
bioreactors containing liters of media and suspension cells, resulting in log increases 
of vector yield over the conventional small-scale methods described above.  
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1.3. Targeting vectors 
AAV-2’s broad host range theoretically allows application of AAV-2 vectors 
for a variety of diseases but is at the same time a drawback in terms of safety since 
tissues or organs different from the target may be transduced when, after local 
application viral vectors are transported away from the target tissue into the body. 
Although tissue specific regulation can be achieved by using cell type specific 
promoters, systemic applied AAV-2 based vectors will accumulate in the liver. Thus, 
they will not be able to transduce other organs.  
One possibility to overcome this limitation is the generation of receptor/tissue 
specific vectors. To do this, viral particles containing a selective receptor binding 
domain have to be engineered. This enables a stringent interaction with a receptor 
specific of the targeted cell (vector re-targeting). Besides this selective infectivity, a 
second advantageous aspect of targeting is the possibility to generate vectors that are 
able to transduce cell types which are refractory to infection with natural occurring 
AAVs.  
 
1.3.1. Genetic capsid modifications 
In a genetic or direct targeting approach, cell-specific targeting of the vector is 
mediated by a ligand that is genetically/directly inserted into the viral capsid. When 
the first attempts were made to target AAV, the three dimensional structure of the 
capsid was still unknown. Thus, it was hard to predict where to insert a peptide ligand 
without interfering with capsid assembly and stability while displaying the ligand on 
the capsid surface in order to mediate binding to the desired receptor.  
Antibodies have proven to be an excellent paradigm for the design of high-
affinity, protein-based binding reagents. Although the general structure of all 
antibodies is very similar, a small region at the tip of the protein is extremely variable, 
allowing millions of antibodies with slightly different tip structures to exist. This 
region is known as the hypervariable region (Figure 6A). Each of these variants can 
bind to a different target, known as an antigen. Recently, recombinant monoclonal 
antibodies (mAbs) have been dissected into minimal binding fragments, rebuilt into 
multivalent high-avidity reagents and fused with a range of molecules limited only by 
imagination (Figure 6B)(85). 
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A)     B) 
 
Figure 6. Antibody and antibody fragments. A) Schematic representation of an intact ‘classic’ IgG 
molecule. B) A variety of antibody fragments are depicted, including Fab, scFv, single domain VH and 
multimeric formats, such as minibodies, bis-scFv, diabodies, triabodies, tetrabodies, and chemically 
conjugated Fab’ multimers (sizes given in kilodaltons are approximate). (85)  
 
Thus, it is not surprising that the first re-targeting ligand genetically fused to 
an AAV capsid was an antibody fragment (208). Yang and colleagues started by using 
three independent plasmids for expression of VP1, VP2 and VP3 respectively. 
Independent transfections with the respective plasmids resulted in a VP1:VP2:VP3 
ratio of 1:1:1 – expression of a wt AAV encoding plasmid results in a 1:1:10 ratio. 
They then inserted a single-chain antibody against human CD34 (a cell surface 
molecule expressed on haematopoietic progenitor cells) at the N-termini of VP1, VP2 
and VP3, and showed that all three fusion proteins were expressed. Furthermore, 
while transfections with VP1 and VP2 only plasmids still resulted in the expression of 
wt VP3, transfections with scFv-VP1 and scFv-VP2 did not. Recent studies have 
shown that VP3 is essential for capsid assembly (189). Thus, co-transfection with 
VP1, VP2 and VP3 only plasmids - with wt VP3 being expressed from the three used 
plasmids - resulted in detectable AAV-2 particles. When substituting one VP by a 
scFv-VP  - which did not show expression of wt VP3 – no particles were detected. 
The authors solved this problem by co-transfecting cells with the three wt VP 
encoding plasmids and one scFv-VP encoding plasmid in addition. Although this 
approach provided the first demonstration that targeting of AAV-2 by direct 
modification of the capsid is possible, vector titers were extremely low. Furthermore, 
mutants were more efficient in transduction of non-target cells than in transduction of 
target cells. In contrast to this first attempt, several recent reports have shown that 
fusions to the N-terminus of VP1 or VP2 can be incorporated into the AAV capsid 
without the need to provide wildtype VP1 (aa 34 (198)) or VP2 (113, 189)). In two 
examples, fusion of GFP to the N-terminus of VP2 yielded GFP-tagged viruses that 
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have been used to visualize AAV infectious pathway (113, 189). Furthermore, it was 
recently shown that the VP1 and probably VP2 N-terminal domains can translocate 
from the inside to the outside of the capsid (model is depicted in Figure 7) (105).  
Recently, in two different approaches, two different scFvs were inserted in the 
capsid of adenovirus type 5. In one, the wt Ad5 fiber-knob was substituted by an 
optimized fiber-fibritin chimera that was genetically fused to a scFv (79). Although 
transduction of target cells was superior to the one achieved with the wt Ad5, when it 
came to non-target cells, scFv targeting mutant and wt Ad5 were equally efficient. 
Thus, although targeting was achieved, de-targeting was not. Furthermore, the 
potential of this vector was not demonstrated in vivo. In the second approach using 
Ad5, a scFv was fused to the minor capsid protein IX via a 75-Ångström spacer 
sequence (187). Binding to the antigen was demonstrated but transduction of target 
cells was not shown due to the nature of the receptor (β-galactosidase).  
In addition, one or two residues downstream from the N-terminal methionine 
of the AAV-2 VP2 start codon have been used for insertions (aa 138 (111, 189, 198) 
and 139 (171)). Since VP1 is an N-terminal extension of VP2, insertions at positions 
138 and 139 are displayed within VP1 and VP2 (Fig. 7). The most abundant capsid 
protein, VP3, remains unmodified. Insertions as large as 32 amino acids were 
tolerated with only marginally lower packaging efficiencies (111). Larger insertions 
like the rat fractalkine chemokine domain (76 aa) or the human hormone leptin (146 
aa) inserted at aa position 138 decreased VP3 expression, which prevented capsid 
assembly (189). Providing additional VP3 in trans (by a VP3- encoding plasmid) 
restored capsid assembly with a remaining 5-log decrease in infectivity (189). 
 
 
Figure 7. Model of the VP1 N-terminus translocation. A part of an equatorial slice of an AAV-2 
capsid where the N-terminal stretch of the VP1 protein (green) was modeled and linked to one of the 
two VP3 subunits (blue) at the twofold symmetry axis is illustrated. On the right side,  partial defolding 
of the VP1 N-terminus which allows its exposure on the capsid surface through a channel at the 
fivefold symmetry axis (105). 
 
 32 
The first successful demonstration that a genetic capsid modification (direct 
targeting) by insertion of peptides into a common region of all three AAV capsid 
proteins can be used to re-target AAV-2 was described by Girod and colleagues in 
1999 (62). By sequence alignment of AAV-2 and CPV, from which the three 
dimensional structure was known at the time, six sites (amino acid positions 261, 381, 
447, 534, 573, 587) were expected to be exposed on the surface of the viral capsid and 
be able to accept the insertion of a ligand without disrupting functions essential for the 
viral life cycle. This was indeed true for one of the positions, 587. In the meantime 
587 and the neighboring position 588, described by Bartlett and colleagues in 2003 
(172), have evolved as the most often used sites for insertion of small peptides (up to 
34 aa) (66, 128, 130, 139, 172, 192, 196, 197). In all these cases, the inserted ligand, 
exposed on the capsid surface was able to mediate the transduction of the respective 
targeting cells. Already five examples of a successful targeting after in vivo 
application of targeting vectors have been described, revealing the potential of this 
technology (local application (172) and systemic (128, 192, 196)). Besides 587/588 
other sites (e.g. amino acid position 34, 161, 261, 328, 381, 447, 448, 459, 522, 534, 
553, 573, 584, 591, 664) have been exploited as peptide insertion sites within the 
AAV cap ORF, but have not been proven to mediate infection of the target cell (61, 
62, 66, 171, 198). Recently, a double mutant containing the RGD4C motif in 520 and 
584 has been created (174). Genomic titers obtained for virions displaying the double 
insertions were ~ 2x107 per ml. Although this titer was only 3- to 4-fold lower than 
titers obtained by the authors for their wild-type preparation, the titers are very low in 
comparison to others (62, 64, 135, 189). The double mutant was unable to bind to 
heparin and transduced the wild-type AAV-2 refractory cell lines SKOV3ip and 
C2C12. However, the comparison between double and single insertion mutants with 
regard to transduction efficiencies is not provided, which renders it impossible to 
judge if a double insertion shows a superior targeting efficiency. In all these studies 
target cells were refractory or hard to transduce by AAV-2 with wild-type capsid and 
targeting resulted in an improved efficiency. But to achieve a real targeting (= 
redirected tropism) the natural receptor binding has to be eliminated. Of interest in 
this regard is the fact that insertions at 587/588 are likely to interfere with the binding 
of two (R585 and R588) of the five positive charged amino acids of the described 
AAV-2 HSPG binding motif (97, 135), explaining the ablation of HSPG binding of 
some targeting vectors. However, in some cases binding is only partially affected or 
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even restored by the inserted peptide. Using our AAV peptide library (see next 
section) separated by heparin affinity chromatography into a pool of AAV capsid 
mutants able to (binder pool) or unable to bind heparin (non-binder pool) we were 
able to propose the following model (141): insertion of bulky or negative charged 
peptides resulted in AAV capsid mutants unable to bind to heparin/HSPG due to 
sterical or charge interference. If the peptide consists of small residues like G and A, 
the insertion is less invasive and the structure of the natural HSPG binding motif 
maintained functional. Insertion of positively charged peptides could lead to an HSPG 
binding phenotype by reconstituting a binding motif with one of the original arginines 
or independently from them.  
The ability of a targeting mutant to infect cells independently of HSPG also 
influences its in vivo distribution. We could show that the inability to bind to HSPG 
correlated with liver and spleen de-targeting after systemic application in mice (141). 
Thus, the in vivo targeting ability of a vector is increased if HSPG-dependent 
retention of vectors in liver and spleen is avoided either by the use of non-HSPG-
binding peptides or the use of a non-binder AAV peptide library for selection of 
cell/tissue specific targeting vectors.  
Stachler and colleagues expanded the targeting field to other AAV serotypes 
(179). In this approach, amino acid position 590 of AAV serotype 1 was used for the 
insertion of the RGD-4C peptide. The respective targeting vector reached remarkable 
higher transduction levels than unmodified AAV-1 on HUVEC, HSaVEC and HeLa 
C12 and transduction could be competed by the addition of soluble RGD containing 
peptides. They have then combined this RGD-4C insertion at amino acid position 590 
of AAV-1 with VPs of AAV-1 containing the sequence of a biotin acceptor peptide. 
These hybrid virions utilized the targeting peptide for endothelial cell entry, while the 
biotin acceptor peptide was used for purification on monomeric avidin affinity 
columns. 
 
1.3.1.1. Peptide libraries 
Depending on their amino acid composition certain peptide insertions may 
interfere with the stability of the capsid or with the infectious process. Furthermore, 
the inserted peptides might be expressed in a non-functional structure when inserted 
in the capsid context. In addition, insertion of a particular sequence for targeting a 
 34 
desired cell type requires receptor-specific binding peptides, which are unknown for a 
large number of clinically interesting tissues. An elegant solution to these problems is 
the use of combinatorial engineering of the capsid and high-throughput selection 
protocols to screen mutants with desired phenotype (see Figure 8). Using an AAV 
library of capsids carrying a random insertion at amino acid position 587 (139) or 588 
(128), an efficient re-targeting to various cell types in vitro and in vivo has been 
achieved. 
 
 
Figure 8. AAV display libraries. Schematic representation of the construction of the library of AAV-
2 capsid modified particles and selection protocol for the isolation of retargeted mutants. A pool of 
randomly generated oligonucleotides was cloned into an AAV-2 genome encoding plasmid at the site 
corresponding to amino acidic site 587 of capsid protein VP1. Following a standard AAV production 
protocol, a library of approximately 4 x 106 diferent capsid modified AAV-2 clones can be generated. 
For the selection of retargeted mutants, target cells were co-infected with the pool of AAV-2 mutants 
and with adenovirus. The viral progeny collected 48 hrs p.i. was used for the next infection round. 
 
Briefly, Perabo and colleagues performed five rounds of selection with an 
AAV peptide library on MO7e, a megakaryocytic cell line, and Mec1, which are 
derived from B-cell chronic lymphocytic leukemia (BCLL) cells in prolymphoid 
transformation (139). Both cell lines are non-permissive for wild type AAV-2. In two 
separate selections they isolated RGD containing peptides (RGDAVGV and 
RGDTPTS) from the MO7e selections able to convey cell transduction, whereas two 
totally different peptides were selected on Mec1 (GENQARS and RSNAVVP). In 
transduction experiments performed with rAAV vectors displaying the selected 
peptides on the capsid surface they observed an up to 100-fold increased efficiency. 
Competition studies proofed receptor-specificity. Furthermore, one of the mutants 
selected on Mec1 was able to transduce primary B-CLL cells (up to 54%) which are 
refractory to AAV-2 infection. Muller and colleagues applied a similar approach for 
the selection of peptides able to mediate the transduction of human coronary artery 
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endothelial cells (128). Most of the selected peptides fitted into the consensus 
sequence NSVRDLG/S and NSVSSXS/A and showed remarkably higher transduction 
levels than AAV-2 with unmodified capsid on the target cells. Furthermore, one of the 
peptides (NSSRDLG) enabled heart transduction after systemic application whereas 
only a weak transduction was observed with unmodified AAV-2 (128). 
 
1.3.1.2. Combinatorial approaches to improve AAV vectors 
Combinatorial approaches utilizing AAV libraries consisting of AAV variants 
with point mutations scattered through wide parts of the capsid have been recently 
applied in the AAV field to improve in vivo application of AAV vectors (115, 140). 
Masheshri and colleagues used a combination of DNA shuffling and error prone PCR, 
whereas Perabo and colleagues used simply error prone PCR to introduce these 
mutations into the cap ORF. From these plasmids AAV capsid variants are generated 
by packaging. To prove the potential of combinatorial libraries and in vitro evolution, 
both groups focused their selections on the identification of AAV variants that escape 
neutralization by anti-AAV-2 antibodies. When recombinant AAV vectors carrying 
the selected mutations in the capsid were analyzed for the immune escaping ability up 
to 5.5-fold higher N50 (amount of serum needed to halve the number of transduced 
cells) values than the corresponding N50 value obtained for AAV-2 with wild-type 
capsid was determined. As mentioned, also the selection performed by Masheshri and 
colleagues aimed to isolate AAV variants able to evade AAV-2 neutralizing 
antibodies (115). They used a serum generated in rabbits by injection of recombinant 
AAV-2 into hind limb muscle. Sequence analysis of these and other mutants 
identified N587I in addition to T716A as key mutations for immune escaping.  In in 
vivo experiments, in which selected AAV variants were incubated with neutralizing 
serum prior to muscle injection 1 to 3 log higher expression levels were determined in 
comparison to AAV-2 with wild-type capsid. That the position 587 is involved in 
recognition by neutralizing antibodies is in agreement with observations made by 
Huttner and colleagues (89). They could show that peptide insertions at this position 
resulted in AAV targeting mutants able to transduce their target cells even in the 
presence of human neutralizing anti-AAV-2 antibodies. The position 716 has not been 
described before although it lies within an already described immunogenic region 
(127). Interestingly, AAV-4, which is able to escape anti-AAV-2 antibodies, displays 
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an alanine at this position. In all the mentioned reports, engineered mutants achieved 
higher transductions values in the presence of neutralizing Ab when compared to wt 
AAV-2. Still, this does not mean that the achieved transductions were the result of a 
lower affinity of the neutralizing Ab. Indeed, such capsid modifications may have 
improved other steps in the transduction process (receptor binding, internalization, 
trafficking, etc…) that lead to a higher transduction efficiency in the presence of 
antibodies. 
 
1.3.2. Non-genetic capsid modifications 
The non-genetic targeting approach utilizes an associated molecule which 
mediates the interaction between the viral surface and a specific cell surface molecule. 
Until now, two different non-genetic approaches have been described for AAV (12, 
146). A bispecific antibody displaying affinities for αIIbβ3 integrin (AP-2 antibody 
part) and the intact AAV-2 capsid (A20 antibody part) was used by Bartlett and 
colleagues to bind rAAV-2 to fibrinogen on MO7e and DAMI cells, which are not 
permissive for wild-type AAV-2 infection (12). The binding is likely to induce a 
receptor-mediated endocytosis and resulted in transduction efficiencies 70-fold above 
background (12). Ponnazhagan and colleagues described another way of indirect 
targeting which is based on the strongest interaction known in nature, avidin/biotin 
(146). They generated a prokaryotic expression vector that expressed a fusion protein 
consisting of the core sequence of streptavidin linked via an eight amino acid linker to 
epidermal growth factor (EGF). The fusion was produced in and purified from E. coli. 
AAV-2 preparations were biotinylated in vitro and incubated with the fusion protein, 
whereby the streptavidin moiety mediated binding to the AAV-2 capsid and the EGF 
ligand targeted the EGF receptor. An identical strategy was used to target FGFR1. 
Transduction of AAV-2 via EGFR in an ovarian cancer cell line (SKOV3ip1) was 
enhanced by 100-fold in comparison to non-modified AAV-2. On the EGFR negative 
cell line MB-453, no difference between modified and non-modified AAV-2 was 
observed indicating that the targeted AAV-2 vector still retained its native tropism. 
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1.3.3. Combining genetic and non-genetic capsid 
modifications 
Inspired by an earlier attempt with Sindbis virus (133, 134), Ried and 
colleagues tried to develop a general targeting vector using a truncated 34 amino-acid 
peptide, Z34C (180), from protein A of Staphylococcus aureus (159). Protein A 
recognizes and binds the Fc part of immunoglobulins (Ig), but not the variable Ig 
domain, which therefore remains free to bind the antigen. Coupling this vector, 
rAAV-587Z34C, with antibodies against CD29 (β1-integrin), CD117 (c-kit-receptor) 
or CXCR4 resulted in a specific, antibody-mediated transduction of haematopoietic 
cell lines. However, transduction levels were low revealing that a universal AAV 
targeting vector can be generated and loaded with different targeting molecules to 
transduce the desired cells via specific receptors, but that further refinements are 
necessary to make this technique attractive for clinical applications. Arnold and 
colleagues evolved another possibility of a universal targeting vector. They 
introduced a biotin acceptor peptide into the AAV capsid protein of AAV-1 at 
position 520, which becomes biotinylated during packaging. Introduction of the same 
sequence within the capsid of AAV-2 to AAV-5 was less efficient. The modified 
vector was able bind to a rat glioma cell line, BT4C, transfected to express an 
artificial biotin receptor. The inserted biotin acceptor peptide can in principle be used 
to couple peptide ligands to the AAV capsid, however, this has not been shown. 
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2. Objectives 
Adeno-associated virus (AAV), discovered in 1965 is a member of the 
Parvoviridae family and belongs to the Dependovirus genus. This virus has received a 
large interest as a vector for gene therapy since it was first cloned into a bacterial 
plasmid in 1982. After more than 25 years and a large number of publications, AAV 
and gene therapy have finally entered the long development phase that is necessary 
for their maturation.  
For the design of safe and efficient gene therapy most approaches require the 
delivery of the genetic material to specific cells after in vivo administration. Thus, 
development of specific targeting vectors is one of the first keys for successful gene 
therapy. Most AAV-2 targeting approaches are based on the insertion of peptide 
ligands on the AAV-2 capsid after amino acid position 587. Such insertions have 
resulted in vectors with modified in vivo tropism.  
Discovery of position 587 was made by sequence alignment of AAV-2 with 
CPV (from which the three dimensional structure was known) (62). Other reported 
positions have not made use of the available three dimensional structure of AAV-2. 
Thus, today, with the three dimensional structure of AAV-2 in hand, we intend to use 
in silico analysis to identify a more prominent position and to explore its potential for 
the development of AAV-2 based targeting vectors. Ablation of wild type tropism 
will be made by previously shown amino acid substitutions (97, 135). Position 587 
will be used as a reference and mutants with insertions at both positions will be tested. 
Known small peptide ligands will be inserted and respective mutants analyzed. After 
assessing that insertions at 453 do not interfere with any essential viral function the 
mutants will be assayed for their capacity to bind the target receptor in cell free based 
assays, to specifically transduce cells in vitro and for their in vivo tropism. 
To the present, only a few number of reports have shown in vivo specific gene 
transfer using AAV-2 targeting vectors based on small peptide insertions. Although 
efficient in the modification of viral tropism such small peptides are usually still able 
to bind a wide variety of receptors. Moreover, in several cases, the acceptor molecules 
are found on various cell types.  Thus, the first report – 1998 – on the development of 
an AAV-2 targeting vector made use of an antibody fragment (208). Antibodies are 
amongst the most specific, well studied and easy to use molecules. Despite the huge 
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potential of antibody molecules and of the large number of publications involving 
AAV targeting vectors only 3 reports combined AAV and antibody molecules for 
vector targeting. All the mentioned reports failed to present in vivo results. Recently 
in our group, a GFP-VP2 fusion protein was incorporated into the AAV-2 capsid 
without the need to supply wt VP2. Thus, this, together with the possibility to use 
well studied single chain antibody fragments as well as the tools required for their 
characterization from our institute colleagues makes us embrace the design of scFv 
directed AAVs. Constructs with different spacer sequences between the scFv and the 
VP2 as well as different scFvs will be used. Also here, known amino acid mutations 
will be used to ablate wild type tropism. Particles will be assessed for their capacity to 
incorporate the fusion protein without affecting any essential viral function. Anti-
idiotypic antibodies against the paratope will be used to identify functional scFvs. 
Receptor positive cell lines will be used and once specific in vitro transduction is 
determined the vectors will be administrated in vivo using appropriate mouse models. 
In summary, this work main objective is the establishment and assessment of 
new rationally designed basic tools for the development of AAV-2 targeting vectors. 
Such tools can be transferred to the development of other vector systems. 
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3. Materials 
3.1. Chemicals, solutions and enzymes 
Table 1 Substances and suppliers 
Substance Supplier 
Agarose Sigma, Deisenhofen, Germany 
Ampicillin Sigma, Deisenhofen, Germany 
Aqua bidest. Millipore, Billerica, Germany 
Biotin Conjugate Streptavidin Dianova, Hamburg, Germany 
Bovine Serum Albumine AppliChem, Darmstadt, Germany 
D-MEM Medium Invitrogen Corporation, Germany 
DNA restriction enzymes MBI Fermentas GmbH, St. Leon-Rot, Germany 
Etidium bromide Roth, Karlsruhe, Germany 
Fetal Calf Serum Invitrogen Corporation, Karlsruhe, Germany 
Heparin  B. Braun Melsungen AG, Germany 
HEPES  Roth, Karlsruhe, Germany 
Iodixanol Sigma, Deisenhofen, Germany 
MassRuler DNA Ladder Mix MBI Fermentas GmbH, St. Leon-Rot, Germany 
McCoy’s 5A Medium Invitrogen Corporation, Germany 
Methanol Roth, Karlsruhe , Germany 
Sodium Chloride Riedel-de Haën, Seelze, Germany 
Sodium Dodecyl Sulfate (SDS)                         Merck, Darmstadt, Germany 
PAA Medium PAA Laboratories GmbH, Pasching, Austria 
PBS    Invitrogen Corporation, Karlsruhe, Germany 
Penicillin/Streptomycin Invitrogen Corporation, Karlsruhe, Germany 
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Peptides: GRGDS, GNGRS, 
 GRGES 
Bachem, Bubendorf, Swiss 
Precision Plus Protein  
Gel Color Standards 
Bio-Rad Laboratories GmbH, München, 
Germany 
Proteinase K                                                   Merck, Darmstadt, Germany 
RNase A (100 mg) Roche Diagnostics GmbH, Mannheim, 
Germany 
RPMI 1640 Medium Invitrogen Corporation, Germany 
Tris Merck, Darmstadt, Germany 
TritonX-100 Sigma, Deisenhofen, Germany 
Trypsin-EDTA                                               Invitrogen Corporation, Karlsruhe, Germany 
Tween20                                                      Merck, Darmstadt, Germany 
 
If not mentioned the chemicals were bought to Sigma-Aldrich, Taufkirchen, 
Germany; Merck, Darmstadt, Germany or Carl Roth GmbH & Co., Karlsruhe, 
Germany. 
 
3.2. Plasmids 
pRC: AAV based helper plasmid containing the AAV-2 Rep and Cap coding 
regions under the control of the wt promoters but lacking the viral ITRs (62). 
 
pXX6-80: encodes for the Adenoviral genes VA, E2A and E4. Kindly 
provided by RJ Samulski (201). 
 
ssGFP: GFP gene controlled by the human cytomegalovirus (CMV) promoter 
and hygromycin resistance gene controlled by the thimidine kinase promoter flanked 
by the AAV ITRs (71). 
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scGFP: GFP gene controlled by the CMV promoter; a deletion in the terminal 
resolution sites interferes with strand displacement resulting in a self complementary 
genome, which is packaged into the viral capsid (72). 
 
pRC A2: contains the AAV-2 Rep and Cap encoding regions just like pRC; 
R585 and R588 (VP1 numbering) are mutated to alanines for elimination of the 
HSPG binding ability. 
 
pRC VP2 ko: contains the AAV-2 Rep and Cap encoding regions just like 
pRC; the start codon of VP2 – ACG - was mutated to ACC. 
 
pRC VP2 ko A2: contains the AAV-2 Rep and Cap encoding regions just like 
pRC; the start codon of VP2 – ACG - was mutated to ACC; R585 and R588 (VP1 
numbering) are mutated to alanines for elimination of the HSPG binding ability. 
 
pRGD4C-587: contains the AAV-2 Rep and Cap encoding regions just like 
pRC; the RGD4C peptide – ACDCRGDCFCA – is inserted between N587 and R588. 
 
pRGD4C-453: contains the AAV-2 Rep and Cap encoding regions just like 
pRC; the RGD4C peptide – ACDCRGDCFCA – is inserted between G453 and T454. 
 
pRGD4C-453&587: contains the AAV-2 Rep and Cap encoding regions just 
like pRC; the RGD4C peptide – ACDCRGDCFCA – is inserted between N587 and 
R588 and between G453 and T454. 
 
pRGD4C-587 A2: contains the AAV-2 Rep and Cap encoding regions just 
like pRC; the RGD4C peptide – ACDCRGDCFCA – is inserted between N587 and 
R588; R585 and R588 (VP1 numbering) are mutated to alanines for elimination of the 
HSPG binding ability. 
 
pRGD4C-453 A2: contains the AAV-2 Rep and Cap encoding regions just 
like pRC; the RGD4C peptide – ACDCRGDCFCA – is inserted between G453 and 
T454; R585 and R588 (VP1 numbering) are mutated to alanines for elimination of the 
HSPG binding ability. 
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pRGD4C-453&587-A2: contains the AAV-2 Rep and Cap encoding regions 
just like pRC; the RGD4C peptide – ACDCRGDCFCA – is inserted between N587 
and R588 and between G453 and T454; R585 and R588 (VP1 numbering) are 
mutated to alanines for elimination of the HSPG binding ability. 
 
pNGRI-587: contains the AAV-2 Rep and Cap encoding regions just like 
pRC; the RGD4C peptide – ACVLNGRMECA – is inserted between N587 and R588. 
 
pNGRI-453: contains the AAV-2 Rep and Cap encoding regions just like 
pRC; the RGD4C peptide – ACVLNGRMECA – is inserted between G453 and T454. 
 
pNGRI-453&587: contains the AAV-2 Rep and Cap encoding regions just 
like pRC; the RGD4C peptide – ACVLNGRMECA – is inserted between N587 and 
R588 and between G453 and T454. 
 
pNGRI-453-A2: contains the AAV-2 Rep and Cap encoding regions just like 
pRC; the RGD4C peptide – ACVLNGRMECA – is inserted between G453 and T454; 
R585 and R588 (VP1 numbering) are mutated to alanines for elimination of the 
HSPG binding ability. 
 
pGEN-587: contains the AAV-2 Rep and Cap encoding regions just like pRC; 
the RGD4C peptide – AGENQARSA – is inserted between N587 and R588.  
 
pGEN-453: contains the AAV-2 Rep and Cap encoding regions just like pRC; 
the RGD4C peptide – AGENQARSA – is inserted between G453 and T454. 
 
pGEN-453-A2: contains the AAV-2 Rep and Cap encoding regions; the 
RGD4C peptide – AGENQARSA – is inserted between G453 and T454; R585 and 
R588 (VP1 numbering) are mutated to alanines for elimination of the HSPG binding 
ability. 
 
pGFP-VP2: encodes the C-terminal fusion of eGFP with the N-terminus of 
VP2 from AAV-2 under the control of the CMV promoter. 
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pRSV-HRS3: encodes the anti-CD30 scFv HRS3 (49). 
 
paCD30-GFP-VP2: encodes the C-terminal fusion of RSV-HRS3 to the N-
terminus of the GFP-VP2 fusion under the control of the CMV promoter. 
 
paCD30-GFP-VP2-A2: encodes the C-terminal fusion of RSV-HRS3 to the N-
terminus of the GFP-VP2 fusion under the control of the CMV promoter; R585 and 
R588 (VP1 numbering) are mutated to alanines for elimination of the HSPG binding 
ability. 
 
paCD30-VP2-A2: encodes the C-terminal fusion of RSV-HRS3 to the N-
terminus of the VP2 from AAV-2 under the control of the CMV promoter; R585 and 
R588 (VP1 numbering) are mutated to alanines for elimination of the HSPG binding 
ability. 
 
paCD30CLVP2-A2: encodes the C-terminal fusion of RSV-HRS3 to the N-
terminus of the VP2 from AAV-2 under the control of the CMV promoter; a 
glycine/serine linker - SSGGGGSGGGGSGGGGS -  is inserted between RSV-HRS3 
and VP2; R585 and R588 (VP1 numbering) are mutated to alanines for elimination of 
the HSPG binding ability. 
 
paCD30CL2VP2-A2: encodes the C-terminal fusion of RSV-HRS3 to the N-
terminus of the VP2 from AAV-2 under the control of the CMV promoter; a double 
glycine/serine linker - SSGGGGSGGGGSGGGGSDPSSGGGGSGGGGSGGGGS -  
is inserted between RSV-HRS3 and VP2; R585 and R588 (VP1 numbering) are 
mutated to alanines for elimination of the HSPG binding ability. 
 
paCD30GLVP2-A2: encodes the C-terminal fusion of RSV-HRS3 to the N-
terminus of the VP2 from AAV-2 under the control of the CMV promoter; the non-
globular C-terminal part of eGFP that is fused to VP2 in the GFP-VP2  - ITLGMDEL 
-  is inserted between RSV-HRS3 and VP2; R585 and R588 (VP1 numbering) are 
mutated to alanines for elimination of the HSPG binding ability. 
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paCD30LGLVP2-A2: encodes the C-terminal fusion of RSV-HRS3 to the N-
terminus of the VP2 from AAV-2 under the control of the CMV promoter; the non-
globular C-terminal part of eGFP that is fused to VP2 in the GFP-VP2  - ITLGMDEL 
-  is inserted between RSV-HRS3 and VP2; a glycine/serine linker - 
SSGGGGSGGGGSGGGGS -  is inserted between RSV-HRS3 and GLVP2 fusion; 
R585 and R588 (VP1 numbering) are mutated to alanines for elimination of the 
HSPG binding ability. 
 
pKaCD30-VP2: encodes the C-terminal fusion of RSV-HRS3 to the N-
terminus of the VP2 from AAV-2 enhanced by the Kozak consensus – 
GCCACCATGG  – under the control of a CMV promoter; R585 and R588 (VP1 
numbering) are mutated to alanines for elimination of the HSPG binding ability. 
 
pCA19.9scFv: encodes an anti-CA19.9 scFv (83). 
 
pCA19-GFP-VP2-A2: encodes the C-terminal fusion of CA19.9scFv to the N-
terminus of the GFP-VP2 fusion under the control of the CMV promoter; R585 and 
R588 (VP1 numbering) are mutated to alanines for elimination of the HSPG binding 
ability. 
 
pBW431-26-scFv: encodes the anti-CEA scFv BW431-26 (86, 87). 
 
paCEA-GFP-VP2-A2: encodes the C-terminal fusion of BW431-26-scFv to 
the N-terminus of the GFP-VP2 fusion under the control of the CMV promoter; R585 
and R588 (VP1 numbering) are mutated to alanines for elimination of the HSPG 
binding ability. 
 
3.3. Primers 
All sequences are listed in 5’-3’ orientation. All oligonucleotides were 
manufactured by MWG-Bioteck AG, Ebersberg, Germany. 
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Table 2 Primers.   
Primer Sequence (5' - 3') 
OP1 RC TACCAGCACGGTTCAGGTGTT 
OP2 RC ACACGCCATTAGTGTCCACAG 
OP1 GL TTTGCTTACTGGGGCCAAGG 
OP1 OS CCTACTTGGCAGTACATCTACG 
OP1 19 CCGTCTAGAGCCCAGGTCAAGCT 
OP2 GL GTCTTTGCCAGTCACGTGGT 
OP2 OS TCCGAACGTGAGAGGATAGG 
OP2 19 CCTAGATCTCCCGTCCGAGGAAACTCA 
IP1 A2 TACCAACCTCCAGCAGGCAACGCACAAGC 
IP1 A2 TACCAACCTCCAGCAGGCAACGCACAAGC 
IP1 RGD4C 
587 A2 
TGCCGCGGAGACTGCTTCTGTGCGGCACAAGCAGCTACCGC
AG 
IP1 RGD4C 
453&587 
CACCTCAATGGCAGAGACTCTCTGGTGAAT 
IP1 
GEN(A) 
GAGAACCAGGCGCGTTCCGCAGCGACCACCACGCAGTCAA 
IP1 GL ATCACTCTCGGCATGGACGAGCTGTACAAGTACTCAGATCC
TCCGGG 
IP1 CL GAGGCGGTGGGTCATACAAGTACTCAGATCCTCCGGG 
IP1 OS AGCGCTACCGGTCGCCACCATGTCTAGAATGGC 
IP1 K1 TCATAATGGTGTCTAGAATGGCCCAGG 
IP1 K GCCACCATGGCCCAGGTGCAAC 
IP2 A2 TGTGCGTTGCCTGCCTGGAGGTTGGTAGAT 
IP2 RGD4C 
587 A2 
GAAGCAGTCTCCGCGGCAGTCACACGCGTTGCCTGCCTGGA
GG 
IP2 RGD4C 
453&587 
TTCACCAGAGAGTCTCTGCCATTGAGGTGGTA 
IP2 
GEN(A) 
CGCCTGGTTCTCGCCTGCGGCAGCTCCACTTGGAGTGTTTG
TTCT 
IP2 GL GTACAGCTCGTCCATGCCGAGAGTGATATCCGCCCGTTTGA
TTTC 
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IP2 LGL GTACAGCTCGTCCATGCCGAGAGTGATTGACCCACCGCCTC
CG 
IP2 CL AGGATCTGAGTACTTGTATGACCCACCGCCTCCG 
IP2 CL2 ATCTGAGTACTTGTATGACCCACCGCCTCCG 
IP2 OS TGGGCCATTCTAGACATGGTGGCGACCGGTAGCG 
IP2 K1 GGCCATTCTAGACACCATGGTGGCGACCGG 
IP2 K CTGGGCCATGGTGGCGACCG 
4066-back ATGTCCGTCCGTGTGTGG 
3201-
forward 
GGTACGACGACGATTGCC 
EGFP-1 
forward 
GCTACCCCGACCACATGAAG 
EGFP-1 
reverse 
GTCCATGCCGAGAGTGATCC 
GFPm_f CTCGATGTTGTGGCGGAT 
GFPm_r  GCGCCGAGGTGAAGTT 
GAPDHm_f GAGTCCACTGGCGTCTTCA 
GAPDHm_r  TTCAGCTCAGGATGACCTT 
BW F Pho-CAGTCATAATGTCTAGAGGTGTC 
BW R Pho-GGATCCACTTTGATCTCCAC 
OL LF Pho-
GATCCGAGTTCCGGTGGCGGAGGGTCTGGCGGTGGAGGCT
CCGGAGG CGGTGGGTCA 
OL LR Pho-
GATCTGACCCACCGCCTCCGGAGCCTCCACCGCCAGACCCT
CCGCCA CCGGAACTCG 
 
3.4. Antibodies and proteins 
Primary antibodies 
Listed as:   antigen; generated in; clonality; manufacturer 
A20:   AAV-2 intact capsid; Mouse; Monoclonal; Progen 
 B1:   VP1, VP2, VP3; Mouse; Monoclonal; Progen 
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Anti-integrin αV: anti-integrin αV C-terminal intracellular; Rabbit; 
Polyclonal; Chemicon 
Anti-integrin αVβ5: anti-human integrin αVβ5; Mouse; Monoclonal; 
Chemicon 
Anti-integrin αVβ3: anti-human integrin αVβ3; Mouse; Monoclonal; Abcam 
Anti-GFP:  anti-GFP; Rabbit; Polyclonal; Molecular Probes 
9G10: anti-HRSV3 anti-idiotypic antibody; Mouse; kindly 
provided by Hinrich Abken, University Hospital of 
Cologne, Germany (145) 
IgG control:  anti-TNP; Mouse; Monoclonal; BD Biosciences 
Anti-CD30: anti-CD30 PE labeled; Mouse; Monoclonal; BD 
Biosciences 
aCD30-hum.Fc: anti-CD30 HRSV3 antibody with human Fc; kindly 
provided by Hinrich Abken, University Hospital of 
Cologne, Germany 
 
Secondary antibodies  
Donkey anti-mouse biotin-conjugated: Jackson ImmunoResearch 
Laboratoires, Inc  
Goat anti-rabbit peroxidase-conjugated: Jackson ImmunoResearch  
Laboratoires, Inc 
Goat anti-mouse phycoerythrin-conjugated: Abcam 
Mouse anti-human IgG (H+L) biotin-conjugated: Jackson ImmunoResearch  
Laboratoires, Inc  
 
Proteins 
Integrin αV β5: Chemicon 
 
3.5. Bacteria strain 
E.coliDH5α:  F-, lac1-, recA1, endA1, hsdR17, ∆(lacZYA-argF), U169,  
  F80dlacZ∆M15, supE44, thi-1, gyrA96, relA1; (75) 
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3.6. Eukaryotic cells  
Listed as: organism; organ; disease; characteristics; medium and serum;  
source; references  
HEK293: humam; kidney; epithelial; transformed with adenovirus 5 DNA, 
contains E1A and E2; D-MEM with 10% FCS and 100units/ml of 
Penicillin/Streptomycin; ATCC CRL-1573; American Type Culture Collection, 
Rockville, USA; (65, 147). 
HeLa: humam; cervix; adenocarcinoma; epithelial; D-MEM with 10% FCS 
and 100 units/ml of Penicillin/Streptomycin; ATCC CCL-2; American Type Culture 
Collection, Rockville, USA; (147, 166). 
CHO KI: chinese hamster; ovarian; epithelial; DMEM/Ham’s F-12 medium 
with 10% FCS and 100 units/ml of Penicillin/Streptomycin; ATCC CCL-61; kindly 
provided by Stefan Weiss, Gene Center of the LMU Munich, Germany; (148). 
CHO pgsA-745: chinese hamster; ovarian; epithelial; xylosyltransferase I 
deficient; DMEM/Ham’s F-12 medium with 10% FCS and 100 units/ml of 
Penicillin/Streptomycin; ATCC CRL-2242; kindly provided by Stefan Weiss, Gene 
Center of the LMU Munich, Germany; (51). 
Primary HUVEC: pooled; primary; human; umbilical vein; endothelial; 
maintained in agreement with supplier instructions; PromoCell.  
HepG2: humam; liver; hepatocellular carcinoma; epithelial; D-MEM with 
10% FCS, 1 mM sodium pyruvate, 1x non-essential amino-acids and 100 units/ml of 
Penicillin/Streptomycin; ATCC HB-8065; kindly provided by Ulrike Protzer, 
University of Cologne, Germany; (101). 
L540: human; lymph node; Hodgkin’s lymphoma; lymphoblast; RPMI-1640 
with 10% FCS and 100 units/ml of Penicillin/Streptomycin; kindly provided by Elke 
Pogge, University of Cologne, Germany; (39). 
LS174T: human; colon; colorectal carcinoma; epithelial; RPMI-1640 with 
10% FCS and 100 units/ml of Penicillin/Streptomycin; ATCC CL-188; kindly 
provided by Hinrich Abken, University of Cologne, Germany; (28). 
C15A3:  murine; colon; colorectal carcinoma; epithelial; RPMI-1640 with 
10% FCS, and 100 units/ml of Penicillin/Streptomycin; kindly provided by Hinrich 
Abken, University of Cologne, Germany; (84). 
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3.7. Data treating software 
Microsoft Office Excel 2004; WinMDI 2.8; Roche Molecular Biochemicals 
Lightcycler Software v3.5; Elisa Reader SofMax Pro v1.2.0; PyMol (35); Clone 
Manager 6;  Primer Design 4; CDTree 3.0; Cn3D 4.2. 
 
3.8. GI and Accession numbers 
Table 3. GI and Accession numbers 
GI Accession Descritpion 
22219269 1lp3 (PDB) Adeno-associated virus type 2 coat protein VP2 
494746 2CAS (PDB)  Canine parvovirus empty capsid (Strain D) viral 
protein 2 
75569401 Q88273 (SwissProt) Simian parvovirus coat protein VP2 
116774 1s58 (PDB), VP2 Human parvovirus B19 probable coat protein 
VP1 
81924813 P87584 (SwissProt) Chipmunk parvovirus coat protein VP1 
81921778 2g8g (PDB), VP2 Adeno-associated virus type 4 coat protein VP1 
81937258 Q67667 (SwissProt) Goose parvovirus coat protein VP2 
116764 1mvm (PDB), VP2 Minute virus of mice coat protein VP1 
81925419 P90329 (SwissProt) Kilham rat virus coat protein VP2 
 
3.9. Laboratory equipment, disposables and kits 
- Eppendorf AG, Hamburg, Germany: Centrifuge 5810 R; Centrifuge 5415 D; 
  Thermomixer Comfort; Reaction viles 1.5ml, 2ml 
- DuPont GmbH, Bad Homburg: Sorval Ultracentrifuge Combi  
- Beckman Instruments GmbH, München: 5-6B Centrifuge 
- Mettler-Toledo GmbH, Schwerzenbach, Switzerland: pH meter SevenEasy 
- Ohaus Corporation, NJ, USA: Balance Adventure Pro  
- Heidolph Instruments GmbH & Co. KG, Schwabach, Germany:  
 Heater/Magnetic Shaker Heidolph MR 3001 
- Molecular Devices GmbH, München, USA: Emax Precision Microplate  
Reader 
 51 
- Heraeus, Sepatech GmbH, Osterode, Germany: Hera -80º freeze; Mamalian  
 Incubator Hera Cell 150; Oven 
- New Brunswick Scientific, Inc, NJ, USA: Incubator Shaker Innova 4430 
- Roche Diagnostics GmbH, Mannheim, Germany: Light Cycler; Roche 
LightCycler FastStart DNA Master SYBR Green I 
- Carl Zeiss Jena GmbH, Göttingen, Germany: Light Microscope Axiovert 25 
  CFL 
- Scientific Industries, Inc, NY, USA: Vortex Genie2 
- Bio-Rad laboratories GmbH, München, Germany: Power Pac Basic;  
Spectophotometer BioRad SmartSpec 3000; Mini-PROTEAN 3 Cell;  
Mini Trans-Blot Electrophoretic Transfer Cell; Mini Sub-Cell GT Gel 
Electrophoresis Unit (nucleic acids); Sub-Cell GT Gel Electrophoresis 
Unit (nucleic acids); Quick Start Bradford Protein Assay 
- Becton Dickinson, Heidelberg, Germany: FACSCalibur  
- Qiagen GmbH, Hilden, Germany: Qiagen EndoFree Plasmid Mega Kit;  
Qiagen EndoFree Plasmid Maxi Kit; Qiagen DNeasy Tissue Kit 
- Amersham Pharmacia Biotech, Freiburg, Germany: Hybond-P PVDF  
Transfer membrane; Pump P-1; RAP Heparin column (1 ml); ECL 
plus Western Blotting Detection System 
- Kodak, Cedex, France: Bio Max Light Film, Scientific Imaging Film 
- Beckton-Dickinson GmbH, Heidelberg: Polyesterol tubes 50ml  
- VWR International GmbH, Darmstadt, Germany: general laboratory ware 
- Beyer GmbH, Düsseldorf, Germany: cell culture plastic ware 
- Schleicher & Schuell MicroScience GmbH, Dassel, Germany: Steril filters  
0.22µm, 0.45µm; 3MM-Paper 
- Nunc, Wiesbaden, Germany: Nunc-Immunoplates 
- Eppendorf, Hamburg, Germany: FastPlasmid Mini 
- Owl Separation Systems, Portsmouth, USA: electrophoresis chamber 
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4. Methods 
4.1. Visualization of structures and molecular modeling 
The molecular graphics system program PyMol (35) was used for 
visualization and the VIPERdb (156) service for construction of the complete viral 
particles. The available X-ray structure of AAV-2 (203) and the SWISS Model 
environment for comparative protein modeling were used for the generation of spatial 
models (69, 138, 168). 
 
4.2. Bacteria culture 
4.2.1. Cultivation of bacteria 
Bacteria were grown at 37 ºC with LB medium. For growing the bacteria on 
plates, agar was added to LB medium for solidification. When growing the bacteria in 
liquid medium, erlenmeyers were filled until 25% with LB medium and bacteria were 
grown at 37 ºC with vigorous shaking. 
 
LB medium (1 l):    10 g tryptone 
5 g yeast 
5 g NaCl 
15 g agar 
ad 1 l H2O 
 
4.2.2. Preparation of competent bacteria  
Bacteria strand DH5α was grown at 37 ºC and vigorous shaking (200 RPM) 
overnight in 5 ml of LB medium. 10 hours later 2.5 ml was transferred into 250 ml of 
LB medium and the bacteria were grown until an optical density (OD) of 0.7 to 0.8 
measured at 600 nm. Incubation on an ice cold water bath was performed for 10 min 
followed by a centrifugation at 3000 RPM during 10 min at 4 ºC. Pellet was carefully 
re-suspended at 4ºC in 7 ml of cold TFBI buffer. Incubation on ice was done and 
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followed by a centrifugation step as before. The pellet was carefully re-suspended at 
4ºC in 10 ml of cold TFBII. Aliquots were frozen in liquid nitrogen. 
 
TFBI buffer:      30 mM KAc 
100 mM CaCl2 
15% Glycerin 
50 mM MnCl2 
in H2O 
 
TFBII buffer:     10 mM MOPS 
75 mM CaCl2 
10 mM KCl  
25% Glycerin 
in H2O 
 
4.2.3. Transformation of bacteria 
Competent bacteria were slowly thawn on ice. After adding 50 µl of 
competent bacteria to the transforming DNA (100 ng – 500 ng) the suspension was 
mixed and incubated on ice for 30 min. Suspension was then incubated for 60 sec at 
42 ºC followed by an incubation on ice for 2 min. 1 ml of LB medium was added and 
the mixture shaken at 200 RPM and 37 ºC for 60 min. 
Bacteria were plated onto plates that already contained LB medium, agar and 
ampicillin (50 µg/ml) or kanamycin (30 µg/ml). Plates were then incubated overnight 
at 37 ºC. 
Next day a single colony was picked from the plate, grown as before and then 
analysed.   
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4.3. DNA techniques  
4.3.1. Plasmid amplification and extraction 
For plasmid extraction the “Qiagen EndoFree Plasmid Mega Kit” was used 
and the protocol for “Plasmid or Cosmid DNA Purification Using EndoFree Plasmid 
Mega Kit” followed.  
Transformed bacteria was taken from a 50% glycerol stock kept at -80 ºC and 
grown in 10 ml of LB medium for approximately 8 h at 37 ºC and vigorous shaking 
(200 RPM). This starter culture was diluted 1/1500 into four 2 l erlenmeyers having 
600 ml of LB medium each. Culture was grown overnight at 37ºC and vigorous 
shaking. 
The bacterial cells were harvested by centrifugation at 5200 RPM (6000 x g) 
for 15 min and bacterial pellet was re-suspended in 50 ml of Buffer P1. Then, 50 ml 
of Buffer P2 was added and mixed gently by inverting 6 times. Incubation was 
performed at room temperature for 5 min. 50 ml of Buffer P3 was added to the 
suspension and mixed immediately and thoroughly by inverting 6 times. After 
screwing the QIAfilter Mega-Giga Cartridge onto a 45 mm-neck glass bottle (500 ml 
flask was used) the suspension was poured into the QIAfilter Mega-Giga Cartridge 
and incubation was performed at room temperature for 10 min. The vacuum source 
was turned on until all liquid had been pulled through, after which 50 ml of Buffer 
FWB2 was added to the QIAfilter Mega-Giga Cartridge and the vacuum source was 
turned on once again until all the liquid had been pulled through completely. 12.5 ml 
of Buffer ER was added to the filtered lysate and mixed by inverting the bottle 
approximately 10 times. Incubation was then performed on ice for 30 min. Qiagen-tip 
2500 was equilibrated by applying 35 ml of Buffer QBT and the column allowed 
emptying by gravity flow. After this and after finishing the 30 min of incubation on 
ice, the lysate was applied to the Qiagen-tip and allowed to enter the resin by gravity 
flow. The Qiagen-tip was then washed with a total of 200 ml of Buffer QC and the 
DNA was eluted with 35 ml of Buffer QN. DNA was precipitated by adding 24.5 ml 
of isopropanol (0.7 volumes, room-temperature) to the eluted DNA. After mixing a 
centrifugation was performed at 4000 RPM for 30 min at 4 ºC. Supernatant was 
carefully decanted and the DNA pellet was washed with 7 ml of 70% ethanol 
(prepared with enendotoxin-free water and kept at room temperature). Then 
centrifugation was performed at 4000 RPM and 4 ºC for 10 min. The pellet was air-
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dried for approximately 10-20 min and the DNA was re-dissolved in approximately 
500 µl of endotoxin-free Buffer TE. 
Alternatively the “Qiagen EndoFree Plasmid Maxi Kit” was used for 
extractions of fewer amounts of DNA or the Eppendorf FastPlasmid Mini and 
respective protocols followed. 
 
Buffer P1 (resuspension buffer):   50 mM Tris-Cl 
pH 8.0; 10 mM EDTA 
100 µg/ml RNase A 
 
Buffer P2 (lysis buffer):    200 mM NaOH 
1% SDS (w/v) 
 
Buffer P3 (neutralization buffer):   3.0 M potassium acetate, pH 5.5 
 
Buffer FWB2 (QIAfilter wash buffer):  1 M potassium acetate, pH 5.0 
 
Buffer QBT (equilibration buffer):   750 mM NaCl 
50 mM MOPS, pH 7.0 
15% isopropanol (v/v) 
0.15% Triton X-100 (v/v) 
 
Buffer QC (wash buffer):    1.0 M NaCl 
50 mM MOPS, pH 7.0 
15% isopropanol (v/v) 
 
Buffer QN (elution buffer):    1.6 M NaCl 
50 mM MOPS, pH 7.0 
15% isopropanol (v/v) 
 
TE:       10 mM Tris-Cl, pH 8.0 
1 mM EDTA 
 
 56 
4.3.2. DNA quantification 
DNA concentration was measured using a BioRad SmartSpec 3000 
spectrophotometer. Quantification is made by measuring absorbance at 260 nm. 1 
A260 unit of double stranded DNA equals 50 µg/ml H2O and 1 A260 unit of single 
stranded DNA equals 33 µg/ml H2O.  Purity is given by the ratio Abs260 nm/Abs280 
nm which should be equal or above 1.8. Values below 1.8 indicate that the 
preparation is contaminated with proteins and aromatic substances while values above 
2 indicate a possible contamination with RNA.  
 
4.3.3. Restriction enzyme digest 
Digestion with restriction enzymes was performed according to the 
manufacture instructions in a 20 µl solution containing 1 µg of DNA, 1-10 U of 
restriction enzyme per 1 µg of DNA and 1x buffer. Alternatively, for cloning, digest 
of inserts or backbones were performed using higher amounts of DNA and higher or 
lower amounts of enzyme. 
 
4.3.4. Agarose gel electrophoresis 
Stock solution for agarose gels was prepared by adding the desired percentage 
of agarose to the TBE Buffer, boiling in the microwaves and keeping the solution in 
the oven at 60 ºC to avoid solidification. When a gel was needed, solution was taken 
out of the oven, mixed with ethidiumbromide (0.25 µg/ml) and added to the casting 
chamber. Comp was inserted and, after solidification the gel was taken into the 
electrophoresis chamber. TBE (1x) buffer was then added to the chamber. 
When analyzing DNA from restriction digests 200 ng of DNA was mixed with 
1x loading buffer in a total volume of 10 µl. These 10 µl were pipetted to a well of an 
agarose gel.   
Electrophoresis was performed at 75 V and 200 mA. 
 
TBE Buffer (10x; 5 l):    540 g Tris Base 
275 g Boric Acid 
200 ml of 0.5 M EDTA pH 8.0 
ad 5 l H2O 
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4.3.5. Cloning 
The following plasmids (Table 4) were obtained by site directed mutagenesis 
of their respective templates using overlapping PCR fragments (using the respective 
primers IP1 and OP2; IP2 and OP1) and ligation of fragments by a second PCR using 
the respective primers OP1 and OP2.  After digest of the insert and backbone with the 
respective DNA restriction enzymes ligation was performed. 
 
Table 4 Plasmids cloned by site directed mutagenesis. 
Plasmid Backbone 
Insert 
Template 
OP1 
(Fw) 
OP2 
(Rv) 
IP1 
(Fw) 
IP2 
(Rv) 
R. Site 
Back. 
R. Site 
Insert 
pRC A2 pRC pRC OP1 
RC 
OP2 
RC 
IP1 A2 IP2 A2 BsiWI/ 
XcmI 
BsiWI/ 
XcmI 
pRGD4C- 
453-A2 
pRGD4C-
453 
pRGD4C 
453 
OP1 
RC 
OP2 
RC 
IP1 A2 IP2 A2 BsiWI/ 
XcmI 
BsiWI/ 
XcmI 
pRGD4C- 
587-A2 
pRC pRC A2 OP1 
RC 
OP2 
RC 
IP1 
RGD4
C 587 
A2 
IP2 
RGD4
C 587 
A2 
BsiWI/ 
XcmI 
BsiWI/ 
XcmI 
pRGD4C 
453&587 
pRGD4C- 
453 
pRGD4C- 
453 / 
pRGD4C- 
587 
OP1 
RC 
OP2 
RC 
IP1 
RGD4
C 
453&5
87 
IP2 
RGD4
C 
453&5
87 
BsiWI/ 
XcmI 
BsiWI/ 
XcmI 
pNGRI-
453 
pRC pNGRI- 
453&587 / 
pRC 
OP1 
RC 
OP2 
RC 
IP1 
RGD4
C 
453&5
87 
IP2 
RGD4
C 
453&5
87 
BsiWI/ 
XcmI 
BsiWI/ 
XcmI 
pNGRI-
453-A2 
pRC pNGRI- 
453&587 / 
pRC A2 
OP1 
RC 
OP2 
RC 
IP1 
RGD4
C 
453&5
87 
IP2 
RGD4
C 
453&5
87 
BsiWI/ 
XcmI 
BsiWI/ 
XcmI 
pGEN(A)- 
453 
pRC pRC OP1 
RC 
OP2 
RC 
IP1 
GEN(A
) 
IP2 
GEN(A
) 
BsiWI/ 
XcmI 
BsiWI/ 
XcmI 
pGEN(A)- 
453-A2 
pRC A2 pRC A2 OP1 
RC 
OP2 
RC 
IP1 
GEN(A
IP2 
GEN(A
BsiWI/ 
XcmI 
BsiWI/ 
XcmI 
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) ) 
paCEA-
VP2 
pGFP-VP2 pBW431-
26-scFv 
BWF BWR     Bsp1407
I/BshTI 
  
pRC VP2 
ko A2 
pRC VP2 
ko 
pRC OP1 
RC 
OP2 
RC 
IP1 A2 IP2 A2 BsiWI/ 
XcmI 
BsiWI/ 
XcmI 
paCEA-
VP2-A2 
paCEA-
VP2 
pRC OP1 
RC 
OP2 
RC 
IP1 A2 IP2 A2 BsiWI/ 
XcmI 
BsiWI/ 
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4.4. Eukaryotic cell culture  
4.4.1. Cultivation of cells 
Cells were cultivated at 37 ºC and 5% CO2 in humid atmosphere. For medium 
information see page 49. Cells were grown with antibiotics - Penicilin/Streptomycin 
(P/S). 
 
4.4.2. Trypsinisation 
Cells were washed with PBS, trypsin (0.5 g/L) was added in an amount that 
covered the bottom of the plates, followed by an incubation at 37 ºC (duration 
depending on the cell line). When the cells detached from the plate, reaction was 
stopped with medium containing at least 10% FCS. 
 
4.4.3. Seeding / Passaging 
Cells were transferred into a new plate or flask containing fresh medium, that 
was warmed up to 37 ºC. Agitation of the plate with movements in cross were made 
in order to spread the cells homogeneous and cultivation was performed. 
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4.4.4. Freezing and thawing cells 
Cells were trypsinized, suspension collected in a falcon tube and pelleted at 
1200 RPM. Supernatant was removed and cell pellet was re-suspended with freezing 
solution. 1 ml of cell suspension was added to each freezing vial and taken 
immediately into a slowly freezing chamber at -80 ºC. 
For thawing the cells, the freezing vials were taken out of liquid nitrogen 
storage and the suspension let to thaw, after which it was taken to a flask or plate and 
medium that was warmed up to 37 ºC was added to the flask or plate. 
 
Freezing solution:     90% FCS 
10% DMSO 
 
4.4.5. Counting 
After trypsinizing and diluting the cells, 10 µl were transfered into a 
hematocytometer. The number of cells in each of the four squares was counted and an 
average was made for more precise determination. The amount of cells (n) determined 
equals n x 104 per ml. 
 
4.5. Production of AAV-2 vectors 
4.5.1. Production of HBS-buffer  
 Weighted: 
 5.955 g HEPES 
 8.18 g NaCl 
 1.5 ml 0.5 M NaP (pH 7.29) 
HEPES and NaCl were dissolved in endotoxin free water (Sigma) to a final 
volume of 400 ml and 5 aliquots of 20 ml were used to adjust the pH to 6.6; 6.7; 6.8; 
6.9 and 7.0, respectively, using a “Mettler Toledo seveneasy” pH meter. The aliquots 
were sterile filtrated and used to test which of the different pH values is more efficient 
in the formation of CaP crystals for transfection of DNA into cells. The pH of the 
original solution was then adjusted and endotoxin free water was added until 375 ml. 
The solution was then sterile filtrated. 
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4.5.2. AAV vector packaging 
15 cm petris dishes were used for seeding 7.5 x106 293 cells/plate in 25 ml 
DMEM with Glutamax plus 10% FCS and 1% P/S. 
24 hours later (cells showed approximately 80% confluence) medium was 
exchanged to 10% FCS and 1% P/S (approximately ~ 25ml/plate). 
The transfection was performed 2 hours later: 
1 ml 250 mM CaCl2 
 
7.5 µg pRC (or mutated pRC plasmid; codes for the viral proteins necessary 
for viral replication and for the capsid proteins) 
7.5 µg pTransgene (codes for the transgene that is flanked by the viral   
packaging signals to allow the transgene to be packaged into the viral capsid) 
22.5 µg pXX6-80 (codes for E2a, E4 and VA of Ad 5) 
(when one of the viral capsid proteins -VP2- was supplied in trans as a fusion 
protein 7.5 µg of pscFv-VP2 were added additionally) 
  
Solution was mixed by vortexing and 1 ml HBS-Puffer slowly added. Solution 
was once more mixed by vortexing and exactly 2 minutes after, the solution was 
added to the cells.  
24 hours later (approximately 100% confluence), medium was exchanged with 
20 ml DMEM with Glutamax plus 2% FCS and 1% P/S. 
The cells were harvested 24 hours later by scrapping them from of the plate, 
collecting them in a conic centrifuge tube and centrifuging them at 1500 RPM for 15 
min. The supernatant was wasted and the pellet re-suspended in 500 µl of lysis buffer 
per plate harvested (150 mM NaCl; 50 mM Tris/HCl, pH 8.5). The cells were 3 times 
submitted to thermal shock by using liquid nitrogen and a water bath at 37 ºC. 
To avoid contaminations with cellular DNA or RNA, or plasmid DNA, the 
suspension was treated with 50 U of Benzonase per ml of suspension at 37 ºC for 30 
min. 
The falcons were centrifuged for 30 min, at 4 ºC, 4000 RPM; solution was 
transferred into a new falcon (pellet was discarded) and filled up with PBS to 11 ml, 
centrifuged again for 30 min at 4 ºC and 4000 RPM. 
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4.5.3. Iodixanol gradient purification 
An iodixanol step gradient centrifugation was performed using four different 
iodixanol solutions (see below for the composition of each solution). After adding the 
viral solution to the tube used for centrifugation a needle reaching the bottom of the 
tube was used to slowly add (using an “Amersham Biosciences Pump P-1”) all the 
solutions starting with the lightest one and ending with the heaviest one. 
The centrifugation was performed at 63000 RPM for 2 h at 4ºC and 
subsequently the 40% iodixanol phase harvested. 
 
 
 
4.6. Vector titration 
4.6.1.  Genomic titer 
For extraction of genomic DNA from viral particles the “Qiagen DNeasy 
Tissue Kit” was used and the protocol for “Isolation of Total DNA from Cultured 
Animal Cells” was performed.  
10 µl of virus were diluted in 200 µl of PBS; 20 µl of Proteinase K (25 mg/ml) 
and 200 µl of Buffer A was added and the solution was mixed by vortexing. After 10 
min incubation at 70 ºC, 200 µl of ethanol (96-100%) was added and the solution was 
again mixed by vortexing. The mixture was then pipetted into the DNeasy Mini Spin 
Column placed in a 2 ml collection tube. A centrifugation at 8000 RPM for 1 min was 
performed, the flow through was discarded and the column placed in a new 2 ml 
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collection tube. 500 µl of buffer AW1 was added and a centrifugation was performed 
as before. After adding a new 2 ml collection tube 500 µl of buffer AW2 were added 
and a centrifugation was done for 3 min at 14000 RPM. The flow through was 
discarded and a clean 1.5 ml reaction tube was used. 200 µl of 100 mM Tris pH 8.0 
was added to the column and incubated for 1 min at room temperature. Elution was 
performed by centrifuging at 8000 RPM for 1 min. 
The genomic titer was then determined by Real Time Polymerase Chain 
Reaction (RT-PCR) using a “Roche LightCycler FastStart DNA Master SYBR Green 
I” kit.  
 
Primers: EGFP-1 forward (sense); EGFP-1 reverse (anti-sense) 
 
LightCycler protocol: 
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1 1 None 95 10 sec 20.00 0 0.0 0 None 
          
2 40 Quantification 95 10 sec 20.00 0 0.0 0 None 
   64 5 sec 20.00 0 0.0 0 None 
   72 10 sec 20.00 0 0.0 0 Single 
          
3 1 Melting 
Curves 
95 0 sec 20.00 0 0.0 0 None 
   67 10 sec 20.00 0 0.0 0 None 
   95 0 sec 0.10 0 0.0 0 Cont 
          
4 1 None 40 30 sec 20.00 0 0.0 0 None 
 
4.6.2. Transducing titer 
7.0x104 HeLa cells were seeded in each well of a 12-well plate. 24 h later 
eight dilutions of the vector solution were made (dilutions of 1 to: 5.0x102; 5.0x103; 
5.0x104; 5.0x105; 1.65x103; 1.65x104; 1.65x105; 1.65x106). The medium in the wells 
was substituted by each vector dilution. Three wells were used as negative control. To 
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verify if vector particles are responsible for cell transduction one well was used to 
perform a “heparin control”. For this the lower dilution of the vector was added 
together with 425 IU of heparin to a well in replacement of the old medium. After 48 
h of incubation at 37 ºC and 5% CO2 the cells were trypsinized, washed with PBS, the 
number of cells in the negative control was counted and the probes analyzed by 
Fluorescent Activated Cell Sorting (FACS). 
A gate was established having 1% of the cells in the control as background 
fluorescence. The same gate was then used for determining the results of the different 
dilutions.  Based on the amount of cells in the control, the amount of GFP expressing 
cells obtained from each dilution and the respective dilution factor, the transducing 
titer was determined using 10% of GFP expressing cells (10% equals MOI = 0.1; each 
GFP expressing cell is the result of a single vector transduction) as reference.  
 
4.6.3. Capsid titer 
The determination of the capsid titer was performed using the monoclonal 
anti-AAV intact particle A20 antibody.  
Based on the genomic titer and the fact that the capsid titer is normally 10x 
higher, eight serial dilutions were made in PBS in order to obtain concentrations in 
the linear range of the ELISA (between 1.0x107 and 1.0x109 capsids/ml). An AAV 
preparation which titer was previously determined using the commercially available 
AAV titration kit (Progen) was used as standard. 
Nunc-Immunoplates were coated with 100 µl of each respective vector 
dilution and incubated overnigh at 4 ºC. Next morning after three washing stepts with 
Washing Buffer using 200 µl per well, Blocking Buffer was added to the wells (200 
µl/well). After an incubation for 2 h at room temperature Blocking Buffer was 
removed and A20 antibody (supernatant, diluted 1:4 in Blocking Buffer) was added 
(100 µl/well). Another incubation step at room temperature was performed this time 
for 1 h followed by another 3 washings like before. Biotin conjugated anti-mouse 
antibody diluted 1:25,000 in Blocking Buffer, was added to the well (100 µl/well) and 
incubation performed for 1 h. After another 3 washings like before, Horseradish-
Peroxidase conjugated streptavidin diluted 1:500 in Blocking Buffer was added to the 
wells (100 ml/well) and incubation was performed for 1 h at room temperature. After 
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performing 3 washings like before and 2 washings with water (200 µl/well) Start 
Solution was added to the wells (100 µl/well).  
Color reaction was stopped by adding 50 µl of Stop Solution into each well 
and the intensity of the color reaction was measured using a photometer at 450 nm. 
 
Washing Buffer:    0.05% Tween20 
in PBS 
 
Blocking Buffer:   3% BSA 
5% Sucrose 
0.05% Tween20 
in PBS 
 
Start Solution:    1 mg TMB 
     100 µl DMSO 
     10 ml of 0.1 M NaOAc pH 6.2 
     1 µl of 30% H2O2 
 
Stop Solution:    1 M H2SO4 
 
4.7. Cell transduction 
Cells were seeded and 24 h thereafter incubated with the respective vectors. In 
transduction assays where GFP was used as transgene the cells were harvested 48 h 
p.t., washed and resuspended in PBS. The percentage of GFP expressing cells was 
determined by flow cytometry using a BD FACS Calibur system. A minimum of 
5000 cells was counted for each sample. 
 
4.7.1. Competition studies 
Competition studies were performed by transducing cells with rAAV-2 capsid 
mutants and respective controls in the presence or absence of 300 µM of GRGDS or 
GRGES peptides or 5 IU/µl soluble heparin. Values were normalized to non-
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competed transductions and the respective inhibition values were calculated as the 
difference to the respective non-competed transductions. 
 
4.7.2. Binding particles 
4 h post-infection cells were washed 4 times with PBS and scraped from the 
wells. For isolation of DNA the “Qiagen DNeasy Tissue Kit” was used and the 
protocol for “Isolation of Total DNA from Cultured Animal Cells” was performed. 
Amount of vector genomes found in the cells was determined by quantitative PCR 
using the primers: EGFP-1 forward and EGFP-1 reverse. Relative amount of binding 
particles was calculated as the ratio of amount of detected particles-to-amount of 
given particles. 
 
4.8. Protein techniques 
4.8.1. Protein quantification 
Protein quantification was done using a BioRad Quick Start Bradford Protein 
Assay. 
The 1x dye reagent was removed from the 4 ºC storage, warmed up to ambient 
temperature and inverted a few times before use. Each standard and unknown sample 
solution was pipeted into separate clean test tubes. The 1x dye reagent was added to 
each test tube and mixed by vortexing. Incubation was performed for 5 min at room 
temperature. Protein solutions and standards were assayed in triplicate. 
The spectrophotometer was set to 595 nm. The zero was made using the blank 
samples (0 µg/ml using water and dye reagent). 
 
4.8.2. Western blot 
Western blot analysis was performed on protein extracts obtained from vector 
packaging (see Page 61, AAV vector packaging) or on iodixanol gradient purified 
vector solutions. Laemmli Buffer was added and the samples were boiled at 98 ºC for 
5 min. If not indicated 30 µg of protein or 1.0x1010 vector particles were loaded into 
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the gel. Running buffer was added in agreement with chamber manufacturer 
specifications and the electrophoresis was performed at 80 V and 25 mA. 
After protein separation by SDS-PAGE the proteins were transferred to a 
nitrocellulose transfer membrane (Hybond-ECL from Amersham Bioscience) using a 
“BioRad Mini Trans-Blot Electrophoretic Transfer Cell” in agreement with the 
manufactures’ instructions. 
After blotting the membrane was blocked using 5% milk powder and 0.1% 
Tween 20 in PBS during 60 min shaking at RT. The blocking solution was substituted 
by the primary antibody solution (B1, supernatant, diluted 1:20 in Blocking Buffer) 
and left for 1h shaking at room temperature. Three washing steps were performed – 
3x 0.1% Tween/PBS shaking for 5 min at RT. The solution on the membrane was re-
placed by the secondary antibody (anti-Mouse/PO diluted 1:10,000 in Blocking 
Buffer) and left for 1 h shaking at RT. Three washing steps like before, and 2 ml of 
the substrate solution for the peroxydase-conjugated secondary antibody was added to 
the membrane after which the substrate solution was spread throw the membrane by 
using a plastic foil in which the membrane was inserted. A radiographic film was 
exposed to the membrane and subsequently the development of the film was done.  
 
Laemmli Buffer:   50 mM Tris pH 6.8 
100 mM DTT 
2% SDS 
50% Glycerol 
0.2 g/ml BPB (stored at -20ºC) 
 
Transfer buffer pH 8.3:  0.30%  Tris Base 
1.44% Glycin;  
0.02% SDS 
 
Stacking gel, 5% (2 ml):  1.4 ml distilled water 
0.33 ml acrylamide stock solution, 30% (w/v) 
0.25 ml 1.0 M Tris (pH 6.8) 
0.02 ml 10% sodium dodecyl sulfate (SDS) 
0.02 ml 10% ammonium persulfate (APS) 
2 µl N,N,N,N-Tetramethylethylenediamine  
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Resolving gel, 8% (5 ml):  2.3 ml distilled water 
1.3 ml acrylamide stock solution, 30% (w/v) 
1.3 ml 1.5 M Tris (pH 8.8) 
0.05 ml 10% SDS 
0.05 ml 10% APS 
3 µl TEMED  
 
4.8.3. ELISA 
4.8.3.1. Integrin binding assay 
Outer surface display of the RGD4C peptide and its ability to bind to soluble 
integrin was determined by ELISA. Two Nunc-Immunoplates were coated with 
purified anti-AAV-2 capsid antibody A20 (1 µg/ml diluted in PBS) overnight at 4 ºC. 
Next, plates were washed three times with Washing Buffer (200 µl/well). Unspecific 
binding was blocked by incubation with Blocking Buffer for 2h at RT (200 µl/well). 
1x1010 particles per well were added to the plate diluted in blocking buffer. Incubation 
was performed for 2 h at RT, followed by a washing step as described above. One 
plate was used to determine soluble receptor binding ability of the different vectors 
(ELISA A), the other plate was used to determine the amount of intact viral capsids 
per well (ELISA B). 
ELISA A: αVβ3 integrin, 1 µg/ml, was added to the plate diluted in Binding 
Buffer (100 µl/well). Incubation was performed as before, followed by another 
washing step and incubation with anti-integrin αV C-terminal intracellular antibody 
diluted in Binding Buffer (1 µg/ml, 100 µl/well). After incubation at RT for 2 h, 
followed by a washing step, a peroxidase-conjugated anti-rabbit antibody diluted in 
Binding Buffer (1:10,000) was applied (1 h at RT, 100 µl/well).  
ELISA B: Biotinylated anti-AAV-2 A20 antibody, diluted 1:20 in Blocking 
Buffer was added to the plate. Incubation and washing steps were performed as before 
followed by incubation with streptavidin-peroxidase.  
After 2 h of incubation with peroxidase-conjugated anti-rabbit antibody 
(ELISA A) or with streptavidin-peroxidase (ELISA B) at RT, plates were washed 
once with washing buffer and twice with water before the peroxidase reaction was 
started as describe above (as described above, 4.6.3. Capsid titer). The reaction was 
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stopped after 10 min and the reaction product was measured (Absλ=450nm). Relative 
receptor binding was calculated as the ratio of ELISA A (αVβ3 binding) to ELISA B 
(intact AAV particles).  
 
4.8.3.2. Anti-GFP and anti-idiotypic ELISA 
ELISA plates were coated with the respective capturing antibody and 
incubation performed for 2 h at room temperature. After one washing step as 
described above unspecific binding was blocked by incubation with Blocking Buffer 
overnight at 4 ºC. 
Next day protein solution was added to the plates diluted in Blocking Buffer 
and incubated for 2 h at RT. After another washing step detection antibody was 
diluted in Blocking Buffer and added to the wells. After 2 h of incubation at RT 
another washing step was performed. A peroxidase conjugated streptavidin or 
secondary antibody was added and incubation performed for another 2 h at RT. After 
one washing step and two times “washing” with water the peroxidase reaction was 
started and stopped as described above. 
Alternatively, plates were coated with the analyzed proteins (vectors). 
 
The following antibodies were used in the various ELISAS. 
Antibody:    Final concentration: 
Anti-GFP    1 µg/ml 
9G10     10 µg/ml (as capture Ab) 
     2.5 µg/ml (as detection Ab) 
 
IgG control    10 µg/ml (as capture Ab) 
     2.5 µg/ml (as detection Ab) 
 
A20     2.5 µg/ml 
 
Washing Buffer:   1% Tween20 
in PBS 
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Blocking Buffer:    1% Milk Powder 
1% Tween20 
in PBS 
 
Binding Buffer :   20 mM Tris-HCl 
15 mM NaCl 
2 mM CaCl2 
1 mM MgCl2 
1 mM MnCl2,  
1% Milk Powder 
1% Tween20 
in PBS 
pH 7.5 
 
4.9. Immunophenotyping 
At the time point of vector transduction, cells in control wells were harvested, 
washed twice and incubated with a primary antibody in agreement with manufacter 
instructions. After 30 min of incubation on ice and two washing steps, incubation with 
a secondary antibody (goat polyclonal anti-mouse IgG Phycoerythrin conjugated) was 
performed.  
Antibody binding was determined by flow cytometry using a BD FACS 
Calibur system. A minimum of 5000 cells was counted for each sample.  
 
4.10. Biodistribution study in mice 
7 week old C57BL6 female mice were purchased from Charles River 
Laboratories (Charles River Laboratories, Wilmington, USA). 1.0x1010 genomic 
particles were injected into the tail vein. Organs were harvested 42 h p.i. and DNA 
was isolated (QIAGEN DNeasy Tissue Kit). Using the GAPDH gene as reference  
relative quantification of transgene was done using quantitative PCR (using the 
ROCHE, SYBR Green kit) and the following primers: GFPm_f and GFPm_r; 
GAPDHm_f and GAPDHm. 
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5. Results 
5.1. G453 as a new AAV-2 insertion site 
Most published targeting approaches are based on insertion of small peptide 
ligands within the cap open reading frame (ORF). This ORF codes for three structural 
proteins  - VP1 (90 KDa), VP2 (72 kDa), and VP3 (60 kDa) - that share most of their 
amino acid sequence and that build up the capsid at a 1:1:10 ratio (105). Preferred 
sites for peptide insertions are amino acid position 587 and 588 (according to VP1 
numbering), which are located in a region common to all three capsid proteins. 
Other sites within the cap gene of AAV-2 also tolerate insertion of small 
peptides (63, 66, 102, 171, 174, 198). Four of these sites (amino acid position 34, 447, 
520 and 584) have been examined for their usefulness in AAV vector targeting (63, 
174, 198). Mapping of all targeting insertion sites and analysis of the accessible 
surface profile of AAV-2 revealed that none is found at the most prominently exposed 
region of the AAV-2 capsid (Figure 9 A, B). Instead, T454, located in the β-turn - 
S452, G453, T454, T455 - connecting the anti-parallel β strands GH2 and GH3 
emerged as the most accessible and exposed residue on the AAV-2 capsid flanked by 
two also well exposed residues – G453 and T455 (Figure 9 A, B, C). Just like N587, 
T454 makes part of one of the 3 GH loops that build up the “threefold-proximal” 
peaks clustered around each icosahedral threefold rotation axis (Figure 9C, D). β-
turns are commonly found to link two strands of anti-parallel β-sheet, forming a β-
hairpin, and such secondary structure elements have been postulated as possible 
nucleation sites for the protein folding pathway (47, 48, 99). Interestingly, insertions 
at N587 – also located in a β-turn – are well tolerated while insertions in the 
GH2/GH3 β-strands are not (62). Indeed, it is also known that helices and β-sheets are 
the major stabilizing structures in proteins. Thus, by comparison with N587, insertion 
of targeting peptides at a better exposed position like G453 (between G453 and T454) 
should result in mutants with higher affinity to their target receptor. 
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A) 
  
B)      C) 
 
D)  
Figure 9. Identification of G453. A) Accessible 
surface profiles of AAV-2. The graphics show the 
distance of respective residues to the virus center as 
calculated by computational analysis. Graphics 
were obtained from the VIPERdb service. B) This 
is a surface rendering of the capsid based on the 
atomic coordinates. The colors are depth cued 
along a color gradient: yellow at a larger radius, 
and greenish blue as the radius decreases. The view 
is down a twofold axis (center of the virus) with 
threefolds left and right of center, fivefolds above 
and below. C) 3d structure of the VP2 capsid 
protein. D) Equatorial cross-section of AAV-2 
emphasizing the elevation of the peaks, each of 
which comprises loops from two subunits that are 
colored differently. (156, 202) 
 
5.1.1. Insertion of the RGD4C peptide 
To explore if position 453 is suitable for the display of targeting peptides and 
to compare the usefulness of this exposed position with the traditionally preferred 
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position (587/588), we designed a set of AAV capsid mutants carrying a model ligand 
at position 453, 587 or both (Figure 10). Mutants carrying an insertion at position 453 
are expected to be able to use HSPG as the primary receptor just like wild-type AAV-
2 (r-wt). Two arginine-to-alanine substitutions of residues R585 and R588 (A2) have 
been shown to eliminate AAV-2’s HSPG binding (135). We therefore designed a 
second 453 insertion mutant with R585A and R588A substitutions. For comparison, 
the same substitutions were combined with peptide insertion at position 587 and with 
a double peptide insertion (Figure 10). As a model ligand we chose RGD4C – 
ACDCRGDCFCA – since it is known to target cellular and soluble integrin receptors 
(eg. αVβ5 and αVβ3 integrins), competing peptides are commercially available, and 
it has already been used for re-targeting of AAV-2 (4, 172, 174). An overview of the 
different capsid insertion mutants with details on the respective capsid modifications 
is provided in Figure 10. 
 
 
Figure 10. Amino acid sequence of the different viral vectors. Depicted is the amino acid sequence 
of r-wt, r-A2 and the different capsid insertion mutants in the region around position 453 and 587. The 
inserted RGD4C peptide motif (ACDCRGDCFCA) flanked by alanine residues is underlined. R585A 
and R588A substitutions are shown in italic. 
 
From all six capsid insertion mutants spatial models were created in silico. 
Based on these models, the inserted RGD motif should be displayed on the capsid 
surface pointing away from the opposite spike. Examples are presented in Figure 11. 
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Figure 11. Spatial models of capsid insertion mutants. A) Close-up of the 3-fold symmetry axis in 
wild-type AAV-2 showing G453 at the top of the spike. Picture B), C) and D) spatial models of 
mutants carrying the RGD4C peptide motif (ACDCRGDCFCA) at position 453, 587 or both positions. 
Colors used in A) to D): white = hydrophobic; yellow = semipolar; cyan = polar; blue = positive; red = 
negative and magenta = aromatic amino acids. 
 
5.1.1.1. RGD4C insertion at 453 does not interfere with vector packaging 
or cell transduction 
We produced the various capsid insertion mutants as recombinant AAV-2 
vectors coding for green fluorescent protein. As controls, r-wt and a r-AAV-2 capsid 
mutant with R585A and R588A substitutions (r-A2) were produced (Figure 10). All 
vectors showed comparable genomic particle titers ranging from 1.55x1011 per ml for 
r-RGD4C-453&587 to 1.11x1012 per ml for r-wt (Table 5).  
The capsid titer was determined by ELISA and used to calculate the total-to-
full particle ratio to directly compare the different vectors for packaging efficiency. 
As depicted in Table 5, all vectors showed comparable ratios ranging from 15 for r-wt 
to 2.2 for r-RGD4C-453&587-A2.  
 
Table 5. Vector titers of r-wt, r-A2 and RGD4C insertion mutants. n.d. = not determined; u.d.l. = 
under detection limit; wt = phenotype comparable to AAV with wild-type capsid according to Kern and 
colleagues. (a): Numbers indicate independent packaging; (b): genomic titers determined by 
quantitative PCR, shown is the mean value of 3 titrations; (c): capsid titer was determined by ELISA 
using A20 (antibody, which recognizes intact AAV-2 capsids), shown is the mean value of 2 titrations; 
(d): definition according to Kern and colleagues (97): wt phenotype indicates a packaging ratio of < 50; 
(e): determined on HeLa cells, shown is the mean value of 2 titrations; (f): provides a simple 
comparison of how many genome-containing particle of each mutant were required to achieve the same 
number of transduced HeLa cells as with one AAV-2 with wild-type capsid (definition according to 
Opie and colleagues (135)). 
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vector preparation (a) 
gen. titer 
(per ml) (b) 
cap. titer 
(per ml) (c) 
packaging 
efficiency 
(cap-to-gen 
ratio) 
phenotype 
based on 
cap-to-gen 
ratio (d) 
transducing 
(inf.) titer 
(per ml) (e) 
cap-to-inf 
ratio 
rel. cap-to-
inf value (f) 
r-wt 7.07E+11 1.09E+13 15.4 wt 6.84E+10 159 1 
r-wt (2) 7.29E+11 7.21E+12 9.9 wt n.d. - - 
r-A2 1.11E+12 1.00E+13 9.1 wt 2.75E+07 365382 2302 
r-RGD4C-453 4.97E+11 1.12E+12 2.3 wt 1.63E+08 6886 43 
r-RGD4C-453-A2 6.12E+11 1.54E+12 2.5 wt 2.55E+08 6047 38 
r-RGD4C-453-A2 (2) 5.32E+11 7.33E+12 13.8 wt n.d. - - 
r-RGD4C-587 4.73E+11 1.17E+12 2.5 wt 1.22E+08 9588 60 
r-RGD4C-587-A2 2.42E+11 2.83E+12 11.7 wt 6.45E+08 4385 28 
r-RGD4C-453&587 1.55E+11 1.34E+12 8.7 wt u.d.l. - - 
r-RGD4C-453&587 A2 2.25E+11 5.02E+11 2.2 wt u.d.l. - - 
 
For detecting if all viral preparations possessed the correct ratio of viral 
proteins VP1:VP2:VP3 – 1:1:10 respectively (105) – Western blot analysis was 
performed (Figure 12). As expected, all viral preparations showed the correct 
VP1:VP2:VP3 ratio and insertion mutants showed a retarded migration pointing 
towards an increase in protein size. Unexpectedly, proteins with A2 mutations also 
showed slower migration when compared to their R585 and R588 homologues.  
 
 
Figure 12. Western blot analysis of iodixanol gradient-purified AAV capsids. After iodixanol 
gradient purification the same amount of viral capsids (1010) were separated by sodium dodecyl sulfate 
- 8% polyacrylamide gel electrophoresis and analyzed by Western blotting with the B1 antibody.  
 
We used the cervix carcinoma cell line HeLa, known to express HSPG (73) 
and αVβ5 (172), and to be susceptible to AAV transduction/infection (73), to 
determine the transduction efficiency of the different capsid insertion mutants in 
 76 
comparison to r-wt and r-A2. The values obtained were used to calculate the capsid-
to-infectious particle ratio to compare the different vectors for their transduction 
ability. 
As depicted in Table 5, r-wt showed the best transduction efficiency while r-
A2s’ ability to transduce HeLa cells was significantly reduced, most likely due to its 
inability to bind to HSPG. Interestingly, both double insertion mutants showed an 
even lower transduction ability than r-A2 revealing that such mutants are severely 
impaired in transduction. With or without the combination with A2 mutations, all 
single insertion mutants were able to efficiently transduce HeLa cells. Of notice is the 
fact that the combination of RGD4C insertion with A2 mutations resulted in a slight 
increase in transduction efficiency (cap-to-inf ratio of: r-RGD4C-453 vs. r-RGD4C-
453-A2 and r-RGD4C-587 vs. r-RGD4C-587-A2). With r-wt as a reference, r-
RGD4C-587-A2 showed the lowest decrease in transduction efficiency on HeLa cells 
(rel. cap-to-inf value). 
 
5.1.1.2. Inserted peptide is displayed on the capsid surface and is able to 
bind its target receptor 
Next, we determined whether the inserted peptide is exposed on the surface of 
the different capsid insertion mutants and is able to bind its receptor, αVβ3 integrin. 
Although at varying degrees all insertion mutants were able to bind the target 
molecule while r-wt and r-A2 did not show any binding (Figure 13).  
Unexpectedly, r-RGD4C-453 and r-RGD4C-587 showed the lowest receptor 
binding ability of all insertion mutants. This was surprising since 453/454 is the most 
exposed position of the capsid (Figure 9) and should therefore allow a good access to 
its target receptor, and 588 has already been used successfully to create RGD4C 
containing AAV-2 based targeting vectors (172). Even more striking was the 
observation that for both insertion sites, the combination of peptide insertion with R-
to-A substitutions significantly enhanced target molecule binding (50-fold for r-
RGD4C-453-A2, 33-fold for r-RGD4C-587-A2). Although to a smaller degree, the 
same was observed with the double insertion mutants (1.1-fold) (Figure 13).  
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Figure 13. Binding of r-RGD4C mutants to their target receptor. The ability of intact viral capsids 
to bind a soluble RGD4C receptor - αVβ3 integrin - was determined by ELISA. Two independent 
experiment were performed. Shown is the mean value of αVβ3 molecules detected per intact capsid 
from triplicate measurements with error bars representing the standard error of the mean. 
 
Since double insertion mutants should contain two RGD4C motifs per capsid 
protein, both double insertions mutants were expected to show superior target receptor 
binding in comparison to single insertion mutants. This was indeed the case when 
comparing the double insertion mutants with r-RGD4C-453, r-RGD4C-587 and r-
RGD4C-587-A2. Interestingly, despite the efficient binding to their target receptor 
double insertions mutants revealed a deficiency in transduction ability (Table 5). r-
RGD4C-453-A2 emerged as the mutant with the highest amount of receptors bound 
per intact capsid. This confirms our initial hypothesis and highlights the potential of 
this position for mediating efficient ligand-receptor interactions. 
 
5.1.1.3. Cell transduction is mediated by inserted peptide  
To assess the specificity of the capsid insertion mutants HeLa cells were 
transduced by the different vectors in the presence of a competing GRGDS peptide, a 
non-competing GRGES control peptide or the HSPG analogue heparin (Figure 14A). 
Both controls, r-wt and r-A2, showed the expected results. No competition 
with GRGDS or GRGES was observed for r-wt and r-A2. Furthermore, addition of 
heparin completely abolished cell transduction by r-wt but not by r-A2. Although the 
r-RGD4C-453 capsid contained RGD4C peptides, no interference was observed after 
addition of GRGDS peptide or GRGES peptide, while addition of heparin abolished 
cell transduction. In contrast, transduction of HeLa cells by r-RGD4C-453-A2, r-
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RGD4C-587, r-RGD4C-587-A2 and the double insertion mutants were competed by 
the GRGDS peptide, whereas the GRGES peptide or heparin had no effect. 
  
A)                B) 
 
Figure 14. Specificity of r-RGD4C mutants. HeLa cells were transduced by the different vectors. 
Approximately 50% of transduction efficiency was achieved with each vecto. A) Transduction was 
performed in the presence of competing GRGDS or control GRGES peptides or soluble heparin. 
Shown is the mean value of two independent experiments performed in triplicates. Error bars represent 
the standard error of the mean. B) 4h post-transduction cells were washed 4 times with PBS and 
scraped out of the wells. Amount of vector genomes found in the cells was determined by quantitative 
PCR. Show is the ratio between the amount of viral genomes used for transduction and the amount of 
viral genomes determined 4h post-transduction. 
 
In agreement with these results and with the fact that both double insertion 
mutants showed an efficient binding to their target receptor (Figure 13) is the 
observation that 4 hours p.i. the same relative amounts of r-RGD4C-453&587 and r-
RGD4C-453-A2 can be found with cells (Figure 14 B) while no r-A2 can be detected. 
This shows that double insertion mutants’ low ability of cell transduction is the result 
of a non-efficent post-binding step. 
These results demonstrate that r-RGD4C-453-A2, r-RGD4C-587, r-RGD4C-
587-A2 and the double insertion mutants transduce cells independently from AAV-2s’ 
primary receptor, but through the specific interaction of the inserted RGD4C motif 
presented on the viral capsid with an integrin receptor expressed on the cell surface. 
 
5.1.1.4. r-RGD4C-453-A2 shows superior transduction on CHO pgsA-745 
Next, we assessed the different capsid insertion mutants for their ability to 
transduce the Chinese Hamster Ovarian (CHO) cell derivative pgsA-745. CHO pgsA-
745 cells contain a defect in xylosyltransferase, an enzyme involved in the first sugar 
transfer in glycosaminoglycan synthesis, and thus do not produce glycosaminoglycans 
like HSPG. However, CHO pgsA-745 cells display integrins on their surface and 
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should therefore be an ideal target for capsid mutants displaying an integrin binding 
motif like RGD4C. CHO KI cells and their cell derivative CHO pgsA-745 were 
transduced with 1,000 genomic particles per cell for each vector and analyzed by flow 
cytometry 48h p.i. (Figure 15 A). 
On CHO pgsA-745 r-wt reached a transduction efficiency of only 7%. This 
low transduction efficiency may be due to the lack of HSPG on the cell surface, since 
a 2-fold higher transduction efficiency was determined for r-wt on CHO KI. 
 
A)                B) 
 
Figure 15. Infection of Chinese Hamster Ovarian Cells (CHO). A) CHO KI cells and their HSPG 
negative cell derivative pgsA-745 were transduced with 1,000 genomic particles per cell and amount of 
transgene expressing cells was determined by flow cytometry 48h p.t.. B) Cells were transduced with 
1,000 genomic particles per cell in the presence of competing GRGDS or control GRGES peptides or 
soluble heparin. Shown is the mean value of triplicate measurements with error bars representing the 
standard error of the mean.  
 
Even lower transduction efficiency was observed on both cell lines for r-A2, r-
RGD4C-453 and both double insertion mutants. Although r-RGD4C-587-A2 was 
superior in receptor binding (Figure 13) and capsid-to-infectious particle ratio (Table 
5), r-RGD4C-587 and r-RGD4C-587-A2 were equally efficient in transducing CHO 
pgsA-745 cells reaching 11% and 10%, respectively (Figure 15). Both mutants were 
significantly less efficient than r-RGD4C-453-A2 in CHO pgsA-745 cell 
transduction. While r-wt showed the best transduction efficiency on CHO KI, r-
RGD4C-453-A2 emerged as the most efficient vector on the HSPG negative cell line 
CHO pgsA-745. Competition studies with soluble RGD containing peptides 
confirmed receptor specificity of CHO pgsA-745 transductions (Figure 15 B). 
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5.1.1.5. Transduction of αVβ3 and αVβ5 positive primary human cells 
Tumor endothelial cells are clinically relevant targets for anti-tumor gene 
therapy, since tumors >1 mm3 depend on vascularization for growth and metastasis 
formation (53). The best available model system for tumor endothelial cells are 
primary angiogenic human umbilical vein endothelial cells (HUVEC) which express 
HSPG (54), αVβ5 and αVβ3 integrins (Figure 16 A). 
Therefore, we decided to test the most efficient capsid insertion mutant, r-
RGD4C-453-A2, for its ability to transduce primary angiogenic HUVEC. r-wt, that 
was used as a control, and r-RGD4C-453-A2 were both able to transduce primary 
angiogenic HUVECs (Figure 16 B). Furthermore, while r-wt transduction was 
dependent on HSPG, r-RGD4C-453-A2 transduced primary angiogenic HUVECs in a 
HSPG independent manner (Figure 16 C).  
 
A)                B) 
 
A)                C) 
Figure 16. Transduction of primary Human 
Umbilical Vein Endothelial Cells (HUVEC) 
by r-RGD4C-453-A2. A) Receptor 
distribution on primary HUVEC at a passage 
number below 5 were determined by staining 
with anti-αVβ3 (blue line) and anti-αVβ5 (red 
line) antibodies as described in Material and 
Methods. B) Primary HUVEC cells analyzed 
for receptor display at day of transduction were 
transduced with 10,000 genomic particles per 
cell of r-RGD4C-453-A2 and r-wt and 
analyzed for the amount of transgene expression 48h p.t. by flow cytometry. C) Cells were transduced 
with 10,000 genomic particles per cell in the presence of soluble heparin. Shown is the mean value of 
two experiments performed with triplicate measurements. Error bars represent the standard error of the 
mean.  
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5.1.1.6. In vivo biodistribution 
r-RGD4C-453-A2 and r-RGD4C-587 transduce cells via the same peptide, 
RGD4C (Figure 14, Figure 15). Furthermore, transduction in both cases occurs 
independently of AAVs’ primary receptor (Figure 14, Figure 15). However, the two 
capsid insertion mutants differ in the position used for peptide insertion and in the 
capsid modification leading to the non-HSPG binding phenotype. In vitro, these 
differences translate into variations in receptor binding (Figure 13) and in 
transduction efficiency (Figure 15). To investigate whether these differences also lead 
to alterations in their in vivo tropism, 1x1010 genomic particles of r-RGD4C-453-A2 
and r-RGD4C-587 were injected into the tail vein of 7 weeks old C57BL6 female 
mice. Mice treated in parallel with r-wt served as controls. We decided to analyze 
vector genomes instead of transgene expression since it allowed us to compare 
different vector tropisms independently from the ability of the cell to process AAV 
correctly and to express transgenes from AAV vector genomes. Animals were 
sacrificed 42 h p.i., liver, spleen, heart, lung, kidney and muscle were harvested and 
vector genome distribution was assessed by quantitative PCR (Figure 9).  
 
 
Figure 17. In vivo biodistribution of different HSPG ko and RGD4C insertion mutants. 1x1010  
genomic particles of r-wt, r-RGD4C-453-A2 and r-RGD4C-587 were infused into the tail vein of 7 
weeks old C57BL6 female mice (n= 3). Organs were harvested 42h p.i. and DNA was isolated. 
Absolute quantification of vector DNA and GAPDH DNA were performed by quantitative PCR. 
Values for vector DNA were normalized to GAPDH levels. Values are the mean of three mice in each 
group analyzed in two independent PCR runs with DNA obtained from two independent isolations. 
Error bars represent the standard error. 
 
As expected, r-wt was mainly detected in liver and spleen. Significantly fewer 
vector genomes were found in other organs (~ 40-fold less). Despite the differences 
observed between r-RGD4C-453-A2 and r-RGD4C-587 in vitro, no differences were 
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detectable in vivo. Both mutants showed an identical biodistribution. However, in 
comparison to r-wt, variations were observed. Vector genomes of r-RGD4C-453-A2 
and r-RGD4C-587 accumulated in heart, lung, kidney and muscle, with the most 
obvious difference to r-wt in the heart and in the lung.  
In a recent publication, we correlated liver and spleen retention of rAAV-2 
based targeting vectors with the ability to interact with HSPG (141). We thus 
expected to see a detargeting from liver and spleen for r-RGD4C-453-A2 and r-
RGD4C-587 in comparison to r-wt. In contrast to our assumption, the amount of 
vector genomes detected in these organs was comparable for all three vectors. To 
further investigate these observations we used the hepatocellular carcinoma cell line 
HepG2 as a model for hepatocytes and transduced this cell line with all three vectors 
in the presence and absence of either GRGDS or GRGES peptides, or of heparin. 
 
A)                B) 
 
Figure 18. Transduction of HepG2 cells. A) The hepatocellular carcinoma cells HepG2 were 
transduced with 1,000 and 10,000 genomic particles per cell respectively and amount of transgene 
expressing cells determined by flow cytometry 48h p.t.. B) Cells were transduced with 10,000 genomic 
particles per cell in the presence of competing GRGDS or control GRGES peptides or soluble heparin. 
Triplicate experiments were performed. Shown is the mean value of one representative experiment 
made with triplicate measurements with error bars representing the standard error of the mean.   
 
As depicted in Figure 18 A, all vectors were able to transduce HepG2 with r-
wt emerging as the most efficient vector.  r-wt mediated transduction of HepG2 was 
dependent on r-AAV-2’s interaction with HSPG (as seen by heparin competition 
studies) and could not be blocked by GRGDS or GRGES peptides (Figure 18 B). In 
contrast, transduction of HepG2 cells by r-RGD4C-453-A2 and r-RGD4C-587 was 
inhibited by addition of GRGDS peptides but not by heparin or GRGES peptides 
(Figure 18 B), suggesting that transduction of liver (and possibly also of spleen) by r-
RGD4C-453-A2 and r-RGD4C-587 was mediated by integrin binding through the 
inserted RGD4C peptide and not by HSPG binding as in the case of r-wt. Thus, r-wt 
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and capsid insertion mutants differ in the ligand-receptor interaction that led to liver 
(and spleen) transduction. 
 
5.1.1.7. Stability of vector particles  
Insertion of peptides in the capsid of AAV-2 is likely to affect its secondary 
and tertiary structure and by doing so, some of the physical properties of AAV-2. The 
CHO pgsA-745 cell line was used to analyze the resistance of our vectors to 
consecutive freezing cycles (Figure 19).  
 
 
Figure 19. Vector Stability. The Chinese Hamster Ovarian cell derivative pgsA-745 was transduced 
with the respective vectors after successive freeze and thaw cycles. Amount of genomic particles per 
cell: r-wt – 8,000; r-A2 – 10,000; r-RGD4C-453 – 10,000; r-RGD4C-453-A2 – 2,500; r-RGD4C-587 – 
4,000; r-RGD4C-453&587 – 10,000. Amount of transgene expressing cells was determined by flow 
cytometry 48h p.t.. Shown is the value of one single measurement. 
 
r-wt transduction efficiency was not affected along the 10 consecutive freezing 
events. r-RGD4C-453, r-RGD4C-453-A2 and r-RGD4C-587 showed a decay in their 
transduction efficiency along the 10 consecutive freezing cycles that dropped to half 
of the initial efficiency. r-A2 and r-RGD4C-453&587 were to low in transduction 
efficiency to allow the visualization of any alteration. Furthermore, r-RGD4C-587-A2 
and r-RGD4C-453&587-A2 were not included in these experiments since they were, 
at this time, not yet engineered.  
 
5.1.2. Insertion of the NGRI peptide 
To investigate if other peptides can also be inserted in position 453, we 
decided to substitute the RGD4C peptide by the NGRI peptide – ACVLNGRMECA.  
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This cyclic NGR peptide homes into tumors more effectively than linear 
peptides containing the NGR motif (4). NGRI targets APN (also known as CD13 
(175)). Although there are several subpopulations of APN (132), which are relatively 
widely distributed in the body, only one isoform is believed to be the receptor for the 
NGR peptide. This isoform was shown to be expressed exclusively in angiogenic 
vessels, such as the neovasculature found in tumor tissues (30, 32). By using a 
different receptor to target the same type of cells that RGD4C does, NGRI directed r-
AAV-2 mutants could complement r-RGD4C mutants and vice-versa. 
 
5.1.2.1. NGRI double insertion mutant is not impaired in cell transduction 
As with r-RGD4C mutants we started by evaluating the packaging efficiency 
of our mutants. As depicted in Table 6, based on their capsid-to-genomic ratio, all 
mutants showed a wt phenotype. r-NGRI-587-A2 and r-NGRI-453&587-A2 were not 
produced as we decided to focus our analysis on 453 single insertion mutants. 
 
Table 6. Vector titers of r-wt, r-A2 and NGRI insertion mutants. u.d.l. = under detection limit; wt = 
phenotype comparable to AAV with wild-type capsid according to Kern and colleagues.. (a): genomic 
titer was determined by quantitative PCR, shown is the mean value of 3 titrations; (b): capsid titer was 
determined by ELISA using A20 (antibody, which recognizes intact AAV-2 capsids), shown is the 
mean value of 2 titrations; (d): definition according to Kern and colleagues (97): wt phenotype 
indicates a packaging ratio of < 50; (d): determined on HeLa cells; (e): provides a simple comparison 
of how many genome-containing particle of each mutant were required to achieve the same number of 
transduced HeLa cells as AAV-2 with wild-type capsid (definition according to Opie and colleagues 
(135)). 
vector preparation 
gen. titer 
(per ml) 
(a) 
cap. titer 
(per ml) 
(b) 
packaging 
efficiency 
(cap-to-
gen ratio) 
phenotype 
based on 
cap-to-
gen ratio 
(c) 
transducing 
(inf.) titer 
(per ml) (d) 
cap-to-
inf ratio 
rel. 
cap-
to-inf. 
value 
(e) 
r-wt 1.40E+12 7.21E+12 5.2 wt 4.34E+10 166 1 
r-A2 1.11E+12 6.47E+12 5.8 wt u.d.l. - - 
r-NGRI-453 1.36E+12 5.33E+12 3.9 wt 4.09E+11 13 0.078 
r-NGRI-453 A2 8.29E+11 3.37E+12 4.1 wt 6.13E+08 5490 33 
r-NGRI-587 8.58E+11 6.57E+12 7.7 wt 9.55E+08 6877 41 
r-NGRI-453&587 5.35E+11 4.81E+12 9.0 wt 5.72E+08 8409 51 
 
Furthermore, western blot analysis revealed that all mutants possessed the 
correct ratio of the capsid structural proteins VP1, VP2, and VP3 – 1:1:10 
respectively – with the insertion of peptides in VP1, VP2, and VP3 resulting in 
proteins with a slower electrophoretic mobility (Figure 20). In agreement with 
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previous observations, A2 mutants also showed slower electrophoretic mobility 
(Figure 12, Figure 20). 
 
 
Figure 20. Western blot analysis of iodixanol gradient-purified AAV capsids. After iodixanol 
gradient purification the same amount of viral capsids (1010), were separated by sodium dodecyl sulfate 
polyacrylamide gel (8%) electrophoresis and analyzed by Western blotting with the B1 antibody. 
 
All mutants were able to transduce HeLa cells (Table 6) with r-NGRI-453 
mutant being even more efficient than r-wt (rel. cap-to-inf value). Interestingly, while 
r-RGD4C double insertion mutants were severely impaired in transduction (Table 5), 
the r-NGRI-453&587 double insertion mutant was able to transduce HeLa cells to the 
same extent as r-NGRI-453-A2 and r-NGRI-587 (Table 6). 
 
5.1.2.2. Efficiency of NGRI mutants in the transduction of primary 
HUVECs 
Primary Human Umbilical Vein Endothelial Cells, a model system for tumor 
endothelial cells, known to express APN, were treated with all r-NGRI mutants and 
respective controls – r-wt and r-A2. As depicted in Figure 21 A, while r-NGRI-453 
emerged as the most efficient vector its A2 homologue, r-NGRI-453-A2 was not able 
to transduce HUCECs.  
Transduction of HUVECs by r-wt and r-NGRI-453 was inhibited by soluble 
heparin while transduction by r-NGRI-587 and r-NGRI-453&587 was not (Figure 21 
B). 
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A)                B) 
 
Figure 21. Transduction of primary Human Umbilical Vein Endothelial Cells (HUVEC) by 
NGRI mutants. A) Primary HUVEC cells were transduced with 10,000 genomic particles per cell and 
analyzed for the amount of transgene expression 48h p.t. by flow cytometry. B) Cells were transduced 
with 10,000 genomic particles per cell in the presence of soluble heparin. Shown is the mean value of 
two experiments performed with triplicate measurements. Error bars represent the standard error of the 
mean. 
 
 
5.1.3. Insertion of an N587 display library selected peptide 
In the recent years, AAV-2 display library approaches for the transduction of 
non-permissive cells and enhancement of specificity have proven to be a valuable tool 
for the generation of targeting AAV-2 mutants and identification of targeting 
peptides. 
Having this in account, we decided to investigate if a peptide selected in 
position 587 of the AAV-2 capsid could be inserted in position 453 and still mediate 
transduction of the target cells. 
The chosen peptide was GEN – AGENQARSA – which was obtained from 
selections on Mec1 cells (a B-CLL cell derivative) (139). Insertion of this peptide in 
position 587 has previously shown to increase the transduction of Mec1 cells in a 
GEN dependent manner (as proven by competition studies with soluble peptides and 
heparin). 
 
5.1.3.1. GEN insertion in 453 does not interfere with vector packaging 
We first analyzed the packaging efficiency of our mutants. As depicted in 
Table 7, based on the capsid-to-genomic ratio all r-GEN mutants showed a wt 
phenotype.  
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Table 7. Vector titers of r-wt and GEN insertion mutants. wt = phenotype comparable to AAV with 
wild-type capsid according to Kern and colleagues. (a): genomic titer was determined by quantitative 
PCR, shown is the mean value of 3 titrations; (b): capsid titer was determined by ELISA using A20 
(antibody, which recognizes intact AAV-2 capsids), shown is the mean value of 2 titrations; (c): 
definition according to Kern and colleagues (97): wt phenotype indicates a packaging ratio of < 50. 
vector 
preparation  
gen. titer 
(per ml) 
(a) 
cap. titer 
(per ml) (b) 
packaging 
efficiency 
(cap-to-gen 
ratio) 
phenotype 
based on 
cap-to-
gen ratio 
(c) 
r-wt 1.68E+11 9.86E+11 5.9 wt 
r-GEN-453 1.58E+12 9.27E+12 5.9 wt 
r-GEN-453-A2 5.49E+11 5.32E+12 9.7 wt 
r-GEN-587 3.69E+11 1.65E+12 4.5 wt 
 
5.1.3.2. GEN insertion in 453 does not result in an improved vector 
For testing the transduction efficiency of our mutants, we used their target 
cells – Mec1. As depicted in Figure 22, r-wt emerged as the most efficient vector for 
transduction.  
 
 
Figure 22. Transduction of Mec1 cells. The B-CLL cell derivative Mec1 cells were transduced with 
10,000 genomic particles per cell and analyzed for the amount of transgene expression 48h p.t. by flow 
cytometry. Shown is the mean value of triplicate measurements. Error bars represent the standard error 
of the mean. 
 
Although r-GEN-587 was only the second best vector, transductions achieved 
by this vector were previously shown to be dependent on the inserted peptide and 
independent of HSPG. r-GEN-453, with an unmodified HSPG binding site was the 3rd 
best vector. Its A2 homologue, r-GEN-453-A2 was not able to efficiently transduce 
the target cells. 
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5.1.4. Translation to other Parvovirinae 
Proteins are generally composed of one or more functional regions, commonly 
termed domains. Different combinations of domains give rise to the diverse range of 
proteins found in nature. The identification of domains that occur within proteins can 
therefore provide insights into their function. Domains can be thought of as distinct 
functional and/or structural units of a protein. These two classifications coincide 
rather often, as a matter of fact, what is found as an independently folding unit of a 
polypeptide chain also carries specific function.  
In molecular evolution such domains may have been utilized as building 
blocks, and may have been recombined in different arrangements to modulate protein 
function. Conserved domains can be defined as recurring units in molecular evolution, 
the extents of which can be determined by sequence and structure analysis. Conserved 
domains can be described by multiple local sequence alignments. Computational 
biologists have compiled collections of such alignments representing conserved 
domains that can be accessed by using services like the NCBI's Conserved Domain 
Database (CDD) (117). The CDD is a collection of multiple sequence alignments for 
ancient domains and full-length proteins.  
Submission of the AAV-2 capsid protein VP2 to the CDD identified one 
major domain. This domain, part of the Parvovirus coat protein superfamily 
(pfam00740, imported from the Pfam database) includes G453 and N587. Within this 
superfamily, the 8 proteins that more resemble AAV-2 VP2, include: other AAV 
serotypes, other Dependovirus, Erythrovirus and Parvovirus (Figure 23 A). Of all, 
AAV-4 seems to have the highest homology to AAV-2 while the Parvovirus Canine 
parvovirus seems to have the lowest  (Figure 23 B). 
Analysis of the respective sequence alignments led to the identification of the 
AAV-2 G453 homologues in the other 8 Parvovirinae (Figure 23 C). The N587 
homologues were also identified. Analysis of the complete capsid of CPV, B19, 
AAV-4 and MVM revealed that the G453 homologues were indeed located in the 
outer surface of the respective viral capsids (Figure 23 C, D, data not shown). Despite 
this, CPV, B19, AAV-4, and MVM G453/T454 homologues are not the best-exposed 
residues in each respective capsid (Figure 23 D, data not shown). Furthermore, in the 
case of B19, the most exposed residue – K396 – matches AAV-2 N587 (Figure 23 C, 
D). 
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A)                B) 
 
C)                 
 
D)                E) 
 
Figure 23. Translation to other Parvovirinae. A-C) Retrieved from the NCBI’s Conserved Domain 
Database after submission of the AAV-2 capsid protein VP2. A) Taxonomy tree. Tree like structure 
that lays out the phylogeny of organisms, as recorded in NCBI’s taxonomy database. B) A 
phylogenetic tree, where the taxa represented at the end nodes are aligned sequences or sequence 
fragments. The length of each tree segment is indicated. C) Protein alignment. D) One quarter of the 
B19 complete capsid is shown. The distances of the respective residues to the virus center as calculated 
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by computational analysis were obtained from the VIPERdb service. E) 3d structure of the B19 VP2 
capsid protein. 
 
Comparison of the 3D structure of AAV-2 and B19 shows that the G453 and 
N587 homologues identified by protein alignment also have a very close homology at 
the structural level (Figure 9 C –Page 72–,Figure 23 D).  In AAV-2 as well as in B19 
both residues are located at the top of two structurally close loops. While in AAV-2 
the G453 loop has higher exposure than the N587 loop, in B19 this relation is 
inverted. Indeed, AAV-2 G453 and its Parvovirinae homologue residues are suitable 
for insertion of small peptides. 
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5.2. Fusing scFvs to AAV-2’s VP2 for the generation of 
new targeting mutants 
Antibodies have been proven to be an excellent paradigm for the design of 
high-affinity, protein-based binding reagents.  
The basic functional unit of each antibody is an immunoglobulin (Ig) 
monomer which is a “Y” shaped molecule that consists of four polypeptide chains; 
two identical heavy chains and two identical light chains connected by disulfide 
bonds. The paratope - responsible for the recognition of the epitope on the antigen 
molecule - is shaped at the amino terminal end of the antibody monomer by the 
variable domains from the heavy (VH) and light chains (VL) at the tip of the “Y”. 
Single chain variable fragments (scFv) can be engineered by fusing the variable 
regions (V) of the heavy and light chains of immunoglobulins with the help of a short 
linker (usually serine, glycine) for the prevention of dissociation. These smaller 
proteins (~ 28 kDa; when comparing for example to IgG ~ 150 kDa) retain the 
specificity of the original immunoglobulin despite removal of the constant regions. 
Such scFvs have emerged in the recent years as credible alternatives to whole Ig 
molecules (85, 123).  
In a recent publication our group fused the C-terminus of a GFP molecule (27 
kDa) to the N-terminus of the AAV-2 capsid protein VP2. Such fusion proteins (99 
kDa) were efficiently incorporated into the AAV-2 capsid without the loss of 
infectivity. 
With the intention of generating a CD30 targeting vector the same approach 
was followed and the C-terminus of an anti-CD30 scFv fused to the N-terminus of 
VP2.  
 
5.2.1. GFP is located on the outer surface of the capsid 
Previously published models of the AAV-2 capsid structure propose a flexible 
N-terminus of VP2 as well as of VP1 (105). In agreement with this model these N-
terminus would be located on the inner side of the viral capsid and, during infection, 
pass through the pores on the 5-fold symmetry axis becoming exposed on the outer 
surface. 
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In order to proper interact with their target receptor, targeting molecules must 
be present on the outer surface of the capsid. We therefore analyzed the location of 
the N-terminus of the GFP-VP2 fusion protein prior to cell transduction. 
Analysis of AAV-2 particles containing the GFP-VP2 fusion protein (r-GFP) 
was first made by immobilization of the particles on an ELISA plate previously 
coated with an anti-GFP antibody. Detection of intact AAV-2 particles was then done 
using the anti-AAV-2 intact capsids monoclonal antibody A20 (Figure 24).  
 
 
Figure 24. Surface exposure of GFP. 1.0x1010 iodixanol gradient purified capsids containing the 
GFP-VP2 fusion protein (r-GFP) were added to an ELISA plate that had been previously coated with 
an anti-GFP antibody as described in the Methods section. r-wt with wt VP2 was used as a control. 
Detection of intact capsids was done using the anti-AAV-2 monoclonal antibody A20. PBS coated 
wells were used as controls and respective values deduced. Shown is the mean value of duplicate 
measurements. Error bars represent the standard error of the mean.  
 
The strong signal obtained from the r-GFP vector preparation in comparison to 
the absence of signal from the AAV-2 preparation possessing wt VP2 (r-wt) reveals 
that the recognized epitope of the GFP molecule is indeed exposed on the outer 
surface of the vector. This observation highlights the potential of the N-terminus of 
VP2 for the insertion/fusion of targeting molecules that once exposed on the outer 
surface of the vector could interact with their respective receptor.  
 
5.2.2. aCD30-GFP-VP2 
Based on the previous observation that GFP is present on the outer surface of 
the AAV-2 capsid we decided to fuse the C-terminus of an anti-CD30 scFv (~ 28 
kDa) to the N-terminus of the GFP-VP2 fusion protein creating the following fusion: 
aCD30-GFP-VP2 (127 kDa). Such construct, by having the GFP molecule as a 
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linker/spacer, should create the possibility for the paratope to interact with the 
antigen. At the same time, GFP tagged capsids can be a useful tool for infectious 
biology studies. 
Analysis of our construct and respective viral preparations was first made by 
Western blotting of protein purified by high-speed centrifugation of cell lysates 
(Figure 25).  
For the production of viral vectors HEK293 cells must be infected with an 
helper virus or transfected with a plasmid encoding helper functions as the plasmid 
pXX6-80. Since the GFP transgene was supplied by the pssGFP plasmid, control was 
done by transfecting cells with pXX6-80 and pssGFP (Figure 25 A, lane: pXX6-80 + 
pssGFP). 
For the production of vectors a plasmid encoding the viral Rep and Cap 
proteins must be supplied - pRC. In the case of vectors with VP2 fusion proteins wt 
VP2 is not expressed from this plasmid – pRC VP2 ko – and the respective fusion is 
supplied in trans (Figure 25 A, lanes: pRC VP2 ko and pGFP-VP2, respectively). 
The anti-CD30-GFP-VP2 fusion was also analyzed by Western blotting 
(Figure 25 A, lane: paCD30-GFP-VP2). 
Wild type AAV-2, produced by transfecting the cells with pXX6-80, pssGFP, 
and pRC was used as reference for the expression and size of the structural proteins 
(Figure 25 A, lane: r-wt). 
Production of vectors containing the GFP-VP2 fusion protein can be achieved 
by transfection with pXX6-80, pssGFP, pRC VP2 ko, and pGFP-VP2 (Figure 25 A, 
lane: r-GFP). The same holds true when using paCD30-GFP-VP2 instead of pGFP-
VP2 for the production of mutants with an incorporated anti-CD30-GFP-VP2 fusion 
protein (Figure 25 A, lane: r-GFP-aCD30). 
For the separation of vector capsids from other extracted proteins an   
iodixanol step gradient purification was performed. Vector capsids were recovered 
from the 40% iodixanol phase and analyzed by Western blotting (Figure 25 B).   
As expected, transfection with pXX6-80, pssGFP and pRC resulted in the 
expression of the different capsid proteins VP1 (90 kDa), VP2 (72 kDa) and VP3 (60 
kDa) with a ratio of 1:1:10 respectively (Figure 25 A, r-wt). After iodixanol gradient 
purification this ratio was still the same (Figure 25 B, r-wt). In contrast, the VP1 : 
GFP-VP2 : VP3 ratio significantly differed from the expected 1:1:10, respectively 
(Figure 25 A, pGFP-VP2 vs. pRC VP2 ko, and r-GFP respectively).  The non-specific 
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antibody binding around 60 kDa and 140 kDa can be used as control for the total 
amount of protein loaded (Figure 25 A). 
 
A)                B) 
 
Figure 25. Western blot analysis of r-GFP-aCD30. A) HEK293 cells were transfected with pXX6-
80, pssGFP and AAV-2 capsid protein coding plasmids. Protein extraction was performed and 30 µg of 
protein were separated by SDS-PAGE and analyzed by Western blotting using the B1 antibody. B) 
After iodixanol gradient purification r-wt, r-GFP and r-GFP-aCD30 were separated and analyzed by 
the same methods (20 µl, 40 µl and 40 µl respectively). 
 
Co-transfection with pXX6-80, pssGFP, pRC VP2 ko and pGFP-VP2 results 
in an AAV-2 vector with incorporated GFP-VP2 fusion proteins – r-GFP (Figure 25 
B, r-GFP). This co-transfection also resulted in a decreased amount of VP1 and VP3 
(Figure 25 A, pRC VP2 ko vs. r-GFP). Since VP3, the most abundant capsid is 
essential for packaging of vector particles, less particles were recovered (data not 
shown and Figure 25 B, r-GFP). 
Lower amounts of the aCD30-GFP-VP2 protein were found in HEK293 in 
comparison to GFP-VP2 (Figure 25 A, paCD30-GFP-VP2 vs. pGFP-VP2 
respectively). The same was observed when trying to package this constructs by co-
transfecting the cells with pRC VP2 ko (Figure 25 A, r-GFP-aCD30 vs. r-GFP 
respectively). Protein extracts revealed a ratio of VP1 : aCD30-GFP-VP2 : VP3 of 
1:1:10 but the fusion protein was not detectable after iodixanol gradient purification 
(Figure 25 A and B, r-GFP-aCD30). This observation points towards an inefficient 
incorporation the aCD30-GFP-VP2 fusion protein into the AAV-2 capsid. The 
amount of genomic particles detected on the 25% and 60% phases of the iodixanol 
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gradient was, for all vectors, inferior to the amount found on the 40% phase – not 
allowing analysis by Western blotting (data not shown, see Table 8). 
 
5.2.3. aCD30nVP2 
The increasing size of VP2 as a capsid protein (from ~ 72 kDa for VP2 to ~ 
127 kDa for aCD30-GFP-VP2) can make the fusion protein intolerable on the AAV-2 
capsid. 
Taking this in account new fusion proteins containing the anti-CD30 scFv and 
the VP2 proteins were engineered (Figure 26 A): 
- aCD30-VP2: a fusion of the C-terminus of the scFv to the N-terminus of 
VP2; an exact parallel to the GFP-VP2 fusion protein. 
- aCD30CLVP2: a version of the aCD30-VP2 construct with a 
glycine/serine linker between the scFv and the VP2; as described above 
glycine/serine linkers are commonly used in the engineering of scFv for 
prevention of dissociation of the VH from the VL; linkers made of such 
small amino acids should provide good flexibility.  
- aCD30CL2VP2: just like aCD30CLVP2 but with a double glycine/serine 
linker. 
- aCD30GLVP2: just like aCD30-VP2 but, the non-globular C-terminal part 
of GFP that is fused to VP2 in the GFP-VP2 construct - ITLGMDEL -  is 
inserted between the anti-CD30 scFv and VP2 as linker.  
- aCD30LGLVP2: just like aCD30GLVP2 but with a glycine/serine linker 
inserted between the anti-CD30 scFv and the non-globular C-Terminal 
part of GFP.  
Although not indicated all these fusions contained mutations on the VP3 
common region leading to R585A and R588A substitutions (see Page 101). 
Western blot analysis of HEK293 cells lysates obtained after co-transfection 
with pXX6-80 and the respective constructs showed once again a lower amount of 
aCD30nVP2 fusion proteins in comparison to the GFP-VP2 construct (Figure 26 B, ~ 
100 kDa). 
When using this constructs to generate vector particles, aCD30nVP2 were not 
detected after density gradient purification (data not shown). 
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A)              B) 
 
Figure 26. Western blot analysis of different aCD30-VP2 constructs. A) Amino acid sequence of 
the different aCD30-VP2 constructs. Sequences are shown in a N-terminus to C-terminus orientation. 
B) HEK293 cells were transfected with pXX6-80 and plasmids coding for different aCD30-VP2 
constructs. Protein extraction was performed and 30µg of protein were separated by SDS-PAGE and 
analyzed by Western blotting using the B1 antibody. 
 
 
5.2.4. Optimizing expression in cis 
Production of AAV-2 particles with 100% substitution of VP2 by the GFP-
VP2 protein showed that in protein extracts the ratio of VP1 : GFP-VP2 is below 1 
(Figure 25 A, r-GFP). Despite this, purification of vectors from such extracts resulted 
in vector preparations with the correct VP1 : GFP-VP2 ratio - 1 : 1 (Figure 25 B, r-
GFP). The same did not hold true when packaging vectors with aCD30nVP2 fusion 
proteins. The inefficient incorporation of aCD30nVP2 fusion proteins into AAV-2 
capsids may be the result of the low amounts of the aCD30nVP2 proteins. Thus, a 
higher expression of the constructs may be required for their incorporation into 
complete capsids. 
The Kozak consensus translation initiation site, known to improve translation 
efficiency in eukaryotic cells, is present in the GFP-VP2 construct encoding plasmid. 
This sequence which occurs on eukaryotic mRNA has the consensus 
(gcc)gccRccAUGG, where R is a purine three bases upstream of the start codon 
which is followed by another G. This consensus was eliminated during the cloning of 
the aCD30nVP2 constructs and is not present in any of the fusion proteins that 
contain the anti-CD30 scFv.  
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Direct fusion of the anti-CD30 scFv to VP2 results in a protein with 
approximately the same size of GFP-VP2 (Figure 26 B, paCD30-VP2 and pGFP-VP2 
respectively). Having this in account, the aCD30-VP2 construct was chosen as 
background for the complete recover of the Kozak consensus as well as the complete 
sequence between the CMV promoter and the start codon. The plasmid pKaCD30-
VP2 was engineered and used for co-transfection of HEK293 cells (Figure 27, 
pKaCD30-VP2) and production of vector particles (Figure 27, r-aCD30-K-A2).  
 
 
Figure 27. Western blot analysis of an aCD30-VP2 construct containing the Kozak consensus. 
HEK293 cells were transfected with pXX6-80, pssGFP and AAV-2 capsid protein coding plasmids. 
Protein extraction was performed and 30 µg of protein were separated by SDS-PAGE and analyzed by 
Western blotting using the B1 antibody. 
 
Inclusion of the Kozak consensus did not increase the amount of the aCD30-
VP2 fusion protein in HEK293 cells after transfection (Figure 27, paCD30-VP2 and 
pKaCD30-VP2). As a result, the ratio of VP1 : aCD30-VP2 remained higher than 1 
(Figure 27, r-aCD30-A2 and r-aCD30-K-A2).  
 
5.2.5. Optimizing expression in trans 
Unlike with AAV-2 vectors containing wt VP2, vectors with VP2 fusion 
proteins are packaged by using two independent plasmids – one coding for the VP2 
fusion, and one coding for VP1 and VP3. Increasing the amount of aCD30nVP2 
plasmid used for transfection should increase the amount of the respective fusion 
protein in the transfected cells.  
 98 
HEK293 cells were co-transfected with pXX6-80, pssGFP, pRC VP2 ko, and 
paCD30-GFP-VP2. The amount of transfected paCD30-GFP-VP2 was raised 2, 3, 4, 
5 and 6 times. Protein extracts were analyzed by Western blotting (Figure 28 A). 
 
       A) 
Figure 28. Western blot analysis of 
r-GFP-aCD30 vectors packaged with 
increased amounts of paCD30-GFP-
VP2. A) HEK293 cells were 
transfected with pXX6-80, pssGFP and 
AAV-2 capsid protein coding 
plasmids.  Amount of paCD30-GFP-
VP2 supplied in trans during 
packaging was raised 1 to 6 times (r-
GFP-aCD30 - 1 to r-GFP-aCD30 – 6 
respectively). Protein extraction was 
performed and 30 µg of protein were 
separated by SDS-PAGE and analyzed 
by Western blotting using the B1 
antibody. B) After iodixanol gradient 
purification r-wt, r-GFP and the several 
r-GFP-aCD30 vectors were separated 
and analyzed as in A (20 µl, 40 µl and 
40 µl respectively). 
 
 
 
 
 
 
 
Increasing the amount of the aCD30-GFP-VP2 encoding plasmids used for 
transfection resulted in a decrease of the VP1 : aCD30-GFP-VP2 ratio.  
The amounts of VP1, VP2, and VP3 found in HEK293 cells increased with the 
amount of paCD30-GFP-VP2 plasmid used for transfection until a threshold value of 
3x. Beyond this threshold the amount of the different capsid proteins started to 
decrease. 
The vector preparations in the above analyzed protein extracts were then 
purified by iodixanol gradient purification. The increase of paCD30-GFP-VP2 used, 
resulted in a decrease of the VP1 : aCD30-GFP-VP2 ratio until this ratio reached a 
value of 1 with the use of 4x more plasmid (Figure 28). The amount of VP1 and VP3 
decreased with the increase of paCD30-GFP-VP2 used. Indeed, the use of 4x more 
B) 
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paCD30-GFP-VP2 resulted in AAV-2 particles with natural amount aCD30-GFP-
VP2. 
As depicted in Table 8 the amount of particles recovered after iodixanol 
gradient purification was significantly lower when packaging vectors with VP2 fusion 
proteins (Table 8, gen. titer, 40% iodixanol phase). This was especially true in the 
case of r-GFP. Surprisingly, more particles of r-GFP-aCD30-x than r-GFP were 
recovered. Moreover, genomic titers are in agreement with the amount of VP1 and 
VP3 detected in these iodixanol purified preparations (Figure 28, for r-wt 20 µl were 
loaded while for the remaining vectors 40 µl were loaded in the well). 
Furthermore, the highest amount of each vector preparation was found within 
the 40% phase of the iodixanol gradient. r-GFP-aCD30 vectors were 1.3 to 2.2 times 
less infectious than r-wt on HeLa cells. This can still be considered a wt phenotype. 
In summary, by increasing the amount of paCD30-GFP-VP2 plasmid used for 
transfection of HEK293 cells during vector production, we obtained infectious 
particles that efficiently incorporated the aCD30-GFP-VP2 fusion proteins. 
 
Table 8. Vector titers of r-wt and aCD30-GFP-VP2 mutants. n.d. = not determined; u.d.l. = under 
detection limit; wt = phenotype comparable to AAV with wild-type capsid according to Kern and 
colleagues. (a) Amount of paCD30-GFP-VP2 supplied in trans during packaging was raised 1 to 6 
times (r-GFP-aCD30 - 1 to r-GFP-aCD30 – 6 respectively). (b): after iodixanol gradient purification 
different phases of the gradient were recovered and genomic titers determined by quantitative PCR, 
shown is the mean value of 3 titrations; (c): transducing titers of the 40% phase were determined on 
HeLa cells, shown is the mean value of 2 titrations; (d): provides a simple comparison of how many 
genome-containing particle of each mutant were required to achieve the same number of transduced 
HeLa cells as AAV-2 with wild-type capsid (definition according to Opie and colleagues (135)). 
gen. titer (per ml) (b) 
vector preparation (a) 
25% 40% 60% 
transducing 
(inf.) titer 
(per ml) (c) 
gen-to-
inf ratio 
rel. 
cap-to-
inf 
value 
(d) 
r-wt 6.63E+09 2.49E+11 2.48E+09 1.65E+09 150.93 1.0 
r-GFP 1.65+09 6.00E+09 1.03E+08 1.52E+07 394.65 2.6 
r-GFP-aCD30-1 3.41E+09 6.53E+10 3.09E+09 2.07E+08 315.62 2.1 
r-GFP-aCD30-2  9.38E+10  4.67E+08 200.77 1.3 
r-GFP-aCD30-3  6.72E+10  3.01E+08 223.28 1.5 
r-GFP-aCD30-4 2.19E09 2.40E+10 1.28E+10 8.54E+07 280.49 1.9 
r-GFP-aCD30-5  1.72E+10  5.57E+07 308.88 2.0 
r-GFP-aCD30-6  5.41E+09  1.65E+07 327.96 2.2 
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5.2.6. Functional scFv 
Interaction between the vector and its receptor is fundamental for transduction. 
In the case of a scFv driven AAV-2 vector this interaction has to be made between the 
paratope (on the scFv) and the epitope (on the antigen). Such interaction can be 
mimicked by the use of an anti-idiotypic antibody that recognizes the paratope. An 
anti-idiotypic antibody recognizes an unique set of antigenic determinants of the 
variable portion of another antibody – the idiotope. 
Protein extracts from vector producing cells and their respective iodixanol 
gradient purified preparations were immobilized in an ELISA plate previously coated 
with an anti-idiotypic antibody - 9G10 - that recognizes the anti-CD30 scFv paratope. 
Detection was then made using an anti-GFP antibody for detection of the anti-
CD30/GFP fusion (Figure 29 A). Detection was also made with an anti-AAV-2 
antibody (A20) for detection of functional anti-CD30 scFv in intact AAV-2 particles 
(Figure 29 B). As negative controls a vector containing different scFv-GFP-VP2 
fusion protein was used (see Figure 33) and a mouse IgG fraction used for the coating 
of the plates. As positive controls, anti-CD30 scFv with human Fc was used (detected 
with an anti-human Fc antibody) and an anti-AAV-2 antibody was used for the 
coating of the plates. 
Functional - antigen recognition and binding - anti-CD30 scFv fused to the 
GFP molecule was detected in protein extracts (Figure 29 A, r-GFP-aCD30 (Prot. 
Ext.)). This is supported by the strong difference between the r-GFP-aCD30/anti-
idiotypic signal, the IgG coated control and the r-GFP-XYX (where XYX stands for 
another scFv that recognizes a different antigen) preparation. The anti-CD30 
scFv/GFP fusion was not detectable after iodixanol gradient purification (Figure 29 
A, r-GFP-aCD30 (Grad)).  
Using the anti-AAV-2 intact capsids A20 antibody it was not possible to 
detect intact AAV-2 capsids with a functional (Figure 29 B, r-GFP-aCD30). Despite 
this, functional anti-CD30 molecules were detected in iodixanol gradient purified 
preparations by coating iodixanol gradient purified r-GFP-aCD30 and detecting the 
paratope with the anti-idiotypic antibody 9G10  (Figure 29 C). 
In summary, functional molecules were detected before and after gradient 
purification but not in intact AAV-2 capids. None of the production and purification 
steps seems to damage the anti-CD30 scFV. 
 101 
A)                B) 
 
C)                 
Figure 29. Identification of a functional scFv. 
To verify that the CD30 binding domain of the 
scFv present in the aCD30-GFP-VP2 construct 
was able to bind its target molecule an anti-
idiotypic ELISA was perform. An ELISA plate 
was coated with an anti-idiotypic antibody, and 
an IgG fraction, and PBS, respectively as 
controls. Vector solutions obtained from either 
protein extracts (Prot. Ext.) or iodixanol gradient 
purification (Grad.) were diluted 1 to 4 and 
applied on the plate. A) Detection was done 
using and anti-GFP antibody. B) Alternatively detection was done using biotinylated anti-AAV-2 
antibody A20. Also, as controls, coating was done using purified anti-AAV-2 antibody A20 and 
aCD30-hum.Fc purified protein was detected with an anti-hum.Fc antibody. C) An ELISA plate was 
coated with iodixanol gradient purified r-GFP-aCD30 (dil 1:4), purified aCD30-hum.Fc as positive 
control and PBS as negative control. Detection was made with an anti-idiotypic antibody. PBS values 
were deduced. Shown is the mean value of duplicate measurements. Error bars represent the standard 
error of the mean. 
 
 
5.2.7. Transduction of target cells 
In gene therapy, transduction of the target cells is in most cases the major goal. 
Vector preparations obtained either by protein extraction of vector producing cells or 
iodixanol gradient purification of such extracts were used in transduction assays. To 
compare the infectivity of vectors in such preparations HeLa cells were transduced 
with r-wt obtained from protein extraction of vector producing cells and in parallel 
with r-wt from iodixanol gradient purified preparations of the same extracts. The 
resulting genomic to infectious ratios values were 92 and 61, respectively. The 
preparations can be considered as equally infectious. 
AAV-2 wt is able to enter a large amount of cell types through the binding to 
its primary receptor – HSPG. Avoiding this binding is a very important tool when 
studying targeting mutants that bind to new receptors. For this, two arginines in the 
VP3 common region of the AAV-2 capsid proteins can be mutated to alanines – 
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R585A and R588A, according to VP1 numbering. Thus, by eliminating the binding to 
wild type receptors one straitens the transduction to the interaction of the new inserted 
ligand with its target receptor.  
A GFP coding AAV-2 vector with an incorporated aCD30-GFP-VP2 fusion 
protein and R585A and R588A (A2) substitutions was packaged and named r-GFP-
aCD30-A2. In agreement with the above described results 4x more paCD30-GFP-
VP2-A2 was used for the packaging of this mutant. r-GFP-aCD30 was packaged as a 
control. r-wt, r-GFP and their A2 homologues were also packaged as controls. 
Following purification r-wt and  r-A2 preparations contained approximately 10x more 
genomic particles than r-GFP-aCD30 and r-GFP-aCD30–A2 preparations and about 
100x more genomic particles than r-GFP and r-GFP-A2 preparations (data not 
shown). 
Western blot analysis of gradient purified vectors indicates that A2 mutants 
possess VP1, VP2, or VP2 fusion proteins, and VP3 with a slightly higher molecular 
weight than their R585 and R588 counterparts (Figure 30 A, e.g. r-wt vs. r-A2). The 
low titers of r-GFP and r-GFP-A2 did not allow a clear detection of the VP1 capsid 
protein. In these r-GFP and r-GFP-A2 vectors the GFP-VP2 : VP1 and the GFP-VP2 : 
VP3 ratios are much higher than the expected values of 1 and 0.1, respectively. r-
GFP-aCD30 and r-GFP-aCD30-A2 showed an aCD30-GFP-VP2 : VP1 ratio slightly 
higher than 1. 
As target cells, the human Hodgkin’s lymphoma derived cell line L540 was 
used. One of the characteristics of this cell line is the high expression of the CD30 
antigen in its entire cell population (Figure 30 B). 
r-GFP-aCD30-A2 was used for transduction of L540 cells (Figure 30 C).  r-wt 
and r-A2 were used as controls. The low titers of r-GFP and r-GFP-A2 forced the 
exclusion of these vectors from this experiment. Vectors obtained after protein 
extraction by high speed centrifugation of cells lysates of vector producing cells 
(Protein Extracts) and following iodixanol gradient purification of the respective 
extracts (Gradient) were used. Since all vectors contain a GFP coding gene (as 
transgene) GFP molecules are expected to be found in preparations that were not 
submitted to iodixanol gradient purification. This molecule may also be able to 
interact with cells. Despite this, there was not any detectable fluorescence 1 h post-
transduction. Apart from r-wt, no other vector was able to transduce the target cells. 
Transduction by r-wt obtained from protein extraction of vector producing cells and 
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following iodixanol gradient purification of the respective extracts resulted in the 
same number of GFP expressing cells. The amount of GFP molecules per cell 
(determined by the mean fluorescence intensity - MFI) was also equal (data not 
shown). 
 
A)                B) 
 
C)                D) 
 
Figure 30. Transduction of CD30+ cells by r-GFP-aCD30-A2. A) After iodixanol gradient 
purification the different vectors were separated by SDS-PAGE, and analyzed by Western blotting 
using the B1 antibody (20 µl of r-wt, 20 µl of r-A2 and 40 µl of each of the remaining vectors). B) The 
presence of the target molecule – CD30 – on L540 cells at the time of infection was determined by 
staining with an anti-CD30 antibody (thicker black line) and analyzed by flow cytometry. C) The 
different vector preparations obtained either from protein extraction of vector producing cells or 
iodixanol gradient purification of the respective protein extracts were used to transduce L540 cells 
(MOI = 10,000 gen.p./cell). Amount of transgene expressing cells was determined by flow cytometry 1 
h and 48 h p.t. D) Alternatively, cells were collected, washed three times in PBS and used to perform 
DNA isolation. Amount of vector genomes found in the cells was determined by quantitative PCR. 
Show is the ratio between the amount of viral genomes used for transduction and the amount of viral 
genomes determined 1 h and 48 h p.t. Shown is the mean value of triplicate measurements. Error bars 
represent the standard error of the mean. 
  
For transduction, after binding of the vector to the target receptor, the vector 
transgene must also find a way to reach the nucleus. To determine if, despite the lack 
of transduction capacity, there was binding of the targeting mutants to the cells 
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carrying the target receptor, detection of vector DNA was performed 1 h and 48 h p.t. 
(Figure 30 D). 1 h at 37 ºC should give enough time for the scFv to bind the antigen 
and at the same time not be enough for the cells to harm the vector (e.g. by 
proteossomal degradation). r-wt vector DNA was detected 48 h p.t. (Figure 30 D). 
Apart from this no vector DNA was detected at any other time point or when other 
vectors were used.  
 
A)                 
 
B)                C) 
 
Figure 31. Transduction of CD30+ cells by different r-aCD30-A2 vectors. Vectors were packaged 
by increasing the amount of the aCD30-VP2 constructs by 4x. A) After iodixanol gradient purification 
the different vectors were separated by SDS-PAGE, and analyzed by Western blotting using the B1 
antibody (20 µl of r-wt, 20 µl of r-A2 and 40 µl of each of the remaining vectors). B) The different 
vector preparations obtained either from protein extraction of vector producing cells or iodixanol 
gradient purification of the respective protein extracts were used to transduce L540 cells (MOI = 
10,000 gen.p./cell). Amount of transgene expressing cells was determined by flow cytometry 1 h and 
48 h p.t. C) Alternatively, cells were collected, washed three times in PBS and used to perform DNA. 
Amount of vector genomes found in the cells was determined by quantitative PCR. Show is the ratio 
between the amount of viral genomes used for transduction and the amount of viral genomes 
determined 1h and 48 h p.t. Shown is the mean value of triplicate measurements. Error bars represent 
the standard error of the mean. 
 
By increasing 4x the amount of paCD30nVP2-A2 used for vector packaging, 
vectors containing the anti-CD30 scFv fused to VP2 (without GFP as linker molecule) 
and with R585A and R588A substitutions were packaged. Western blot analysis 
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indicated once more that R585A and R588A substitutions result in a VP1, a VP2 and 
a VP3 of higher molecular weight (Figure 31 A, r-wt vs. r-A2). The aCD30nVP2 : 
VP1 ratio was in all vectors very close to 1 (Figure 31 A, r-aCD30-A2 to r-
GLLaCD30-A2).  
Once more, only r-wt was able to transduce L540 cells (Figure 31 B). The 
amount of vector DNA found with L540 cells 48 h p.t. was the same when using r-wt 
after protein extraction from vector producing cells and gradient purified particles 
(Figure 31 C, r-wt, 48 h, Protein Extracts vs. Gradient). Despite this and the equal 
transduction efficiency, the amount of vector DNA found 1 h p.t was higher when 
using r-wt obtained only by protein extraction (Figure 31 C, r-wt, 1 h, Protein Extracts 
vs. Gradient). Furthermore, in this case, the amount of DNA found after 1 h, equals 
the amount found after 48 h (Figure 31 C, Protein Extracts, 1 h vs. 48 h). No 
significant amount of vector DNA was found when using any of the other vectors. 
 
5.2.8. anti-CA19.9 scFv 
To determine if the lack of transduction and binding efficiency of r-GFP-
aCD30 was due to the anti-CD30 scFv, a different scFv was fused to N-terminus of 
the GFP-VP2 protein and vectors with R585A and R588A substitutions packaged. 5x, 
10x and 15x higher amounts of the plasmid coding for the aCA19-GFP-VP2 fusion 
protein were used during packaging. Western blot analysis revealed that the best 
aCA19-GFP-VP2 : VP1 ratio – 1 : 1 – could be achieved by using 5x more of the 
respective plasmid (Figure 32 A). This vector was used in following experiments and 
named r-GFP-aCA19-A2.   
r-wt, r-A2 and r-GFP-aCA19-A2 obtained by protein extraction from vector 
producing cells (Protein Extracts) or following iodixanol gradient purification of the 
respective extracts (Gradient) were used to transduce the CA9.9 positive human colon 
carcinoma derived cell line LS174T (Figure 32 B,  C). Transduced cells were only 
detectable 48 h p.t. when using r-wt (Figure 32 C, r-wt, Protein Extracts and 
Gradient). The same holds true for the amount of vector DNA, which was only found 
in relevant amounts 48 h p.t. when using r-wt (Figure 32 D, r-wt, Protein Extracts and 
Gradient). The low fluorescence detected with r-GFP-aCA19-A2 is an artefact that 
results of a change in cell granularity and shape (as detected by flow cytometry; data 
not shown), which were probably due to the high percentage of vector volume. 
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A)                B) 
 
C)                D) 
 
Figure 32. AAV-2-GFP-aCA19.9 A) r-GFP-aCA19 was packaged by increasing the amount of 
paCA19-GFP-VP2 supplied in trans 5 to 15x (r-GFP-aCA19-A2-5 to r-GFP-aCA19-15 respectively). 
After iodixanol gradient purification the different vectors were separated by SDS-PAGE, and analyzed 
by Western blotting using the B1 antibody (20 µl of r-wt, 20 µl of r-A2 and 40 µl of each of the 
remaining vectors). r-GFP-CA19-A2-5 was used in the following experiments.  B) The presence of the 
target molecule – CA19.9 – on LS174T cells at the time of infection was determined by staining with 
an anti-CA19.9 antibody (thicker black line) and analyzed by flow cytometry. C) The different vector 
preparations, obtained either from protein extraction of vector producing cells or iodixanol gradient 
purification of the respective protein extracts, were used to transduce LS174T cells (MOI = 5,000 
gen.p./cell). Amount of transgene expressing cells was determined by flow cytometry 1 h and 48 h p.t. 
D) Alternatively, cells were collected, washed three times in PBS, and used to perform DNA isolation. 
Amount of vector genomes found in the cells was determined by quantitative PCR. Shown is the ratio 
between the amount of viral genomes used for transduction and the amount of viral genomes 
determined 1 h and 48 h p.t. Shown is the mean value of triplicate measurements. Error bars represent 
the standard error of the mean. 
 
 
5.2.9. anti-CEA scFv 
One other scFv was used for exclusion of idotype specific problems in the 
construction of AAV-2 vectors with scFv/VP2 fusion proteins. 
An anti-CEA scFv was fused to the N-terminus of the GFP-VP2 fusion 
protein.  Western blot analysis of vector purified particles revealed that the best 
aCEA-GFP-VP2 : VP1 ratio is achieved by using 10x more of the paCD30-GFP-VP2 
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plasmid (Figure 33 A, r-GFP-aCEA-A2-10). This vector was used in the following 
experiments and named r-GFP-aCEA-A2. 
 
A)                 
 
B)                C) 
 
D)                E) 
 
F)                G) 
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Figure 33. AAV-2-GFP-aCEA A) r-GFP-aCEA was packaged by increasing the amount of paCEA-
GFP-VP2 VP2 supplied in trans 5 to 15x (r-GFP-aCEA-A2-5 to r-GFP-aCEA-15 respectively). After 
iodixanol gradient purification the different vectors were separated by SDS-PAGE, and analyzed by 
Western blotting using the B1 antibody (20 µl of r-wt, 20 µl of r-A2 and 40 µl of each of the remaining 
vectors). r-GFP-aCEA-A2-10 was used in the following experiments. B) The presence of the target 
molecule – CEA – on LS174T cells and C) C15A3 cells at the time of infection was determined by 
staining with an anti-CEA antibody (thicker black line) and analyzed by flow cytometry. D-G) The 
different vector preparations obtained either from protein extraction of vector producing cells or 
iodixanol gradient purification of the respective protein extracts were used to transduce D, E) LS174T 
cells and F, G) C15A3 cells – for the transduction of C15A3 cells only protein extracts were used - 
(MOI = 5,000 gen.p./cell). D, F) Amount of transgene expressing cells was determined by flow 
cytometry 1 h and 48 h p.t. E, G) Alternatively, cells were collected (C15A3 were first scraped out of 
the plates), washed three times in PBS, and used to perform DNA isolation. Amount of vector genomes 
found in the cells was determined by quantitative PCR. Show is the ratio between the amount of viral 
genomes used for transduction and the amount of viral genomes determined 1 h and 48 h p.t. Shown is 
the mean value of triplicate measurements. Error bars represent the standard error of the mean. 
 
r-wt, r-A2, and r-GFP-aCEA-A2 preparations were obtained by protein 
extraction from vector producing cells and iodixanol gradient purification of the 
respective extractions. Only r-wt was able to transduce the CEA positive human 
colorectal carcinoma derived cell line LS174T (Figure 33 B; D, r-wt, 48 h, Protein 
Extracts and Gradients). Surprisingly, not only r-wt but also r-GFP-CEA-A2 (used 
after protein extraction) vector DNA was found with the cells (Figure 33, E, Protein 
Extracts, r-GFP-aCEA-A2, 48 h). 
To clear this result as a r-GFP-aCEA-A2 specific interaction with the CEA 
antigen, preparations obtained from protein extraction were used to transduce a highly 
positive CEA cell line – C15A3 (Figure 33 C). Only r-wt was able to transduce 
C15A3 cells (Figure 33 F, r-wt, 48h). Furthermore, in contrast to the results obtained 
on LS174T cells, only r-wt vector DNA was found with C15A3 cells (Figure 33 G, r-
wt, 48h). 
In summary, it was not possible to detect full (capsids + transgene) AAV-2 
mutants containing a scFv bound to their target cells. As a result, target cells were not 
transduced. 
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6. Discussion 
A prerequisite for successful application of gene therapy is the achievement of 
efficient and selective gene transfer into target cells with little or no toxicity to non-
target cells. Modification of vector tropism by non-genetic and genetic approaches 
aims to develop such vector systems. 
Peptide insertion into the capsid of AAV vectors based on serotype 2 has been 
shown to enable transduction of cells refractory to AAV-2 infection (61, 62, 66, 128, 
130, 139, 159, 172, 173, 192, 196, 197). Furthermore, improved specificity of gene 
transfer has been shown in small animal models after local (172) and systemic 
application (128, 192, 196). The most popular sites for insertion of small peptides into 
the AAV-2 capsid are 587 and 588. Here, by in silico analysis of the now available 
three dimensional structure of the AAV-2 capsid a more prominent position was 
identified. This analysis revealed that T454 is the less bulked residue in the outer 
surfaced of the capsid and at the same time one of the most distant residues from the 
virus center (Figure 9). 
T454 like 587/588 maps to the GH loop which is the longest loop of the AAV-
2 capsid (Figure 9). GH loops of two adjacent capsid subunits contribute to the 3-fold-
proximal peaks, which cluster around the 3-fold symmetry axis and protrude from the 
capsid surface (203). 587/588 map to the second highest peak of this region and are 
located in a loop region connecting the anti-parallel β-sheets GH12 and GH13 (203). 
453, instead, is found at the β-turn which connects the anti-parallel β-sheets GH2 and 
GH3 and which together contribute to the highest peak of the AAV-2 capsid (203). 
Thus, peptide insertions between G453 and T454 should be more protruding from the 
capsid surface than insertions at 587/588. Therefore, targeting peptides inserted at this 
position should be more accessible for the binding to their target receptor.  
The β-sheets of the highest peak have been used for peptide insertion in 
previous attempts. Initially Girod and colleagues (62) inserted the β1 integrin binding 
peptide L14 (QAGTFALRGDNPQG) at 447. This was followed by Grifman and 
colleagues (66), who successfully inserted a Myc epitope and the CD13 binding 
peptide NGR, respectively, at position 448. In two different approaches, Bartlett and 
colleagues (5, 171) used 459 to insert an AgeI restriction site, a 6 amino acid (aa) 
peptide from bovine papillomavirus (TPFYLK), a 10 aa peptide from human 
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luteinizing hormone (HCSTCYYHKS), and a 15 aa biotin acceptor peptide. Only one 
of the three positions, namely 447, was investigated for its usefulness in vector 
targeting. Interestingly, although the inserted L14 peptide conveyed cell binding, it 
failed to mediate target cell transduction (62).  
Recently, also the β-turn was investigated for its ability to harbor peptide 
insertions (102). With the aim of identifying positions that tolerate a His6-tag for 
vector purification by affinity chromatography, Koerber and colleagues generated a 
library of capsid mutants carrying a His6-tag at various positions. Applying this 
library to a Ni-NTA-column selected a capsid mutant carrying the His6-tag at 454. 
This result corroborates our hypothesis concerning the exposure of peptides inserted 
at this small loop. However, in contrast to r-RGD4C-453 and r-RGD4C-453-A2 for 
which we determined a genomic-to-infectious ratio of ≤3.0x103, their insertion mutant 
showed poor infectivity (genomic-to-infectious particle ratio of >105; determined on 
HeLa cells). One likely explanation for this discrepancy is that we inserted a peptide 
that unlike His6-tag interacts with cellular receptors, as is the case for r-RGD4C-453-
A2, or does not interfere with natural receptor interaction, as is the case for r-RGD4C-
453. The latter may not be possible if a His6-tag is inserted at 454. Taking into 
account that mutants displaying the His6-tag in 587 remained infectious (102), these 
examples reveal the importance of the interplay between insertion site and the nature 
of the inserted peptide. 
Neither insertion of RGD4C at 453 nor insertion combined with R585A and 
R588A substitution, interfered with viral packaging as indicated by the total-to-full 
capsid ratios which are comparable to r-wt. The same holds true for the transduction 
efficiencies, since capsid-to-infectious ratios of 6.3x103 and 6.0x103 were determined 
in HeLa cells for r-RGD4C-453 and r-RGD4C-453-A2, respectively. Thus insertion at 
453 does not interfere with vector genome packaging or with essential viral functions. 
Particles with R585A/R588A substitutions showed a decreased electrophoretic 
mobility (Figure 12, Figure 20, Figure 30 A, Figure 32 A and Figure 33 A). In a 
reducing SDS-page such lower protein mobility can only be the result of an increase 
in protein weight. Both VP1, VP2 and VP3 showed a 2-3 kDa increase in molecular 
weight. Although not commented, this has already been observed by others (135). 
Since substitution of one amino acid by a smaller one cannot result in a heavier 
protein, such change in molecular weight can only be the result of post-translation 
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modifications that do not occur in wt capsids but do occur in mutants with R585A and 
R588A substitutions (or vice versa). Interestingly, 2 residues N-terminally of R585 – 
S580 and T581 – are prone to phosphorylation. A previously published computer-
simulated heparin-docking experiment involving the AAV-2 capsid surface showed 
that T581 is located at the top of the channel through which heparin enters and that 
T581 can indeed contribute to heparin binding via hydrogen bond stabilization (97). 
Thus, blocking this channel by modifying a residue situated at its entrance would 
leave almost no residues available for heparin binding. In summary, the absence of 
R585 and R588 may facilitate the phosphorylation of T581, which may result in the 
blocking of the HSPG binding channel. One other example is N496, which has polar 
contacts with R585 of an adjacent subunit. N496, part of an NxS motif (where x can 
be any amino acid except P), is a potential N-glycosilation site. Submission of one 
AAV-2 subunit to the GlyProt modeling tool resulted in a N496 connected N-Glycan 
that was modeled over the top of the R585/R588 loop of an adjacent subunit (data not 
shown; (60, 202)). Unfortunately this and other modeling tools are not able to process 
more than one subunit at once. Thus, it is possible that R585 and R588 prevent the 
glycosilation of N496 either by helping in the construction of such a sterically 
interfering loop or by establishing hydrogen bonds with N496. Although it is clear 
that capsid modifications can lead to new structures from which a new phenotype  
may result, further work must be done to prove the hypotheses described above. For 
this, the use of phosporylation or glycosilation deficient cell lines or chemical 
inhibitors could be of use. 
The accessibility of RGD4C on the capsid surface was assessed by ELISA 
determining the amount of intact viral particles that were able to bind soluble αVβ3 
integrin. Interestingly, r-RGD4C-453 as well as r-RGD4C-587 showed only marginal 
receptor binding. The combination of peptide insertion with amino acid substitutions 
(R585A and R588A) dramatically improved the receptor binding capacity (Figure 13) 
revealing for the first time that modification of residues linearly distant from the 
insertion site can promote such effects. Although r-RGD4C-453&587, in contrast to 
the single insertion mutants, showed efficient interaction with αVβ3 integrins, 
receptor binding was also enhanced when introducing the R585A and R588A 
substitutions. This enhancing effect of R585A and R588A substitutions may be the 
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result of a change in electrostatic interactions and/or structural conformation resulting 
in either better exposure of the inserted peptide or diminished sterical hindrance.  
As demonstrated by many previous attempts (62, 128, 130, 139, 141, 196) and 
also in this study (Figure 14 A), peptides inserted at position 587 mediate cell 
infection by binding to their target receptor if primary receptor binding is prevented 
by the peptide insertion. The same holds true for peptides inserted at position 453 
(Figure 14 A). r-RGD4C-453-A2 transduction of HeLa cells is inhibited by the 
addition of soluble RGD containing peptides and is not affected by the addition of 
heparin, which abolishes HSPG binding. In contrast, transduction by r-RGD4C-453 - 
containing an unmodified HSPG binding motif – was inhibited by the addition of 
heparin and not by soluble RGD peptides. This does not necessarily means that r-
RGD4C-453 does not use RGD4C for cell entry. Thus, heparin binding to the capsid 
may result in an heparin coated capsid that is then shielded from the receptor by the 
bound heparin. Moreover, competitions with soluble RGD peptides may not be 
effective if a strong binding to the primary receptor – HSPG – is still possible.  
Shi and colleagues created a double insertion mutant by inserting the RGD4C 
peptide simultaneously at positions 520 and 584 (173). When used to infect HeLa-
C12, an AAV-2 rep- and cap-transfected HeLa derivative, the infectious titer was 
comparable to wild-type control. In our study, both of our double insertion mutants 
showed severely reduced transduction capacities even though they efficiently 
packaged vector genomes, bound soluble integrins and showed cell binding (Table 5, 
Figure 15 A, Figure 13 and Figure 14 B respectively). Both studies used the same 
peptide, but different insertion positions. We showed that RGD4C, displayed either at 
position 453 or 587 is able to mediate viral infection (Figure 14 A). Therefore, the 
non-infectious phenotype of our double insertion mutants may be the result of 
simultaneous receptor binding mediated by the peptides displayed by the two different 
peaks. This may result in either interference with structural rearrangements necessary 
to undergo the next steps in cell transduction (6) or with endosomal escape due to 
excessive receptor binding. Peptides in positions 520 and 585 show a different 
topological arrangement and may not face these problems. 
Despite the differences observed in vitro, when compared in vivo, r-RGD4C-
587 and r-RGD4C-453-A2 showed identical biodistributions. Thus, peptides inserted 
in 453 and 587 are equally efficient in re-directing AAV’s tropism if primary receptor 
 113 
binding is avoided. Furthermore, in vivo tropism was independent of the modification 
that led to an HSPG non-binding phenotype.  
Assessment of RGD4C mutants particles stability was made by transduction 
of HSPG negative cells after consecutive freezing cycles. r-A2 and r-RGD4C-
453&587 were to low in transduction efficiency to allow the visualization of any 
alteration. These low levels of transduction might as well be achieved by unspecific 
uptake bypassing the need for a stable functional particle. While the transduction 
efficiency of the analyzed capsid mutants dropped to half after 10 freezing cycles, the 
efficiency of unmodified particles remained unaffected. 
Besides RGD4C also other (alternative) peptide insertions after G453 are 
tolerated. As with RGD4C, insertion of NGRI or GEN resulted in efficiently 
packaged particles that were able to transduce cells. Interestingly, while r-NGRI-453-
A2 was not infectious, r-NGRI-453 was more infectious on HeLa cells and HUVEC 
than r-wt revealing that the inserted NGRI peptide may indeed contribute to cell 
transduction (Table 6, Figure 21). Despite its higher transduction efficiency r-NGRI-
453 transduction was still inhibited by the addition of soluble heparin. The fact that a 
heparin covered mutant like r-NGRI-453 may not be able to efficiently bind to its 
target receptor (APN) - as a result of its heparin cover - and the high transduction 
efficiency of r-NGRI-453 shows that this vector may be able to bind HSPG and APN. 
Furthermore, r-NGRI-587 transduction was not inhibited by the addition of heparin 
and interestingly, the transduction efficiency of the double insertion mutant – r-NGRI-
453&587 – was inferior to r-wt on HeLa cells but equal on HUVEC. Thus, it is 
possible, that also in this case both inserted peptides are able to bind their receptor. 
The insertion in 453 of an AAV display peptide that was selected in position 587 did 
not result in an improved vector. However, this could be expected since the selection 
protocol should lead to a peptide that best fits the position that was used during 
selection. Moreover, while the selection protocol was done using a single-stranded 
genome in this work a self-complementary genome was used for fast onset of gene 
expression – by overcoming the rate limiting step of second strand synthesis. Further 
competition experiments using GEN and cyclic NGR soluble peptides would be 
required for a better analysis of these insertions. 
Submission of the AAV-2 capsid protein VP2 to the NCBI's Conserved 
Domain Database (CDD)(117) identified one major conserved domain (Figure 23). 
This domain, part of the Parvovirus coat protein superfamily (pfam00740, imported 
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from the Pfam database) includes G453 and N587. Analysis of the respective 
sequence alignments led to the identification of the AAV-2 G453 and N587 
homologues in the other 8 Parvovirinae. Analysis of the complete capsid of CPV, 
B19, AAV-4 and MVM revealed that the G453 homologues were indeed located in 
the outer surface of the respective viral capsids (data not shown). Interestingly, while 
the most distant and less bulked (more separated from other residues) residue in the 
AAV-2 capsid is T454, in B19 it is K396, which is the AAV-2 587 homologue 
(Figure 23 C, D and E). Thus, G453 emerges as a position for insertion of small 
peptides in the capsid of Parvovirinae. 
In summary, using rational design we have identified a new position for 
peptide insertions - 453. R585A and R588A mutations resulted in an improved target 
receptor binding of RGD4C inserted either at 453 or at 587. These are the first two 
examples showing that single point mutations of capsid residues can improve target 
receptor binding of AAV-2 based targeting vectors. All these results highlight the 
important relations between target receptor, inserted peptide, insertion site and 
neighboring regions for the design of specific and efficient targeting vectors. By using 
the recently developed AAV libraries (115, 128, 139, 140) and high-throughput 
selection protocols, tools are available to take this into account and identify the most 
suitable combination of target receptor, inserted peptide, insertion site, and 
modification of surrounding residues for the development of optimized targeting 
vectors. 
 
Monoclonal antibodies have long been used as specific targeting reagents for 
the manipulation of the immune system in order to improve protection against tumors 
and pathogens (123). Fragments containing variable regions of the antibodies, such as 
the 100 and 50kDa F(ab’)2 and Fab fragments have also been used in clinical trials 
(85). By genetic engineering, single-chain Fv recombinant proteins of approximately 
28 kDa can be generated by connecting the gene encoding the heavy-chain and light 
chain variable regions by an oligonucleotide linker. These molecules retain the 
recognition ability of the whole immunoglobulin, and their small size and lack of 
carbohydrate groups allows them to be expressed in prokaryotic systems. To increase 
the functional affinity of the construct and improve targeting efficiency, bivalent or 
multivalent forms of scFv can also be generated by connecting subunits non-
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covalently, covalently or with disulfide bonds. Thus, fusion of a scFv to an AAV 
should allow re-targeting of the viral vector.  
The most suitable place for such fusions is the N-terminus of VP2. Insertions 
at the commom VP C-terminus are not tolerated (198). Insertion of peptides with 
more than 34 a.a. in non-terminal regions are not expected to result in the formation 
of viral particles (66, 128, 130, 139, 172, 192, 196, 197). The N-terminus of VP1 
caries a phospholipase A2 domain that is essential for efficient transduction. The N-
terminus of VP3 seems to be located in the inner part of the capsid and peptide 
insertions in this region are not tolerated (198). The viral protein VP2 is not necessary 
for capsid assembly and its presence is not required for a productive infection in vitro 
(113, 189). VP1 and probably VP2 N-terminal domains seem to translocate from the 
inside to the outside of the capsid during infection (105).  
In the first ever genetic fusion of a ligand to an AAV capsid Yang and 
colleagues fused a scFv to the N-terminus of VP2 (208). The low expression of VP3 – 
probably as a result of the elimination of its Kozak consensus – did not allow the 
assembly of viral particles. It is now known that VP3 is essential for capsid assembly 
and that 10 VP3 particles are required per each VP1 and VP2. Not aware of this the 
authors supplied more wt VP2 and VP3 in trans to achieve capsid assembly. The 
resulting VP1 : scFv-VP2 : VP2 : VP3 chimeric particles were able to transduce their 
target cells with very low efficiency. Non-target cells were also efficiently transduced 
and in vivo experiments were not performed. In two recent reports, fusion of GFP (27 
kDa) to the N-terminus of VP2 yielded GFP-tagged virus with 100% substitution of 
wt VP2 that were used to visualize the AAV infectious pathway. Thus, the unique N-
terminal region of VP2 is the most appealing site for insertion of ~28 kDa molecules 
like the scFvs. Substitution of the wt VP2 by a scFv-VP2 fusion protein should result 
in a viral capsid with five scFv molecules. By comparison to other multivalent forms 
of scFv such pentavalente constructs should possess a good affinity to the target 
antigen. 
The exact location of the N-terminus of VP2 is not known. The available three 
dimensional structure of AAV-2 does not include this region. The incapacity to 
resolve this region in crystallography studies is probably due to the fact that, as 
proposed by more recent models, this region is versatile, it can pass through the pores 
on the 5-fold symmetry axis being either in the inner or outer part of the capsid. For 
efficient targeting the ligand must be exposed on the outer surface of the capsid. 
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Using an anti-GFP antibody and an antibody against intact AAV-2 particles (A20), 
we were able to demonstrate that the recognized GFP epitope is located on the outer 
surface of intact capsids (Figure 24). However, this result can not exclude that other 
parts of the GFP molecule are not located on the inner part of the capsid. In an AAV-2 
capsid with 100% substitution of the wt VP2 (72 kDa) per the GFP-VP2 fusion 
protein (99 kDa) five GFP proteins should be present per capsid. Having this and the 
small size of AAV-2 (diameter of 25nm) in account, it was indeed unlikely that this 
protein would be totally contained in the inner part of an intact capsid. This result is 
also in agreement with previous work where insertion of ligands on the VP2 N-
terminus region led to an enlargement of the viral tropism (111, 198).  
Not knowing the exact location of the N-terminus of VP2 but knowing that at 
least a part of the GFP molecule (on GFP-VP2 tagged AAV-2 particles) is located on 
the outer surface of intact capsids, we started by engineering a construct in which a 
scFv was fused to the N-terminus of GFP. Such particles would then be targeted and 
at the same time their infectious pathways could be followed. 
As seen in Figure 25 A co-transfection of pGFP-VP2 and pRC VP2 KO (r-
GFP) results in lower amounts of the VP1 and VP3 proteins when comparing to 
single transfections and wt plasmids. The GFP-VP2 ORF is under the control of a 
CMV promoter while VP1 and VP3 expression is controlled by the AAV-2 specific 
p40 promoter. Thus, while the expression of GFP-VP2 was expected to be superior to 
the expression of VP1 and VP3 (as seen on Figure 25 A), co-transfections were not 
expected to result in a decrease of the amounts of VP1 and VP3.  Moreover, 
production of mutants with incorporated GFP-VP2 fusion proteins resulted in the 
recovery of approximately 100-fold less vector particles (by comparison with r-wt). 
Despite this, iodixanol gradient purification revealed that r-GFP particles contain the 
correct VP1 : GFP-VP2 : VP3 ratio (1:1:10). This did not hold true for all the r-GFP 
preparations made along this work. As it can be seen in Figure 30 in some r-GFP 
preparations there was an overrepresentation of the GFP-VP2 protein. The same was 
seen in previous reports where r-GFP vectors were produced (113, 189). Furthermore, 
as shown above it was possible to detect GFP on the outer surface of these capsids 
(Figure 24). 
Very low amounts of the aCD30-GFP-VP2 protein were detected in cells 
transfected with paCD30-GFP-VP2 in comparison to GFP-VP2 in pGFP-VP2 
transfect cells (Figure 25 A). As seen in the production of r-GFP, co-transfection of 
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paCD30-GFP-VP2 and pRC VP2 ko also led to lower amounts of VP1 and VP3. r-
GFP-aCD30 purified vectors did not show any aCD30-GFP-VP2 protein (Figure 25 
B). The same result was observed when using smaller constructs where the aCD30 
scFv was fused to the N-terminus of VP2 either directly or by means of a small linker 
(Figure 26). Since such smaller constructs have approximately the same molecular 
weight as GFP-VP2, the differences observed in the incorporation of GFP-VP2 and 
aCD30-GFP-VP2 do not seem to be due to their different size.  
The Kozak consensus translation initiation site, known to improve translation 
efficiency in eukaryotic cells, is present in the GFP-VP2 encoding plasmid. This site, 
not present in the remaining fusion proteins was cloned into the aCD30-VP2 encoding 
plasmid but no improvement in the amount of the fusion protein was visible before or 
after vector purification (Figure 27). pGFP-VP2 encodes a red-shifted variant of wild-
type GFP which has been optimized for higher expression in mammalian cells. The 
coding sequence of GFP gene contains more than 190 silent base changes which 
correspond to human codon-usage preferences. Thus, since such optimization has not 
been done for the aCD30 coding sequence, it is reliable to say that the lower amount 
of aCD30-GFP-VP2 found in HEK293 cells after transfection is likely the result of 
non-favorable codons.  
To overcome the low expression of aCD30-GFP-VP2, we increased the 
amount of the respective plasmid used for transfection. As expected, this increased the 
aCD30-GFP-VP2 : VP1 ratio (Figure 28).  Surprisingly, this also resulted in the 
increase of the amount of VP1 and VP3. Although, after a threshold of 4 (4-fold 
increase in the amount of plasmid), increasing the amount of paCD30-GFP-VP2 
resulted in a decrease in the protein amount of aCD30-GFP-VP2, VP1, and VP3. This 
was probably due to an increase in the amount of dying cells or slower proliferation 
due to the overload of DNA.  
Particles containing total substitution of  wt VP2 by aCD30-GFP-VP2, can 
still be obtained from the 40% fraction of an iodixanol gradient. A 10-fold decrease in 
the amount of recovered particles was seen in r-GFP-aCD30-4 (Table 8). Despite this, 
these particles remained infectious with a mere 1.9-fold reduction in infectivity (when 
compared to r-wt). Vector production using a paCD30-GFP-VP2 : pRC VP2 ko ratio  
of 4:1 did not always result in vector particles with an aCD30-GFP-VP2 : VP1 ratio 
of 1:1 (Figure 28 and Figure 30). Differences were seen when using different batches 
of cells, plasmid preparations, when up-scaling the transfection protocol and, 
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independently of this, from transfection to transfection. As discussed above, the same  
was seen when packaging r-GFP vectors along this work and in previous reports (113, 
189). Thus, this is one of the major hurdles of supplying one plasmid in trans. Such 
hurdle might be overcome by designing a system were both XXX/VP2 (where XXX 
stands for any fused protein) and RC VP2 ko sequences are under the control of the 
same promoter (eg. p40). Although, the need to over express the XXX/VP2 fusion in 
relation to VP1 in order to have the fusion protein incorporated in the viral capsid 
could render this approach unsuccessful. Furthermore, having two gene sequences 
under the control of the same promotor may also decrease the overall expression of 
both ORFs. The sequence coding for the fused protein should be optimized for 
expression in mammalian cells. Alternatively, using the same approaches, 
construction of a pXXX-VP2/VP3 and a pVP1 plasmid could also be of use. 
Although, previous reports have shown that such constructs can result in the loss of 
VP3 expression (189). Moreover, both ORF could be included in one single plasmid. 
When establishing such systems one should keep in mind the need to achieve 
extremely high vector titers and the required protocol. This would be especially 
important when engineering scFv driven vectors. Separation of empty from full 
particles by ion exchange chromatography can also be of use. 
Previous reports (189) have shown that complete absence of VP1 can lead to 
an 100-fold reduction in infectivity due to the lack of the PLA2 domain (presumably 
necessary during infection for endosomal escape). Despite this, the minor decrease in 
the amount of VP1 within our vector particles do not represent a serious obstacle to 
transduction as r-GFP-aCD30-6 only showed a 1.2-fold reduction in infectivity when 
compared to r-GFP-aCD30-4 (Table 8, Figure 28 and Figure 30). Thus, we were able 
to purify infectious AAV particles with an incorporated aCD30-GFP-VP2 fusion 
protein in substitution for the wt VP2. 
Analysis of iodixanol purified and not purified r-GFP-aCD30 preparations 
revealed that the incorporated scFv was able to bind its antigen – determined using an 
anti-idiotypic antibody that recognizes the paratope (Figure 29 A and C). 
Unfortunately, it was not possible to make cross detection of such molecules with 
intact capsids (Figure 29 B). This may be a result of the low amount of scFv found in 
each capsid. Thus, while 60 A20 antibodies can bind each AAV-2 capsid, only 5 
scFvs are available for anti-idiotypic binding. Sterical hindrance involving the 2 
antibodies and the modified capsid may also be an hurdle.  
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Also, using an anti-GFP antibody it was possible to detect the GFP-aCD30 
fusion after protein extraction of vector producing cells but not after iodixanol 
gradient purification (Figure 29 A). While in protein extracts there are incorporated 
and non-incorporated fusion proteins in solution, in the iodixanol gradient purified 
preparations all present fusion proteins are incorporated in the AAV capsid. It should 
be noticed that, in a western blot, for obtaining the correspondent fusion protein bands 
with the same signal intensity, about 10x more volume of the iodixanol purified 
preparation had to be used in relation to protein extracted from cell lysates. 
To better differentiate between an AAV-2 wt phenotype and a scFv driven 
mutant, binding of AAV-2 to its primary receptor was abolished.  For this, the known 
and above discussed R585A and R588A substitutions were added to our vectors 
(Figure 30 A and Figure 31 A). L540 cells, with a high expression of the target 
antigen – CD30 – were chosen as target cells (Figure 30 B). Anti-CD30 scFv driven 
vectors were not able to transduce the target cells (Figure 30 C and Figure 31 B). To 
discriminate between binding to the target cells and post-binding barriers amount of 
vector DNA was quantified 1 h and 48 h p.t. (Figure 30 D and Figure 31 C).  Vector 
DNA was only detected in the target cells 48h p.t. when applying r-wt. The low 
permissibility of this cells did not allow the detection of vector DNA 1 h p.t..  Despite 
this, 1 h (at 37 ºC) should give enough time for the scFv to bind its target molecule. 
Immunological stainings can be done by incubating the antibodies and antigens for 30 
min. Thus, our scFv targeting mutants, if bound but not internalized should be 
detectable by this assay (specially when the antigen is highly expressed on the cell 
surface). Indeed, it seems that the inability of the scFv targeting mutants to transduce 
their target cells is the result of their incapacity to bind the target antigen (Figure 30-
33).   
To increase the concentration of vector particles and cells in solution, cells 
were pelleted and ressuspended in viral solution (data not shown). Unfortunately, this 
has not resulted in detectable transduction.  Comparison of performed transduction 
assays with immunophenotyping assays indicates that, indeed, the low titers of our 
vectors may not allow scFv / antigen binding events (Table 9). Although nearly the 
same particles-to-cell ratio is used, in immunophenotyping assays concentration of 
whole Ig molecules and cells is approximately 5.0x104 times higher. To perform 
transduction assays that would completely parallel immunophenotyping assays, 
vectors would have to be highly concentrated – 1.0x1015 genomic particles / ml. 
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Although one previous report has shown that wt AAV vectors can be produced with 
titers near the 1.0x1015 genomic particles/ml value, our mutants show a 10- to 100-
fold decrease in packaging efficiency making it impossible to achieve such titers. 
Furthermore, the fact that whole Ig molecules have higher affinity to their antigens 
then scFvs indicates that even higher titers my be required. 
The inefficient targeting 
capacity of our anti-CD30 driven 
vectors is not idiotype specific. This is 
supported by the fact that vectors 
where the anti-CD30 scFv was 
substituted either by an anti-CA19.9 
scFv or an anti-CEA scFv were also 
not able to bind and transduce their 
target cells (Figure 32 and Figure 33). 
Interestingly, assembly of r-GFP-
aCEA-A2 particles with an aCEA-
GFP-VP2 : VP1 ratio of 1:1 required a 10-fold increase in the amount of paCEA-
GFP-VP2 plasmid used (while vectors with anti-CD30 and anti-CA19 scFvs only 
required a 4- and 5-fold increase in the amount of plasmid used in transfection). 
Although surprising results could appear from in vivo assays, our preliminary 
in vitro data does not support such experiments. 
In contrast to Yang and colleagues  - 1998 - we were not able to generate 
targeting AAV-2 based particles by fusion of a scFv to the N-terminus of VP2 (208). 
One of the differences between this two works is the type of assays used for 
determination of the transduction efficiencies. Yang and colleagues used a β-
galactosidase gene as a reporter gene and determined the transducing titers by 
counting under a microscope the amount of cells stained with X-Gal. In contrast, we 
used a GFP gene as a reporter gene and determined the transducing titers by 
fluorescent activated cell sorting (FACS) analysis. Also, while we used an adenovirus 
free production system for our vectors, Yang and colleagues did not. In their study, 
the best obtained titer was equal to 1.9x102 transducing units/mL. Furthermore, Yang 
and colleagues have not shown complete AAV particles with an incorporated scFv. 
One year after this report, another approach made use of antibody molecules. A 
bispecific antibody displaying affinities for αIIbβ3 integrin (AP-2 antibody part) and 
 
r-AAV-
aCEA 
(scFv) 
anti-CEA 
(whole Ig) 
Particles/Cell 1.00E+04 4.34E+04 
Cells/ml 4.00E+04 6.67E+08 
Particles/ml 4.00E+08 2.90E+13 
Table 9. Transduction with AAV-scFv particles 
vs. Immunophenotyping with whole Ig 
molecules. Comparison of C15A3 cells transduction 
by an AAV/scFv targeting vector with 
immunophenotyping protocols using whole Ig 
molecules. 
 121 
the intact AAV-2 capsid (A20 antibody part) was used by Bartlett and colleagues to 
bind rAAV-2 to fibrinogen on MO7e and DAMI cells, which are not permissive for 
wild-type AAV-2 infection (12). The binding is likely to induce a receptor-mediated 
endocytosis and resulted in transduction efficiencies 70-fold above background (12). 
In 2002, Ried and colleagues inserted the immune globulin binding domain Z34C in 
position 587 (159). rAAV-2-Z34C vectors were coupled to antibodies and specifically 
transduced their target cells. Although they used a GFP gene as a reporter gene 
quantification of transduced cells was made by fluorescence microscopy. Transducing 
titers were also here extremely low. All mentioned reportrs failed to present in vivo 
results. Despite the large number of publications involving AAV targeting only the 3 
reports mentioned above involved antibody molecules or antibody fragments. 
Although previous works have shown that insertion of peptide ligands in the VP2 
unique region (VP1 + VP2) can lead to an increase in transduction efficiency, it is still 
to be shown that such result is due to the binding of the ligand to its receptor (111, 
198). Moreover, the same group demonstrated that ligands as large as 146 amino 
acids can be exclusively inserted in the N-terminus of VP2, but no targeting or 
enlargement of tropism was shown until now (189). Furthermore, while one work 
showed success in vitro with scFv driven adenovirus type 5 vectors, others have failed 
to show targeted gene delivery (79, 187). 
In summary, we were able to produce AAV-2-scFv infectious particles. Beside 
showing how such highly specific molecules can be fused to the vector capsid we 
demonstrate how proteins as big as the GFP-scFv can be fused to the N-terminus of 
VP2. The scFv-GFP fusion represents the biggest described fusion to the AAV-2 
capsid. These particles had an incorporated scFv/VP2, whixh was recognized by an 
anti-idiotypic antibody directed against the paratope, re-enforcing the theory that the 
N-terminus of VP2 can indeed be displayed on the outer surface of the capsid.  
Unfortunately, these particles were not able to bind their target antigen when 
displayed on the surface of cells. Improved packaging systems and increased number 
of scFv molecules per capsid emerge as pre-requisites for the construction of scFv 
directed vectors. Despite this, in experimental designs where it is not necessary to 
have such high concentration of the fused protein, fusions to the N-terminus of VP2 
can be of good use. 
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Abbreviations 
a.a. amino acid 
AAV adeno-associated virus, specifically 
adeno-associated virus type 2 
AAVS1 AAV integration site 1  
(located in human chromosome 19) 
Ab antibody 
Ad adenovirus 
B19 B19 human parvovirus 
bp base pair  
BSA bovine serum albumin 
Cap capsid protein  
ch chromosome 
CMV cytomegalovirus 
Da Dalton 
DMEM Dulbecco's Modified Eagle 
Medium 
DNA Deoxyribonucleic Acid 
e.g. for example (Lat.: exempli gratia) 
ELISA enzyme-linked immunosorbent 
assay 
FACS fluorescence-activated cell sorting  
FCS fetal calf serum 
FGFR fibroblast growth factor receptor 1 
FITC fluorescein isothiocyanate 
GFP green fluorescence protein 
h hour 
HSPG heparan sulfate proteoglycan 
i.e. that is (Lat.: id est) 
ITR inverted terminal repeat 
kb kilobases 
mAb monoclonal antibody 
MHC major histocompatibility complex 
min minute 
MOI multiplicity of infection 
NPC nuclear pore complex 
nt nucleotide 
ori origin of replication  
ORF open reading frame 
p.i. post-infection 
p.t. post-transduction 
PAGE polyacrylamide gel electrophoresis 
r-AAV recombinant AAV 
RBS Rep binding site 
Rep viral regulatory protein 
rpm rounds per minute  
RT room temperature 
scAAV AAV containing self 
complementary DNA 
SDS sodium dodecyl sulfate  
Stav streptavidin 
ssAAV AAV containing single stranded 
DNA 
TRS terminal resolution site 
VP viral protein (AAV capsid protein) 
wtAAV            wild-type AAV 
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